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Abstract 
West Nile virus (WNV) is a globally significant mosquito-borne neurotropic virus.  In 2011, a 
large-scale arboviral encephalitis outbreak occurred in Australia, involving close to 1000 horses.  A 
virulent WNV strain, WNVNSW2011, was isolated from the brain of an encephalitic horse during this 
outbreak.  Preliminary assessment showed that this strain is intermediate in virulence and belongs in 
the same lineage as the highly virulent North American strains.  However, the pathogenesis of 
WNV in general, let alone this novel Australian strain, remains largely unclear.   
The first part of the project aimed to investigate the pathogenesis of lethal WNVNSW2011 infection in 
the established young adult Swiss white (CD1) mouse model, since previous survival challenge 
experiments demonstrated high lethality (~70%) of WNVNSW2011 in this animal model.  I conducted 
a pilot time-course experiment, which demonstrated only benign pathological and virological 
outcomes in sacrificed mice on day 3 and 7 post-infection (pi), despite the relatively high lethality 
seen in previous survival trials.  In a subsequent experiment, I characterised the disease phenotype 
in moribund/dead and surviving mice after WNVNSW2011 infection.  Notably, I detected a high 
degree of intra-group variability in the neuropathology, neural infection and glial cell activation.  
Similar variability was also observed in CD1 mice challenged with another Australian WNV strain 
of intermediate virulence, WNVNSW2012.  These inconsistencies in the end-point disease suggest that 
random sacrifice of infected mice at any given time-point may not give reliable information of the 
pathogenic processes towards lethal encephalitis.  Therefore, conventional sacrifice experiments 
may not be the best approach for investigating pathogenesis of virus strains of intermediate 
virulence.  This previously unacknowledged challenge to investigating pathogenesis of virus strains 
of intermediate virulence should inform the planning and execution of future studies with such virus 
strains. 
The second part of the project addressed the need for a resistant small animal model for studying 
the in vivo control of virulent WNV infections.  Since rodent models typically produce lethal 
disease after infection with virulent WNV strains, they may not reflect what happens in the natural 
“dead-end” hosts, humans and horses, in whom most WNV infections (> 90%) are non-lethal.  
Even cases with neuroinvasion are typically not fatal, unless underlying co-morbidities or 
immunosuppressive disease exist. 
I chose rabbits as a candidate for a novel animal model, due to the ease of performing intra-vital 
sampling and monitoring, as well as the possibility for tissue sharing in different assays, given the 
larger size of rabbits than mice.  Rabbits are also hind-gut fermenters, and thus may be a better 
representation of a horse than a mouse.  New Zealand White (NZWRs; Oryctolagus cuniculus) and 
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North American cottontail rabbits (CTRs; Sylvilagus sp.) were challenged with WNV strains of 
different virulence (WNVNSW2011 and WNVTX8667), and the prototype Murray Valley encephalitis 
virus strain (MVE1-51), by the footpad route.  The rabbits were consistently resistant to developing 
severe disease after virulent WNV and MVEV infection, regardless of age, gender and species, 
despite productive virus replication in the draining popliteal lymph node (PLN).  The resultant 
viraemia for all rabbits was also of low magnitude and transient.  Furthermore, establishment of 
virus infection in the brain was not a feature of the disease, despite mild to moderate 
neuropathology in a subset of rabbits.  This capacity to control flavivirus infection may be 
explained by the rapid antiviral innate immune response detectable by day 3 pi, as well as a fast 
anti-WNV neutralising antibody response detectable from day 7 pi. 
Comparisons of the tissue-specific transcriptional profile of important cytokine and chemokine 
genes suggested that virus control in rabbits was achieved differently depending on the virus, as 
well as the rabbit species.  However, common transcriptional upregulation of IFNγ in the draining 
PLN, TNFα in the non-draining PLN and IL6 in the spleen was detected in all rabbits on day 3 pi, 
suggesting a common tissue-specific innate immune response signature against flavivirus infection.  
Involvement of anti-viral, pro- and anti-inflammatory signalling molecules, such as NF-kB2, 
STAT1, and STAT3, was also detected mostly in infiltrating mononuclear leucocytes in brain 
sections with elevated levels of IFN-I/II, TNFα, IL6 and IL10 transcripts.  Thus, immunocompetent 
rabbits are able to resolve virulent flavivirus infections via a well-coordinated antiviral, pro- and 
anti-inflammatory immune response.  Given the similarities to the non-lethal disease profile of most 
human and equine infections, rabbits are a valuable model for studying the mechanisms of virus 
control and pathogenesis of non-lethal disease. 
This project has therefore advanced the field of WNV research by describing a previously 
unacknowledged complication for studies of the pathogenesis of infection involving virus strains of 
intermediate virulence, as well as having established an alternative animal model for studying virus 
control and induction of non-lethal disease. 
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Chapter 1. Literature review 
1.1 Manuscript information 
A large proportion of the content of this literature review chapter has been included in my published 
review [1].  An introduction to the immune mechanisms associated with the control of WNV 
infections and a short review of WNV epidemiology in the Australian context have also been 
included in this chapter. 
1.2 Introduction 
West Nile virus (WNV) continues to pose a significant disease burden in both human and animal 
populations, with new emerging or re-emerging strains since the mid-1990s appearing to be more 
neurotropic [2, 3].  WNV was first isolated from the blood of a febrile woman in 1937 in the West 
Nile region of Uganda [4].  The typical disease seen in these early human infections were generally 
mild and self-resolving (reviewed in [5]).  However, since the 1990’s, outbreaks involving patients 
with fatal encephalitis has been observed globally [6-9].  In 1999, the first WNV case was identified 
in the US and since then WNV has been responsible for several human and equine outbreaks across 
the country with neurological disease being a notable feature of infected individuals [9, 10].  In 
2012, the USA Centers for Disease Control and Prevention (CDC) reported the highest number of 
human WNV cases in the US since 2003 [11].  Of the 5674 cases, 51% were reported to be 
neuroinvasive, amounting to the highest number of human neuroinvasive cases caused by an 
arbovirus in US history [3]. Prior to 2012, US patients with neuroinvasive disease per year 
accounted for less than 1% of symptomatic cases [10, 12-14].  Meningitis, encephalitis and 
poliomyelitis appear to be the main pathological features in human disease [10].  Horses present 
with similar neurological disease, with neurological cases in WNV-infected equids reported to be 
approximately 10% [13, 15]. 
WNV is a mosquito-borne Flavivirus belonging in the family Flaviviridae [16].  This virus group is 
further separated into several lineages (lineage 1 to 4), each with a specific geographic association 
and virulence [17].  Specific to lineage 1, there are three clades within the lineage, with clade 1a 
mostly found in North America, clade 1b in Australia, and clade 1c in India [17].  The genome of 
WNV is a positive sense, single-stranded RNA which encodes a single polyprotein, that is post-
translationally cleaved into three structural (C, prM/M, E) and seven non-structural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, NS5)[16].  A natural transmission cycle of WNV exists between 
mosquito vectors and reservoir hosts, mainly aquatic birds [18].  Infection in incidental hosts, such 
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as humans and horses, usually results in low level viraemia and plays little role in the transmission 
cycle [19].  However, neurological disease can manifest in these incidental hosts [20, 21]. 
For a neurotropic virus, such as WNV, to invade the central nervous system (CNS), it must 
overcome both the extraneural and neural barriers present.  This process is commonly referred to as 
neuroinvasion.  Although extensive studies have been conducted on the virological and 
immunological mechanism of WNV neuroinvasion, the hypotheses that arose from these studies 
often require further validation.  Furthermore, most human and equine WNV infections are not 
lethal, and yet, the mechanism by which these incidental hosts resolve this virus infection remains 
mostly unclear, since human and equine studies are largely restricted to in vitro/ex vivo analysis of 
blood, urine or cerebrospinal fluid (CSF) samples [22-24].  Moreover, the high susceptibility of 
mice to virulent WNV infection has led investigators to use attenuated WNV strains to study 
mechanisms of virus control [25], which may not be representative of the human and equine control 
mechanisms against virulent WNV strains.  
This literature review chapter aims to first systematically appraise the current hypotheses of WNV 
neuroinvasion, notably the: 1) haematogenous and 2) transneural hypothesis of neuroinvasion.  
Largely unexplored and potentially promising areas of research, such as the blood-CSF barrier, the 
CSF-brain barrier and the blood-spinal cord barrier (BSCB), will also be evaluated in detail.  
Additionally, I will appraise the current findings and hypotheses on the mechanisms of WNV 
control from studies using the conventional mouse models. 
1.3 Mechanism of West Nile virus neuroinvasion and neuropathogenesis 
1.3.1 Haematogenous route of neuroinvasion 
As viraemia from peripheral infection with WNV is a common feature in various animal models 
(reviewed in [26]), the hypothesis of haematogenous dissemination of the virus into the CNS has 
been a common focus of investigation.  According to current literature, viraemia develops following 
peripheral replication locally in the dermis at the site of virus inoculation [27-29] and/or in the 
draining lymph nodes [27, 30, 31], both resulting in systemic dissemination of the virus.   Viral 
presence in the CNS is commonly observed shortly thereafter, especially in studies using 
immunocompromised rodents [31-41].  This temporal kinetics of WNV infection has led many 
investigators to suspect the blood-brain interface, the blood-brain barrier (BBB), as the most likely 
route of neuroinvasion.  For this reason, the role of the BBB in WNV neuropathogenesis remains 
the most common focus of investigation. 
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1.3.1.1 Blood-Brain Barrier 
The BBB functions as a physical and immunological “shield” to prevent haematogenous pathogens 
and noxious substance from entering the brain, via its four main cellular components: endothelial 
cells and their basement membrane, astrocytes and their foot processes, microglial cells and 
pericytes [42, 43].  The endothelium is the first line of defence against viral neuroinvasion.  As 
such, in vitro endothelial models have been developed to study the mechanism of WNV 
translocation across this barrier (e.g. [44, 45]).  Mechanisms suggested for WNV include: a) 
transcellular transport of virions across the infected endothelial cells (see Section 1.3.1.2) and b) an 
increased permeability of the BBB, which can then facilitate a paracellular entry of the virus into 
the CNS parenchyma (see Section 1.3.1.4). 
1.3.1.2 Transendothelial viral entry 
Being a largely impermeable barrier under normal conditions, the BBB possesses many specialised 
transcellular transport systems that facilitate supply of essential nutrients into the brain [43].  But 
some of these strategies present an opportunity for neurotropic viruses to invade the CNS.  In vitro 
experiments, using Japanese encephalitis virus (JEV), a closely related virus to WNV, demonstrated 
that transcytosis across both cerebral endothelial cells and pericytes via endocytic vesicles was 
achievable [46].   Specifically regarding WNV, Hasebe et al. [45] showed that virus-like particles 
(VLPs) could be transported from the apex to the basolateral sides of endothelial cells in culture, 
further supporting this transcellular transport hypothesis.  The delay in the emergence of West Nile 
virions on the abluminal side from an infected endothelial cell monolayer was also suggestive of a 
transcellular passage of the virus, instead of the more rapid process of paracellular diffusion [44].  
However, as observed by Hasebe et al. [45] and Dropulic & Master [47], the ability of virus to 
infect endothelial cells could be virus species specific and could even be strain 
specific.  Furthermore, in vivo evidence of endothelial cell infection is lacking.  One human case 
report noted the presence of JEV antigen in the endothelial cells of infected brains by 
immunohistochemical labelling [48].  However, on closer examination of the published 
microphotomicrograph, the stained focus did not appear to be located in the endothelial cells, but 
was adjacent to it [48].  Indeed, brain endothelial cell infection by WNV is absent even in the face 
of pronounced neuronal infection in mice (Figure 1-1).  More importantly, brain endothelial cell 
infection is not a feature of WNV infection in the common target host, the equids [49].  This 
illustrates that the behaviour of in vitro grown endothelial cells can be quite different to that seen in 
vivo, especially when endothelial cells are cultured alone, as was the case in the studies by Verma et 
al. [44] and Hasebe et al. [45].  Therefore, the transcellular passage hypothesis suggested for WNV 
neuroinvasion requires further validation in an appropriate in vivo model. 
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Figure 1-1 Immunohistochemical labelling with anti-flavivirus NS1 monoclonal on brain 
section from a Swiss CD1 mouse, infected with an Australian WNV subtype, WNVKUN.  
Despite ample neuronal infection (red stain, arrowhead), the endothelial cells are not infected 
(arrow).  (Antibody binding was visualised using AEC substrate and the section counterstained with 
Mayer’s haematoxylin; magnification at 400x)[1]. 
1.3.1.3 Molecules for blood-brain barrier integrity 
While in vitro infection of endothelial cells may result in transcytosis of virions, another hypothesis 
of neuroinvasion involves a paracellular migration of virions across a disrupted BBB.  The 
mechanism by which this disruption occurs has been investigated again mostly in in vitro models, 
especially at the level of the endothelial junctions.  The BBB possesses specialised tight junctions 
between brain endothelial cells.  These junctions are made up of various junction proteins, mainly 
grouped as either tight junction proteins or adherens junction proteins.  Claudins and occludins are 
the two major tight junction proteins responsible for the intercellular contact [42]. 
In general, most junctional proteins appear to have either an increased or stable genetic expression, 
but are present at a reduced level post-WNV infection both in vivo and in vitro (Table 1-1).  This 
may suggest degradation of these proteins.  The breakdown of these molecules have been suggested 
to be associated with BBB disruption, especially in the face of pro-inflammatory cytokines, such as 
tumour necrosis factor (TNF)-α, interleukin (IL)-6, macrophage migration inhibitory factors, and 
proteases, such as matrix metalloproteinases [50-54].  This area of WNV research is marred by a 
lack of consistency in the in vitro methodology employed, such as the use of different cell lines, 
ranging from epithelial cells to endothelial cells from different anatomical origins, for infection [44, 
55, 56].  This inconsistency is likely the reason for some of the discrepancies observed (Table 1-1), 
such as the level of claudin-1 mRNA and protein levels.  It is also interesting to note that the genetic 
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expression of some of these proteins also differs between in vitro and in vivo studies (Table 1-1).  
This further highlights the difference in behaviour of cells grown in vitro as compared to those in 
vivo.  
 
Table 1-1 Genetic expression and protein levels of tight junction and adherens junction 
proteins post-WNV challenge in in vitro BBB models and in vivo models. 
Junction Proteins mRNA Protein Level 
Claudin-1 [44, 56]; NC [54] [44]; [53-56] 
Claudin-3 [56] No information 
Claudin-4 [56] No information 
Claudin-5 NC [44] No information 
ZO-1 Mild [44, 56]; NC [54] [53, 54]; NC [55, 56] 
Occludin Mild [44]; NC [54, 56] [54]; NC [56] 
JAM-A (JAM-1) [56]; NC [54] [54, 56] 
Beta-catenin No information [54] 
Vascular Endothelial Cadherin No information [54] 
ZO-1: Zona occludens-1; JAM-A(JAM-1): Junctional adhesion molecule-A or 1;  increased level;   decreased level; 
NC no change; Y yes; N no; Red highlight indicates findings supported by in vivo evidence [54]. 
 
In addition to tight junction molecules, cell adhesion molecules are another group of endothelial 
molecules of particular interest in BBB pathophysiology.  These molecules may be upregulated in 
the presence of certain cytokines during inflammation (Table 1-2) [44, 57, 58].  Their functions 
include regulating leucocyte signaling and controlling movements of leucocytes in tissue during 
inflammation [59].  In the case of WNV infection of endothelium, ICAM-1, VCAM-1 and E-
selectin appeared to be upregulated in vitro (Table 1-2) [44, 57].  Dai et al. [58] have attempted in 
vivo characterisation of the role of ICAM-1 in WNV neuroinvasion and concluded that cell 
adhesion molecules may facilitate viral neuroinvasion either by acting as a cell surface receptor on 
endothelial cells or by aiding infiltration of peripherally infected leucocytes into the CNS (see 
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Section 1.3.1.4.2 for the “Trojan Horse” route of neuroinvasion) [44, 58].  However, the evidence 
presented by the authors does not support the claim that neuro-infiltration of leucocytes and 
neuronal damage were significantly more pronounced in wild-type mice than in ICAM-1 knockout 
mice.  On closer inspection of the photomicrograph in “Figure 3G” of the paper, the “perivascular 
mononuclear infiltration” indicated by the arrows more closely resembles the normal layer of 
ependymal cells lining the ventricles of the brain [58].  Furthermore, the suggested neuronal 
damage was gauged only on haematoxylin and eosin stained sections [58].  This can be challenged, 
as without immunohistochemical confirmation of cell death using necrosis or apoptosis markers, 
normal neurons may morphologically appear similar to damaged neurons and vice versa, depending 
on variability in sample preparation for histology [60].  Hence, the significance of cell adhesion 
molecules in an in vivo context requires further investigation. 
 
Table 1-2 Genetic expression and protein levels of cell adhesion molecules, during WNV 
infection of endothelial cells in vitro 
Cell adhesion molecules mRNA  Protein levels 
ICAM-1 No information  [57] 
ICAM-3 NC [44] No information 
VCAM-1  (WNV dose-dependent) [44]  [44, 57] 
E-Selectin  (WNV dose-dependent) [44]  [57] 
P-Selectin No information NC [57] 
PECAM NC [44] No information 
ICAM, Intercellular adhesion molecule 1; VCAM, Vascular cell adhesion molecule ; PECAM, platelet and 
endothelial cell adhesion molecule;  increased level;   decreased level; NC no change.  
1.3.1.4 Paracellular viral entry 
As a consequence of BBB leakage, plasma protein and inflammatory cells could migrate across 
paracellular junctions between endothelial cells into the brain parenchyma.  Two methods of viral 
entry, as a result of BBB breakdown, have therefore been hypothesised: 1) via passive diffusion as 
cell-free virions, or 2) via infected-leucocyte trafficking, i.e. the “Trojan Horse” method. 
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1.3.1.4.1 Via passive diffusion 
The hypothesis of passive diffusion of cell-free virions across a more permeable BBB has been put 
forth in several reviews [2, 61, 62].  However, searches in two separate literature databases 
(Pubmed and Web of Science) for this hypothesis failed to yield any study that directly 
demonstrated actual diffusion of WNV across the BBB. 
Referring to the reviews by Clark et al. [2], Sips et al. [62] and Samuel and Diamond [61], the 
studies that were cited in support of this particular hypothesis for WNV, did not actually 
demonstrate this diffusion phenomenon.  For example, Sips et al. [62] cited Verma et al. [44].  
However, this latter study demonstrated the contrary.  The time taken for WNV to cross the more 
permeable BBB fitted better with the idea of a transendothelial transport of the virus, rather than via 
passive diffusion [44].  This was further validated by the lack of fluorescein isothiocyanate (FITC) 
dextran diffusion across the endothelial monolayer post-WNV infection [44].  Similarly, Samuel 
and Diamond [61] cited Kramer-Hammerle et al. [63], which was a review on the mechanism of 
neuroinvasion by human immunodeficiency virus (HIV)-1.  As well as referring to a virus in a 
different family, the relevant section in the paper by Kramer-Hammerle et al. on paracellular 
diffusion across the BBB lacked any referencing [63].  Clark et al. [2] cited reference [51].  While 
this study investigated the role of Toll-like receptor (TLR)-3 and its downstream cytokines in WNV 
neuropathogenesis, it did not directly demonstrate cell-free virion migration across BBB via the 
paracelluar junction.  It was only hypothesised [51]. 
While the notion of passive diffusion across a permeabilised BBB is conceptually possible, in light 
of the lack of evidence, this hypothesis of neuroinvasion requires further investigation.  Until solid 
evidence is produced to show serum-derived cell-free virions diffusing across the endothelial 
junctions of the BBB, this hypothesis should be mentioned with caution.  Also while many in vivo 
studies concluded that there is a correlation between BBB disruption and WNV infection of the 
brain, the direction of this potential causal relationship is unclear.  Studies such as that by Roe et al. 
[54] showed that the timing of increased BBB permeability does not precede viral neuroinvasion.  
Indeed, WNV infected neurons are capable of producing pro-inflammatory cytokines, such as IL1β, 
IL6, IL8 and TNFα, in vitro, which may disrupt the BBB [64].  So perhaps the post-infection 
permeability changes in the BBB may only be a result of an initial viral neuroinvasion via one of 
the other routes [65], such as the transneural option (see Section 1.3.2).  This ultimately questions 
the true relevance of the BBB permeability in the process of WNV neuroinvasion, especially if it 
may only be an effect rather than a cause of viral entry into the CNS. 
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1.3.1.4.2 Via a “Trojan Horse” mode of entry 
The “Trojan Horse” hypothesis, as proposed in many reviews [62, 66, 67] and primary studies [44, 
53, 68, 69], involves the trafficking of infected leucocytes across a permeabilised BBB, via the 
paracellular junction, into the CNS parenchyma.  Garcia-Tapia et al. [68] suggested that WNV 
infected Langerhan cells migrated from the site of inoculation to draining lymph node, where 
infection could then be relayed to mononuclear cells, such as monocytes and certain subsets of 
CD4
+
 lymphocytes.  As hypothesised from a later study, Garcia-Tapia et al. suggested that the 
expression of lymphocyte and monocyte chemoattractants, such as Interferon-gamma-inducible 
protein 10 (IP-10)/ C-X-C motif chemokine 10 (CXCL10) and monocyte chemoattractant protein-5 
(MCP-5)/ chemokine (C-C motif) ligand 12 (CCL12), respectively, in WNV infected brains, post-
footpad inoculation, could recruit peripheral mononuclear cells into the perivascular space in the 
CNS [28].  Here, the recruited leucocytes could produce pro-inflammatory cytokines, such as TNFα 
and interleukins, which as mentioned above could compromise the BBB integrity [28, 51].  Infected 
monocytes/macrophages and CD4
+
 lymphocytes could also facilitate productive viral replication in 
this region [68, 70], providing a source of infection for brain microvascular endothelial cells, which 
in turn may exacerbate the BBB permeabilisation via the degradation of inter-endothelial tight 
junctions and upregulation of CAM expression [44, 58].  Further recruitment, margination and 
transmigration of leucocytes across the paracellular junction of the BBB could result in viral 
neuroinvasion and dissemination [28].  
While this hypothesis could be drawn from findings compiled from multiple in vitro and in vivo 
studies, direct demonstration of WNV-infected leucocytes trafficking across the BBB could not be 
located in the literature.  Furthermore, the function and trafficking behaviour of WNV infected 
leucocytes have not been examined, as noted by King et al. [71] and Bielefeldt-Ohmann et al. [72].  
Therefore, further testing of this hypothesis is required.  Real-time fluorescent imaging techniques 
involving fluorescent reporters, such as mCherry (e.g. [73]) or dsRed (e.g.[74]) in  WNV infectious 
clones may provide new tools for demonstrating the behaviour of these infected leucocytes in vitro 
and in vivo. 
1.3.2 Transneural route of neuroinvasion 
Transneural invasion of the CNS by WNV is an emerging area of investigation.  As compared to the 
literature available on the haematogenous mechanism of neuroinvasion, the number of studies that 
investigated the hypothesised transneural mechanism is under-represented.  Overall, two 
neuroanatomical areas have been hypothesised to be involved in this mechanism: 1) from the 
peripheral somatic nerves into the CNS, or 2) from the olfactory nerves into the CNS. 
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1.3.2.1 From peripheral nervous system (somatic nerves) to central nervous system 
Through direct injection of WNV inoculum into the sciatic nerve, investigators have shown that 
transneural spread of the virus from the peripheral nervous system (PNS) to the CNS could be a 
putative route for neuroinvasion [75, 76].  Both studies utilised a direct intrasciatic nerve 
inoculation model in hamsters to demonstrate viral antigen in the spinal cord post-inoculation.  
Wang et al. [76] specifically noted that WNV appeared to travel preferentially up motor nerves 
rather than sensory by their observation that WNV antigen was present in only the motor neurons, 
rather than the dorsal root ganglia.  In vitro experiments showed that intact axons were required for 
intra-neuronal spread and transmission of virions between neurons appeared to be via transfer 
across synapses [75]. Compartmentalised neuron methods also showed that bidirectional spread of 
WNV was possible [75].  Samuel et al. [75] speculated that the anterograde axonal transport would 
play a role in disseminating the virus across the nervous system.   
However neither study investigated brain viral load or pathology following intrasciatic nerve 
inoculation [75, 76].  This potentially questions the ability of this model to demonstrate the 
complete transneural transport of WNV to the brain.  Moreover, the sciatic nerve contains a mixture 
of sensory and motor fibres [77].  Delineation between the sensory and motor pathway was only 
achieved by indirect means in the study by Wang et al. [76].  For conclusive evidence that WNV 
does indeed preferentially escalate up the motor nerve fibres, double immunolabelling of 
sensory/motor nerves and WNV antigen with specific anti-sensory or motor nerve antibodies, such 
as anti-CV2 [78] for sensory nerve fibres, at an appropriate time-point post-infection is needed.  
Moreover, WNV infection of the autonomic nervous system in hamsters further highlights a 
potentially broader tropism than just motor neurons [79]. 
Studies of other well-characterised neurotropic viruses, such as rabies virus and herpes simplex 
virus, suggested that molecular investigation into the involvement of the intracellular dynein and 
kinesin motor system in retrograde axonal transport may help advance the understanding of the 
transneural route of WNV neuroinvasion.  Brault et al. has already noted an interaction between the 
ectodomain of the WNV membrane protein (ectoM) and Tctex-1, a light chain on the human dynein 
protein, during late stage viral replication [80].  While the neuroinvasive aspect of this ectoM-
Tctex-1 interaction was not the focus of the study, the interaction appeared to be important for 
internal transport of viral particles within infected cells [80].  The relevance of ectoM for WNV in 
retrograde axonal transport should therefore be investigated further in vivo, especially when 
suggestive observations of this route of neuroinvasion are emerging from studies using WNV foot-
pad challenge [27, 69, 81]. 
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1.3.2.2 From olfactory nerve to olfactory bulb 
As evident in a few in vivo challenge studies using neurotropic flaviviruses inoculated by either an 
intraperitoneal [82], subcutaneous (footpad) [27] or intranasal [83] route, the initial detection of 
viral antigen in the brain began in the olfactory bulb.  As suggested from the sequential distribution 
of viral antigen along the olfactory pathway, a general hypothesis of the olfactory route of 
neuroinvasion has been proposed for flaviviruses. 
In some studies using footpad inoculation, viraemia preceded the initial appearance of viral antigen 
in the olfactory bulb [27, 84].  This suggested a potential haematogenous source of infection, likely 
initiated at the level of the olfactory neuroepithelium, which contains fenestrated blood vessels [85].  
But the point of entry at this level is still controversial.  Monath et al. [82], in a study that is 
commonly cited in WNV literature, suggested that St. Louis encephalitis virus (SLEV) traversed 
from the dendrites of the bipolar olfactory neurons in the olfactory neuroepithelium.  However, 
detection of flaviviral antigen in the olfactory neuroepithelium was not common [86].  When viral 
antigen was present, the results were often biased, due to the use of an intranasal route of 
inoculation [83].  Inconsistent sampling of the olfactory neuroepithlium in challenge studies was 
another source of potential bias. 
While the initial site of virus entry remains elusive, the rostral-caudal spread of flaviviral antigen, 
and specifically for WNV, from the olfactory bulb to the remaining structures of the brain has been 
documented in a few studies [27, 83, 84].  This was observed by mapping the sequential distribution 
of viral antigen in brains of infected animals terminated at various time points [27, 83, 84].  Since 
trans- and inter-neuronal spread was possible across synapses, as demonstrated in vitro with WNV 
[75], viral dissemination along the brain neural circuits after olfactory bulb invasion may explain 
the temporal pattern of virus distribution, as suggested by McMinn et al. for Murray Valley 
encephalitis virus (MVEV) [84]. 
However, on analyzing the data in a selection of these studies, the increased spread of viral antigen 
across the brain occasionally coincided with a concurrent persistent viraemia (e.g. [84]).  This 
viraemia may have provided an additional source for virus entry into the various parts of the brain 
over this period, and may have therefore confounded the apparent intra-cranial dissemination of 
virus.  To further support this interpretation, when concurrent viraemia was not persistent or 
negligible, as in the case of mice infected with the attenuated BHv1 strain of MVEV [84], the viral 
infection was confined to just the olfactory lobe, and intra-cranial dissemination was halted.  Again, 
real time fluorescence imaging techniques may provide a novel tool for investigating the movement 
of tagged viral particles post-invasion into the olfactory bulb and elsewhere in vivo. 
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Lastly, report of WNV antigen in the olfactory lobes in horses and humans is rare.  Viral antigen 
was primarily observed in mid to hindbrain and spinal cord in horses and humans [49, 87].  
However, post-mortem examination was often conducted on cases that were already showing 
symptoms, at which time initial viral neuroinvasion into the olfactory bulb may not have been 
captured.  Inconsistent sampling of the olfactory bulb in these hosts may also lead to under-
reporting of viral antigen in this region.  Therefore, the relevance of this route of neuroinvasion in 
incidental hosts remains unknown. 
1.3.3 Multiple routes of neuroinvasion 
Drawing together the conclusions from the above in vivo and in vitro studies, the route of WNV 
neuroinvasion may be much more complex than one distinct path from the peripheral site of 
inoculation to the CNS.  Hence the hypothesis of multiple routes of neuroinvasion has been 
proposed [27, 54, 69].  In these studies, suggestive signs of utilisation of more than one route were 
observed.  Brown et al. [27] noticed the sites of initial WNV neuroinvasion occurred in both the 
olfactory bulbs and spinal cord, following footpad injection in mice.  This might imply transneural 
CNS invasion via both the peripheral somatic nerve, ending in the spinal cord, and the olfactory 
nerve, ending in the olfactory bulb.  Similarly, Hunsperger et al. [69, 81] hypothesised that WNV 
utilised axonal retrograde transport to gain entry into the spinal cord and brainstem early in the 
course of the infection.  But they also hypothesised the involvement of the blood-CSF barrier in the 
choroid plexus in neuroinvasion, though the validity of this particular point of the study can be 
challenged (see Section 1.3.4) [69, 81].  Finally, Roe et al. observed a biphasic pattern of WNV 
CNS infection [54].  They detected an initial viral entry without compromising the BBB, followed 
by a second wave of CNS re-infection, possibly achieved by the “Trojan Horse” mode of 
neuroinvasion [54].   While the studies mentioned above concluded with different interpretations, 
they have nevertheless observed some signs indicative of multiple points of WNV entry into the 
CNS.  Indeed, the traditional question of which singular route is responsible for viral neuroinvasion 
should now be reconsidered and expanded to which multiple routes are involved. 
1.3.4 New avenues for research 
While the focus of many WNV pathogenesis studies has been directed mainly at the BBB and the 
transneural transport theories, there remain several routes of viral entry into the CNS that have 
received little attention.  In the brain, the role of the blood-CSF and the CSF-brain barriers in WNV 
neuroinvasion is unknown.  In fact, the “BBB” have occasionally been inaccurately used to describe 
the blood-CSF barrier [88] and the arachnoid (meningeal) barrier [54].  This indicates a lack of 
consensus in the interpretation of the term “blood-brain barrier”.  A distinction of the different 
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barrier mechanisms in the CNS is important, since there are some significant differences that may 
determine the success or failure of viral neuroinvasion (Table 1-3). 
The main distinction between the BBB proper and the other barrier mechanisms is the presence of 
the support cells surrounding the former, suggesting a functionally more complex barrier in the 
blood-brain interface in the cerebrum.  The difference in the components of the barriers may also 
imply a difference in the susceptibility to breakdown.  In fact, the arachnoid (meningeal) barrier has 
been shown to be the first barrier to be disrupted four hours post-intracisternal injection of IL1β and 
lipopolysaccharide (LPS) in rats [89].  The blood-CSF barrier of the choroid plexus and the BBB 
were not affected within the time frame of the study [89].  The significance of the arachnoid 
(meningeal) barrier in relation to viral neuroinvasion has not been explored. 
 
Table 1-3  Characteristics of the different barrier mechanisms in the brain 
Barriers Blood-brain 
(neurovascular 
unit) 
Blood-CSF 
(ventricular 
system) 
Blood-CSF 
(arachnoid/ 
meningeal) 
Inner CSF-
brain 
Outer CSF-
brain 
Anatomical 
location 
Cerebral blood 
vessels 
Choroid 
plexus & CVO 
blood vessels 
Dural +/- pial 
blood vessels 
Ependyma of 
the ventricular 
system 
Pia mater 
Cellular 
components 
 Endothelial 
cells (non-
fenestrated) 
 Pericytes 
 Astrocytes 
 Microglia 
 Neurons 
 Endothelial 
cells 
(fenestrated) 
 Epithelial 
cells of 
choroid 
plexus 
 Tanycyte-
like cells of 
CVO 
 Endothelial 
cells 
(fenestrated 
dural 
vessels) 
 Arachnoid 
epithelial 
cells 
 Neuro-
ependymal 
cells (the 
ventricular 
system) 
 Glial foot 
processes 
 Pial 
epithelial 
cells 
Restriction 
point 
Endothelial cells 
(tight junction)  
Epithelial & 
tanycyte-like 
cells (tight 
junction) 
Arachnoid 
epithelial cells & 
pial blood vessel 
endothelial cells 
(tight junction) 
Neuro-
ependymal 
cells (strap 
junction, only 
in immature 
brains) 
Glial foot 
processes 
(various 
junctions, only 
in immature 
brains) 
CVO, circumventricular organs.  This table is a synthesis of several reviews [90-95] 
However, the meninges constitute a complex region.  The following interfaces are present in the 
meninges: 
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1. A blood-CSF barrier at the level of the outer arachnoid layer (Figure 1-2) (e.g.[89, 94]). 
2. A blood-brain interface in the pial microvessels (Figure 1-2) [92]. 
3. A hypothetical blood-CSF interface in the pial blood vessels (Figure 1-2).   
4. An outer CSF-brain interface in the pia mater (Figure 1-2) [91].   
Of the above interfaces, only the first and occasionally the second were referred to as the arachnoid 
(meningeal) barrier, even though pial microvessels are not situated in the arachnoid  (Figure 1-2).  
The pia mater, with the glial foot processes underneath, forms the outer CSF-brain barrier, which is 
only impermeable in the immature brain [91].  There is no report of a blood-CSF interface at the 
level of the pial blood vessel.  But it is a possible interface given its proximity to the subarachnoid 
CSF (Figure 1-2).  Such complex architecture of the meninges creates challenges in interpreting 
findings from studies involving this region, such as that by Ichikawa et al. [89].  Precise attention to 
the separate interface should be attempted, as the significance of each interface will be different 
given the different cell types involved.  But despite this, the meninges represent a convergence 
point of several interfaces.  Because of this, a unique interaction may be present between them.  
Whether this interaction generates an environment conducive for viral neuroinvasion remains to be 
determined. 
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Figure 1-2 The different barrier mechanisms in the meninges. The meninges consists of the 
dura, arachnoid, subarachnoid and the pia mater.  (*) Pial blood vessels differ from cerebral blood 
vessels in two regards.  The former lacks astrocytic ensheathment that is observed in the latter [96].  
Tight junctions between pial endothelial cells are also different [96].  So the “blood-brain barrier” in 
this region differs from the BBB proper in the cerebrum.  (#) A blood-CSF interface possibly exists 
between pial blood vessels and CSF in the subarachnoid.  But no information can be found on this 
hypothetical interface.  This diagram has been constructed based on information collected from [89, 
91-94, 97].  
While little is known about the involvement of the arachnoid (meningeal) barrier in viral 
pathogenesis, the blood-CSF barrier in the choroid plexus has received some attention in simian 
immunodeficiency virus (SIV) [98] and  highly pathogenic avian influenza virus (H7N1) research 
[99].  Both studies have highlighted virus entry via this route is possible, either by a “Trojan horse” 
method [98] or a direct involvement with cell surface receptors of the choroid plexus epithelial cells 
[99].  For WNV, one research group has suggested the involvement of this barrier [69, 81].  But 
their observation of WNV antigen in the nuclei of choroid plexus epithelial cells should be 
interpreted with caution, especially when immunohistochemistry was performed using a polyclonal 
primary antibody [69].  One cannot exclude the possibility of non-specific staining artifact in this 
case, especially when details of control sections used were not outlined in the publication.  
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Nevertheless, the choroid plexus contains fenestrated blood vessels with restriction points only at 
the level of the choroid plexus epithelium, and therefore is a theoretically possible route for viral 
neuroinvasion [90].  A recent investigation of the circumventricular organs has led to the detection 
of a blood-CSF barrier in association with the fenestrated blood vessels in these regions [95].  The 
barrier consists of a specialised type of ependymal cells, named tanycyte–like cells, held together by 
tight junctions [95].  Once perceived as a free exchanging area of CSF and blood, this barrier in 
CVOs may now open a new avenue for viral neuropathogenesis investigation. 
In the literature, the CSF-brain interface has been broadly split into two barriers: inner and outer 
CSF-brain barrier (Table 1-3).  An age—related permeability difference in these barriers has been 
suggested by Saunders et al. [91].  This is an interesting note, since it suggests that depending on 
the age of the animal, viruses that have successfully passed into the CSF from the blood, for 
example SIV as mentioned above, may not necessarily enter the brain parenchyma [91].  
Implications of this dynamic behaviour of the CSF-brain barrier on viral neuroinvasion have not 
been examined, even though an age-related difference in susceptibility has been observed for WNV 
infection in mice (e.g.[100, 101]).  Furthermore, the pial membrane, which is part of the CSF-brain 
interface, is also not a completely uninterrupted membrane lining the outer surface of the neural 
axis [97].  Fenestrations have been detected by scanning electron micrograph at the conus 
medullaris and the nerve roots in the spinal cord [97].  These findings present another set of 
potentially vulnerable points of entry for neurotropic viruses, such as WNV. 
In fact, apart from investigations into the transneural hypothesis of neuroinvasion, the spinal cord 
has been a largely neglected topic in WNV neuropathogenesis research.  But there are some 
important distinctions in this region as compared to the brain.  The blood-spinal cord barrier 
(BSCB) is a good example.  While the BSCB shares the same cellular components as the BBB, 
emerging evidence indicates that it is more permeable than the BBB proper, potentially due to the 
lower number of pericytes [102] and/or the expression of different junctional proteins between 
endothelial cells in the BSCB  [103].  Cytokines, such as IFNs and TNFα, which can be neurotoxic 
(e.g.[64, 104]), have also been reported to diffuse across the BSCB more readily than the BBB 
[103].  This potentially implies that neuropathology in the spinal cord can be instigated without the 
need for viral neuroinvasion, if neurotoxic cytokines can diffuse into the neuropil from a 
haematogenous source, such as during an episode of cytokinaemia.  Indeed, this example of the 
BSCB emphasises the need for a better delineation of the role of the spinal cord in the 
neuropathogenesis of WNV.  
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Overall, there are some major gaps in the current knowledge of how WNV enters the CNS.  As 
indicated in this section, it may be time to consider switching the current research focus away from 
the popular areas, such as the BBB, and towards the unexplored avenues. 
1.3.5 Molecular determinants for WNV neuroinvasion 
Historically, WNV mainly manifested as a febrile disease, termed West Nile fever, in humans 
[105].  Since the mid-1990’s, larger WNV outbreaks with more severe neuroinvasive cases have 
been reported in humans globally [15].  This also coincided with an increase in morbidity and 
mortality in equine and avian species [15, 105].  Several studies have characterised the evolution of 
the WNV genotype, particularly strains in lineage 1 and 2 [106, 107].    A consistent shift in both 
lineage 1 and 2 WNV strains to a more neuroinvasive phenotype appeared to have taken place 
[107].  Extensive efforts into locating virulence determinants in lineage 1 strains are summarised in 
Table 1-4.  For lineage 2 strains, amino acid positions 159 for E, 338 for NS1, 126 for NS2A, 421 
for NS3, 20 for NS4B and 254 for NS5 appeared to be important regions that differentiated 
attenuated and virulent strains [107].   
However, the mechanism of these virulence determinants is often unclear.  Factors unrelated to viral 
neuroinvasion, such as systemic illness, were also frequently not assessed or reported.  This has 
great implications in lethality studies, especially when peripheral disease in vital organs such as the 
heart has been reported in humans, birds and horses [49, 108-113].  The contribution of WNV 
induced extraneural disease to mortality has not been well defined.  Furthermore, brain viral load 
does not necessarily correlate to the overall mortality and vice versa.  This has been demonstrated 
by Appler et al. [114] where WNV persistence in both CNS and peripheral tissue was observed in a 
surviving subset of WNV challenged mice.  Conversely, in horses succumbing to WNV-infection, 
viral antigen was mostly undetectable or of low magnitude in the brain, despite mortality 
(Bielefeldt-Ohmann et al., 2016, and unpublished data) [49].  So while the determinants listed in 
Table 1-4 may be important for causing mortality in mice, their role in WNV neuroinvasion in 
humans and horses remains unknown. 
Some efforts have been placed in characterising the viral factors specifically for the mechanism of 
WNV neuroinvasion.  Table 1-5 provides a summary of the current understanding of these potential 
determinants, particularly via their role in interacting with the host cell surface for cellular uptake, 
or intracellular proteins for intracellular trafficking, immune evasion, instigating neuroinflammation 
or breakdown of junctional proteins.  However, as compared to other important neurotropic viruses, 
such as rabies virus, the characterisation of the viral mechanism(s) for WNV neuroinvasion is only 
at its infancy.  
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Table 1-4 Summary of WNV lineage 1 in vivo virulence determinants in naturally occurring strains of lineage 1 and in artificially engineered 
variants (e.g. NS1 glycosylation mutants, NS4B mutants) 
Region Position (amino 
acid/nucleotide) 
Mutation studied Effect on in vivo 
virulence 
WNV strain Citations 
prM 141#
 
Isoleucine Threonine Attenuation (birds) NY99 & TM171-03-pp1 
(Mexico) 
[115] 
E 
 
 
Whole prM-E prM-E of ETH76a inserted into NY99 backbone Attenuation (mice) ETH76a & NY99 [116] 
Glycosylation Motif (154-
156)
 
AsparagineSerine (154)$ Attenuation (mice) NY99 [117] 
  SerineProline (156)# Attenuation (birds) NY99 & TM171-03-pp1 
(Mexico) 
[115] 
NS1 250 ProlineLeucine Attenuation (mice) Kunjin [118] 
  Glycosylation sites (130-2, 
175 & 207)
$ 
Asparagine Serine/Glutamine/Alanine (130-2); 
AsparagineAlanine (175 & 207) 
Attenuation (mice) NY99 (382-99) [117, 119] 
NS1’ & 
NS2A 
Frameshifting motif (NS2A) Silent mutation Partial attenuation 
(mice) 
Kunjin [120] 
  30 AlanineProline Attenuation (mice) Kunjin [120, 121] 
NS3 Helicase domain (249) ThreonineProline Enhanced virulence 
(birds) 
KN-3829 (Kenyan) & 
NY99 (382-99) 
[122] 
NS4A (and 
2K) 
2K protein (9) ValineMethionine Enhanced virulence 
(mice & birds) 
North American (Texas 
2003 & NY 2002 & 1999) 
[123-125]  
NS4B 38 &166 ProlineGlycine (38); ThreonineIsoleucine (116) Attenuation (mice) NY99 [126, 127] 
  249 GlutamateGlycine at 249 Attenuation (mice & 
bird) 
North American (Texas 
2003 & NY 2002 & 1999) 
[125, 128, 
129] 
5’UTR 50-52@
 
NY99’s 5’UTR substitutes KUN’s Enhanced virulence 
(mice) 
Kunjin & NY99 [101] 
#
 these two prM and E mutations work in conjunction; 
$
 these two E and NS1 mutations work in conjunction; 
@
 nucleotide positions;  amino acid substitution 
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Table 1-5 Summary of virus determinants relevant for WNV neuroinvasion 
Region Position (amino acid/nucleotide) Mutation studied Effect of mutation In vivo/ vitro WNV strain Citations 
C Unknown N/A Immune evasion In vitro NY99 [130] 
Unknown N/A Neuroinflammation  In vivo (rats) NY99 [131] 
Unknown N/A Tight junction protein degradation In vitro NY99 (385-99) [55] 
prM/M ectoM domain N/A Interacts with Tctex-1 In vitro IS-98-ST1 & other 
flaviviruses  
[80] 
E αA’ structure (156-160) [domain I] N/A Affinity to DC-SIGN/DC-SIGNR  In vitro NY99 and Egypt [45] 
RGD motif [domain III] N/A Interacts with cellular integrin In vitro Sarafend & DEN-2 
(New Guinea) 
[132] 
NS2A 30 Alanine Proline Reduction in immune evasion via IFNβ 
and unknown antiviral pathway 
In vitro & in 
vivo (mice) 
Kunjin [121] 
NS3 NTPase domain (365) SerineGlycine Immune evasion via resistance to 2’,5’-
OAS1b 
In vitro NY99 (382-99) [123] 
NS4B 22 & 24 N/A Immune evasion by inhibiting IFN 
cascade 
In vitro Subgenomic WNV 
replicons (without 
structural genes) 
derived from KUN 
[133] 
38 &166 ProlineGlycine at 38; 
Threonine  Isoleucine 
at 116 
Attenuation in neuroinvasiveness (mice) 
by enhanced IFN and T cell response 
(only residue 38) 
In vivo NY99 [126, 
127] 
NS5 653 SerinePhenylalanine Immune evasion by inhibiting JAK-
STAT pathway 
In vitro Kunjin [134] 
 amino acid substitution; N/A no mutation was investigated 
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1.4 Mechanism of virus control 
The process of host control of WNV replication and dissemination involves a well-orchestrated 
sequence of molecular pathway activation in a number of important immune cells.  The innate and 
adaptive immune responses against WNV have been investigated extensively using in vitro and 
wild-type and genetically modified mouse models (e.g. [135, 136]).   
1.4.1 Molecular basis of innate immunity against WNV 
In vitro experiments have shown that the initial detection and restriction of WNV replication 
involves the detection of double-stranded RNA replication intermediates by pattern recognition 
receptors (PRRs) such as TLR-3, retinoic acid-inducible gene (RIG)-I and melanoma 
differentiation-associated protein 5 (MDA5) [137] (Figure 1-3).   Involvement of TLR-7 is also 
possible via the direct stimulation from the single-stranded RNA of the virus, itself [138] (Figure 
1-3).  DNA-sensing PRR, cyclic GMP-AMP synthase (cGAS), has also been reported to be 
upregulated during WNV replication, though mechanism of this remains uncertain [139]. 
Activated RIG-I and MDA5 signal via MAVS and IRF3 to induce IFN-I production, whereas TLR-
3 and TLR-7 signal via IRF3 and/or IRF7 in a cell-specific manner [66, 136, 138, 140].   
Specifically, the IRF3- and IRF7-induced IFN-I responses are important for restricting viral 
replication in the nervous system, whereas IRF7 and not IRF3 is required for virus-induced IFN-I 
response in dendritic cells and macrophages [66].  This highlights the importance of cell- and 
tissue-specificity of virus control mechanisms. 
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Figure 1-3 Schematic diagram of the induction of IFNα/β and ISGs during WNV infection. 
dsRNA, double-strand RNA; ssRNA, single-strand RNA; RIG-I, retinoic acid-inducible gene-I; 
MDA5, melanoma differentiation-associated protein 5; TLR, Toll-like receptor; IRF, interferon 
regulatory factory; MAVS, mitochondrial antiviral-signalling protein; IFN, interferon; IFNAR, 
IFNα/β receptor; JAK, janus kinase; STAT, signal transducer of transcription; ISG, interferon-
stimulated gene. Adapted from [66, 139]. 
 
The expressed IFN-I then induces, in an autocrine and paracrine fashion, further expression of IFN-
I and antiviral effectors, such as interferon stimulated genes (ISGs), via first the IFN-alpha-receptor 
(IFNAR), then JAK-STAT signalling, with phosphorylation of STAT-1 and -2, and finally the 
translocation of the STAT1-STAT2-IRF9 transcription factor complex (collectively termed ISGF3 
complex) into the nucleus for transcriptional upregulation of ISGs [139] (Figure 1-3).  ISGs 
involved in direct antiviral actions against WNV replication in vitro and in vivo include Interferon-
induced proteins with tetratricopeptide repeats (IFIT)-1, IFIT2, viperin, RNase L, PKR, and  2 ',5 '-
oligoadenylate synthetase 1b (2’,5’-OAS1b), though  effectiveness of control by these molecules 
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may be virus-strain specific  [139, 141, 142].  ISGs that have been investigated in in vitro 
experiments, but requiring in vivo validation, include ISG20, MAFK, MCT4, NAMPT, PAK3, 
PHF15, SAMD9L, SC4MOL, C6orf150, DDX24, HPSE, IFI44L, IFI6, IFITM2, IFITM3, IFRD1, 
and IL13RA1, details of which have been discussed in the review by Lazear et al. [139].  
1.4.2 Cells involved in immunity against WNV 
The general innate immune response described above occurs in many lymphoid (macrophages, 
monocytes, microglial cells, dendritic cells) and non-lymphoid cell types (keratinocytes, dermal 
fibroblasts, astrocytes, neurons).  The adaptive immune responses are also mediated by a variety of 
T lymphocyte subtypes and B lymphocytes.  Many of these cells play a temporally coordinated and 
likely a tissue-specific role during control of WNV infection. 
1.4.2.1 Macrophages/monocytes 
Macrophages/monocytes are essential immune cells that play an important role in early control of 
WNV [143].  In particular, macrophages are present throughout peripheral tissues and may directly 
inhibit virus replication via the production of antiviral cytokines such as IFN-I or activate or shape 
the subsequent adaptive immune response.   
In the lymph node draining the site of inoculation, subcapsular macrophages are vital to limiting 
early WNV dissemination, since depletion of such cell population  in single cycle flavivirus 
(SCFV)-infected B6 mice led to the spread of virus particles to the spleen [143].  However, the 
authors claimed that this restriction was unlikely to be related to IFN-I production by the 
macrophages, since subcapsular macrophage-depleted mice had higher levels of serum IFN-I as 
compared to wild-type mice [143].  Furthermore, they suggested, based on this observation, that 
plasmacytoid dendritic cells may be more important producers of IFN-I [143].  However, direct 
IFN-I assay or IHC of downstream signalling molecules on the draining lymph node were not 
performed in that study, and serum IFN-I levels may not necessarily correlate with that in the lymph 
node and thus IFN-I production by the subcapsular macrophages [143].   Therefore, the role of IFN-
I production by subcapsular macrophages in limiting WNV dissemination cannot be dismissed and 
warrants further investigation.  Furthermore, other direct means of WNV control by macrophages, 
such as via nitric oxide production and other antiviral cytokines (e.g. TNFα), require 
characterisation. 
The authors in that same study also concluded that subcapsular macrophages present WNV antigens 
to T cells, but are not essential for inducing an antigen specific CD8
+
 T cell response or effector T 
cell function [143].  However, the limitations of the use of SCFV in this study were not discussed.  
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It is unknown whether appropriate virus replication is required for subcapsular macrophages to 
activate these T cell responses.  Therefore, whether this finding is representative of natural WNV 
infection remains unclear. 
Similar to tissue macrophages, monocytes in the peripheral blood may be essential sentinel cells for 
early detection of WNV, based on the detection of a notable IFN-I response in monocytes, purified 
from the peripheral blood mononuclear cells (PBMCs), and following WNV inoculation in vitro 
[144-146].   However, this response may be WNV strain specific [144].  The in vivo role of 
circulating monocytes in early defence against WNV has also not been thoroughly investigated.  
However, given that mosquitoes extract a blood meal from the vertebrate host during feed, a 
mosquito inoculum of WNV should interact with elements in the host blood (e.g. peripheral blood 
leucocytes) during the early phase of the host-virus interaction.  Therefore, the role of PBMCs, in 
particular monocytes, in the peracute phase of infection warrants further investigation. 
Inflammatory monocytes may also migrate into the CNS in response to neural virus infection [147, 
148].  However, there is conflicting evidence as to whether these monocytes provide protection or 
cause immunopathology [147, 148].  In particular, deficiency of CC chemokine receptor (CCR)-2 
on monocytes [147] or its ligand CC chemokine ligand (CCL)-2 [148] both yielded decreased 
number of monocytes in WNV-infected CNS, but resulted in either decreased  or  increased 
survival, respectively.  It is uncertain whether the difference in the results between the two studies 
was due to the different means in achieving the deficiency (antibody neutralisation vs genetic 
modification), or the difference in receptor or ligand deficiency, or the use of different WNV strains 
in the study (WNVSarafend vs WNVNY99). 
In the brain, the role of microglial cells in limiting early flaviviral neuroinvasion and replication in 
the CNS has been demonstrated in vitro and in vivo [149, 150].  Using ex vivo WNV-inoculated 
slices of murine spinal cord, Quick et al. identified that microglial cells became activated and 
played an important role in phagocytosis of WNV-infected neurons and astrocytes [149].  Several 
chemokines (e.g. CXCL10, CXCL1, CCL5, CCL3, and CCL2) and cytokines (e.g. TNFα, TRAIL 
and IL6) were upregulated during microglial cell activation [149].  These responses are also 
observed in in vitro infected microglial cells [151].   In vivo evidence also exists for the role of 
microglial cells in clearing WNV-infected neurons.  When sterile alpha and HEAT/Armadilo motif 
(SARM), a highly conserved Toll/interleukin-1 receptor-containing adaptor protein expressed 
specifically in CNS cells, was genetically knocked out in  C57BL/6 mice, microglial cell activation 
was decreased post-WNV infection, corresponding to higher neuronal death and mouse mortality 
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than seen in wild-type mice [150].  However, while microglial cells may be important for control of 
WNV infection in the CNS, they have also been implicated in neurocognitive diseases post-
recovery of initial WNV insult, via synaptic remodelling in the hippocampus [152].  Furthermore, 
in the study by Getts et al., CNS-infiltrating inflammatory monocytes developed a “microglial 
phenotype”, and it has been proposed that these monocytes/microglial cells may play a potential 
role in mediating immunopathology in the CNS, since neutralisation of monocyte attractant 
chemokine CCL2 led to reduced monocyte/microglial cell number in WNV-infected mice, and 
prolonged life of infected animals [148].  However, whether CNS-infiltrating inflammatory 
monocytes truly develop into and replace/contribute to the resident microglial cell population 
remains a matter of intense debate [153].  It has been demonstrated that during neuroinflammation 
the pool of microglial cells is expanded, but it remains highly debated whether this expansion is due 
to CNS-infiltrating monocytes developing into microglial cells or due to the expansion of the local 
resident microglial cell pool [153].  A recent study has named the myeloid derived CNS-infiltrating 
monocytes “monocyte-derived macrophages”, since the study has shown that these cells, instead of 
replacing resident microglial cells, act to provide fast-acting protection in the CNS before resident 
microglia can timely respond to the insult [154].  Further in vivo studies are required into the exact 
role of monocyte-derived macrophages and resident microglial cells during WNV infection. 
1.4.2.2 Dendritic cells 
Dendritic cells are characterised as either myeloid or plasmacytoid.  Myeloid dendritic cells (mDCs) 
are present in many tissue types, particularly in sites interacting with the external environment, and 
in circulating blood, phagocytosing antigens for transportation and presentation to B and T cells in 
lymphoid organs, as well as regulating T cell immunity and tolerance [155]. Plasmacytoid dendritic 
cells (pDCs) on the other hand lack phagocytic functions, are located in peripheral lymphoid organs 
and in circulating blood, and are potent producers of IFN-I [156].  Both types of dendritic cells play 
major roles in WNV control [157].  Specialised mDCs in the skin, Langerhans cells (LCs), have 
been observed to migrate to the draining lymph node from the skin, after cutaneous WNV infection 
via an IL1β mediated process [158].  This process may be important for transporting and presenting 
WNV antigens to lymph node T cells [158].  mDCs may also control virus replication locally via 
production of IFN-I, though this appears to require WNV to replicate in these cells, the kinetics of 
which may be strain specific [144, 157].  In contrast to mDCs, pDCs can produce IFN-I 
independent of WNV replication, via direct engagement and activation of TLRs [157, 159].   
Therefore, pDCs may also play an important role in controlling early WNV infection. 
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1.4.2.3 Polymorphonuclear leucocytes 
Polymorphonuclear leucocytes (PMNs) are often the first leucocytes to be recruited to a site of 
inflammation [160, 161].  However, one study showed that acquired depletion of PMNs in C3H 
mice before WNV infection resulted in lower viraemia on day 2-3 pi and increased survival relative 
to control (non-depleted mice), suggesting that the lack of PMNs at the time of infection is 
beneficial [162].  The authors concluded that the presence of PMNs during the early phase of 
infection may be facilitating virus replication and dissemination, rather than providing protection 
[162].  The same study also showed that depletion of PMNs on day 1 and 2 pi with WNV resulted 
in worse outcomes than untreated mice, and concluded that PMNs are important for protection at 
later stages of the infection [162].  However, the survival percentage (ranging from 0 to ~25%) and 
viraemic levels of the control groups used for these survival experiments were notably inconsistent 
between the experiments [162].  These inconsistencies invariably affect the comparison between 
animals depleted of PMNs before or after WNV inoculation against the controls, and may place 
questions on the model.  So far, this study is the only investigation into the role of PMNs in WNV 
pathogenesis.  The role of PMNs in controlling other important infections such as influenza virus 
and some herpesviruses have been amply demonstrated [160, 163, 164]. Therefore, further 
investigations into the role of this important early phase immune cell in WNV replication and 
control are required.   
 
1.4.2.4 Natural Killer cells 
Natural Killer (NK) cells are an important part of the innate immune response against pathogens, 
since they respond in an antigenically non-specific manner [165].  They achieve direct cytolysis of 
target cells by secretion of perforin and granzymes, and are potent producers of IFNγ, especially in 
the presence of IL12 [165].  Their cytolytic functions, proliferation and IFNγ production are also 
regulated by a wide range of cytokines, including IFNα/β [165, 166].  
The role of NK cells in controlling WNV infection has been investigated in vitro [167] and in vivo 
[168].  However, conflicting findings are observed between in vitro and in vivo experiments.  In 
particular, NK cells isolated from brains of WNV-infected CBA/H mice were shown to be able to 
lyse in vitro grown WNV-infected and uninfected cells [167], but depletion of NK cells in vivo in 
C57BL/6 mice, by using antibody against NK1.1 and genetic modification, showed that NK cells 
are not essential for survival after WNV infection, since similar mortality, morbidity and viral load 
were observed regardless of the number of circulating NK cells in the mice [168].  Furthermore, in 
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vitro WNV-infected astrocytes are resistant to cytolysis by NK cells [167].  Therefore, NK cells 
may not be a major contributor to the clearance of WNV-infected neural cells, unlike CD8
+
 T cells 
(see below).  However, the role of NK cells in supporting a competent and appropriate innate and 
adaptive immune response against various strains of WNV remains unclear. 
NK cells have recently been classified as cytolytic innate lymphoid cells  (ILCs)[165].  Non-
cytolytic ILCs also exist and are functionally similar to T helper cells, though unlike T helper cells, 
ILCs lack antigen specificity due to the lack of expression of somatically rearranged antigen 
receptors [165].  The role of non-cytolytic ILCs in WNV immunity has not been investigated. 
1.4.2.5 T cells 
T lymphocytes are important immune cells that play vital roles in innate immunity (γΔ T cells) and 
adaptive cell-mediate immunity (αβ T cells).  The latter includes CD8+ and CD4+ T cell-mediated 
response. 
1.4.2.5.1 γΔ T cells 
γΔ T cells are early effector cells that can respond rapidly to pathogens without the need for 
conventional antigen processing and binding to MHC molecules, though likely in a tissue-specific 
manner [169-171].  Their widespread distribution in mucosal sites suggests that they play an 
important role in innate mucosal immunity [170].  Also similar to NK cells, γΔ T cells are potent 
producers of IFNγ, along with TNFα and IL17 [169, 172].  In fact, the production of these cytokines 
by this cell type has been shown to be important in controlling WNV infections in mice [35, 41].  
Adoptive transfer experiments of IFNγ producing or deficient γΔ T cells into TCRΔ knockout mice 
identified higher viraemia and brain viral load in the latter after WNV infection [35].  γΔ T cells 
may also control WNV infection in spleen via cytolysis, since the lower levels of perforins in 
splenic T cells in TCRΔ knockout mice correlated with the worse outcomes in these mice relative to 
wild-type control [35].  The study did not identify whether the T cells with lower perforin 
expression were γΔ- or αβ-T cells [35].  However, in a later review, the authors proposed that γΔ T 
cells modulate the cytolytic activity of CD4
+
 T cells in the spleen during WNV infection, though 
the findings were unpublished [173].  γΔ T cells are also required to form an appropriate CD8+ 
memory T cell response, since adoptive transfer of CD8
+
 T cells from TCRΔ knockout mice that 
survived primary WNV challenge failed to provide protection against lethal WNV infection [41].  
Therefore, γΔ T cells are important immune cells that link and modulate the innate and adaptive 
immune response against WNV infection. 
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1.4.2.5.2 αβ T cells 
Extensive studies have been conducted into the role of CD8
+
 and CD4
+
 T cells in controlling WNV 
infection [36, 174-176]. 
1.4.2.5.2.1 CD8+ T cells 
CD8
+
 T cells have been shown to be needed for control of WNV infection in the CNS. Specifically 
primary or memory CD8
+
  T cells are needed to eliminate WNV infected neurons that present WNV 
antigens on MHC-I molecules [36].  Using knockout mouse models and observing the resultant 
survival, this cytotoxic mechanism appeared to require perforin [168], Fas ligand [177], or TRAIL 
[178], which may be modulated by the MDA5 adaptor [179].  IRF-1 signalling may also shape the 
CD8
+
 T cell response [180].  CD8
+
 T cells isolated from in vivo WNV-infected mouse brains 
produced IFNγ and TNFα when co-cultured in vitro with WNV-infected cells [181], suggesting 
these cytokines are important for virus control in the CNS.  However, CD8
+
 T cells have also been 
implicated in causing immunopathology in the CNS, since infection of CD8
-/-
 mice with a high dose 
of WNVSarafend
 
resulted in increased survival [182].  The suggested mechanism might involve 
increased death of WNV-infected neurons caused by activated CD8
+
 T cells in wild-type mice 
[182].  However, this detrimental effect was not observed in CD8
-/-
 mice infected with a low dose of 
WNVSarafend, highlighting that this proposed mechanism of immunopathology may be dose-
dependent and possibly WNV strain specific, since demonstration of this detrimental aspect of 
CD8
+
 T cells have not been observed in other mouse studies using different WNV strains (e.g., 
NY99) [36].   
1.4.2.5.2.2 CD4+ T cells 
Using genetic and acquired deficiency techniques, CD4
+
 T cells have been identified as important 
cells for maintaining a sustained CD8
+
 T cell response in the CNS for WNV clearance [176].   
CD4
+
 T cells are also important for inducing a robust humoral response [176].  When mice were 
deficient in CD4
+
 T cells, immunoglobulin (Ig)-G levels were significantly lower than those of 
wild-type mice early in the infection, while IgM levels were decreased only later in the infection 
course [176].  Nevertheless, this influence of CD4
+
 T cell deficiency on the kinetics of antibody 
production did not affect serum and splenic viral load [176].  This may be highlighting the 
importance of the presence of early IgM in restricting peripheral viral load, as suggested in [34].  
Apart from their role in supporting CD8
+
 T cell and humoral responses, a direct protective role of 
CD4
+
 T cells independent of CD8
+
 T cells or B cells have been demonstrated, using adoptive 
transfer experiments of naïve CD4
+
 T cells in recombination activating gene (RAG)
-/-
 mice [175].  
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CD4
+
 T cells isolated from spleen of WNV-infected mice were also shown to have upregulated 
expression of IFNγ and granzyme B (GzB), a robust marker expressed on effector T cells with lytic 
functions [175].  Therefore, CD4
+
 T cells likely play a direct protective role against WNV via the 
production of cytolytic granules and effector cytokine such as IFNγ [175].   
1.4.3 B cells (Humoral response) 
B lymphocytes are important for mediating protective humoral responses in the form of IgM and 
IgG against WNV [31, 34].  Within the lymph node draining the site of inoculation, IFN-I has been 
identified to elicit rapid non-specific and later (~ day 7 pi) WNV-specific activation of B cells, as 
supported by the upregulation of B cell surface markers, CD69, class II major histocompatibility 
complex (MHC-II) and CD86 [183].  This activation may not involve subcapsular macrophages, 
since loss of this cell type, by genetic knockout or liposome depletion, did not influence B cell 
activation [183].  Dendritic cells, as mentioned above, may serve as an important cellular source of 
IFN-I and B cell activation, though specific experiments have not been performed to address this.  
In mice infected with WNV, myeloid differentiation primary response 88 (MyD88) has also been 
shown to be important for B cell activation, germinal centre activation and generation of a B cell 
memory response [184].  Activation of B cells then leads to antibody production, which may 
directly neutralise or opsonise WNV particles for direct or indirect destruction.   
1.4.3.1 Neutralisation 
The process of neutralisation of WN virions involves binding of a threshold number of antibody 
molecules to various sites of the WNV E protein [185].  Monoclonal antibodies (mABs) targeting 
the lateral surface of domain III of the E protein in particular have been shown to protect mice from 
WNV infection with higher efficiency than those that target epitopes on domain I and II [186].   The 
binding strength of the mAB to the epitope (affinity) determines the concentration of mABs 
required to neutralise virus particles [185].  One study has estimated that approximately 30 antibody 
molecules are required to neutralise a WNV virion via binding to the E Domain III-LR site [185].  
In addition, approximately 50% of the virions are neutralised when approximately 25% of the 
accessible sites of the E protein are bound by antibodies [185].  
1.4.3.2 Non-neutralising antibodies (Opsonisation) 
Few studies have suggested that non-neutralising antibodies against flavivirus prM or E 
glycoproteins may activate or promote infectivity of immature virus particles [187, 188].  However, 
the importance of non-neutralising antibodies in controlling in vivo WNV infection has been 
demonstrated [189].  In this study, passive transfer of poorly neutralising antibodies against the 
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fusion loop of the domain II of the WNV E protein protected C57BL/6 mice from lethal WNV 
infection [189].  The protective mechanism appeared to involve Fcγ receptors, complement opsonin 
C1q, and phagocytic cells, and was independent of T lymphocytes, B lymphocytes, NK cells, 
inflammatory monocytes, or neutrophils [189].  Therefore, this demonstrated the important role of 
antibodies in restricting WNV infection, regardless of their neutralising ability. 
1.4.3.3 Non-leukocytic cells 
Non-leukocytic cells, such as fibroblasts, epithelial and neural cells, contribute to the early detection 
and mediation of cytokine and chemokine expression, as part of the antiviral defence mechanisms 
[53, 64, 149-151, 190-194].  In the skin of WNV-infected 6 week-old C3H mice, cells within the 
epidermis and adnexal glands (likely keratinocytes) were identified as targets for WNV replication, 
and may contribute to the persistence of virus in the skin, due to the slow turnover rate of 
keratinocytes (~ every 52 to 75 days for humans) [195].  However, despite this, keratinocytes are 
potent producers of IFNα, IL1β, IL6 and IL12, which may likely promote migration of LC from the 
skin to the draining lymph node for immune modulation and virus control [190].  TLR-7 activation 
has been shown to be an important determinant for expression of these cytokines in keratinocytes 
[190].  Similarly, dermal fibroblasts have been demonstrated to produce IFNβ, IL6 and granulocyte 
macrophage colony-stimulating factor (GM-CSF) after in vitro inoculation with dengue virus [191].  
Therefore, together these dermal cells likely facilitated early local innate immune response at the 
site of inoculation. 
In the CNS, the role of neurons and astrocytes in WNV restriction has been investigated extensively 
in vitro [53, 64, 149-151, 192-194].  In modelling the responses of neurons to WNV infection, in 
vitro WNV-infection of neurons (human neuroblastoma cell line, SK-N-SH) have been shown to 
result in their expression of a range of pro-inflammatory cytokines, such as IL1β, IL6, IL8 and 
TNFα [64].  The UV-treated supernatant from these infected neurons was then able to mediate the 
activation of in vitro grown astrocytes, resulting in further pro-inflammatory cytokine production 
[64].  In a separate study, in vitro grown human brain cortical astrocytes were shown to produce 
IFNα/β after WNV infection at MOI of 0.01, but in a strain dependent manner [193].  In particular, 
the highly virulent WNVNY99 induced significantly higher levels of IFNα/β from the astrocytes than 
did the less virulent strain, WNVMAD78 [193].  Interestingly, WNVNY99 infection of in vitro grown 
human astrocytes at the higher multiplicity of infection (MOI) of 1 yielded different results, in that 
it did not induce the production of IFN-I/II, IL1β, TNFα, IL6, and IL10 [151].  Instead, only 
chemokines CXCL10, CCL2 and CCL5 were induced, suggesting an important role for astrocytes 
in chemotaxis of leucocytes in infected brains, along with microglial cells [151].  Collectively, the 
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findings from these three studies suggest the role of astrocytes in cytokine production may depend 
on the virus strain and the MOI used [64, 151, 193].  Further investigations into these aspects are 
required. 
The observation of concurrent neuronal death associated with high cytokine levels in in vitro 
cultures led investigators to conclude that neuron/astrocyte/microglial-derived cytokines may 
contribute to WNV-induced neurotoxicity and neuronal death [64].  However, the internal 
environment of the brain is much more complex than what can be modelled by in vitro neuronal and 
glial cell culture experiments.  The brain is composed of an organised arrangement of astrocytes, 
oligodendrocytes, microglial cells, many different subtypes of neurons, and cerebral and cerebellar 
blood vessels and their support cells, within a specialised complex neural extracellular matrix that 
frequently remodels in response to various insults [196].  Furthermore, the complex mix of 
extracellular ions and neurotransmitters normally present in the CNS is not modelled using in vitro 
cultures.  The ex vivo spinal cord slice culture as used by Quick et al. [149] is an improved 
technique over the conventional in vitro methods, since the complex organisation of the neuropil is 
retained.  However, this method lacks the dynamics of blood flow, normally present in vivo, and the 
cellular components quickly deteriorate but at different rates (Bielefeldt-Ohmann, personal 
communication), thus making this system difficult to control.  Appropriate assessment of the 
protective and/or neurotoxic effect of cytokines in the CNS requires in vivo methods that allow 
identification of specific inflammatory markers in specific neural cells e.g. immunohistochemistry 
of inflammatory signalling molecules on brain sections from in vivo challenged animals.  Intravital 
monitoring of CNS virus replication and cytokine production by the use of bioluminescence 
technology may also allow identification of the in vivo sequence of immunological events leading to 
CNS virus control with or without neuronal death.  This aspect of neuropathogenesis may be an 
interesting avenue for future investigation, but is currently not tenable due to lack of suitable marker 
molecules for a small virus like WNV. 
1.5 Animal models for WNV pathogenesis and immune control investigation 
Several aspects of the disease profile of WNV infection in rodents are not representative of that in 
incidental hosts (Table 1-6).   
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Table 1-6 Comparison of the general disease profile between rodent hosts, such as mice and 
hamsters, and intermediate hosts, such as horses and humans.   
Feature Mouse Hamster Horse Human 
Peak 
Viraemia  
Moderate 
(~10
4
PFU/mL) 
[31, 54, 69, 81] 
Moderate  
(10
5
 TCID50/mL)  
[197] 
Low  
(10
1-3 
PFU/mL) 
 [198] 
Very Low 
(only detectable by 
real-time RT-PCR) 
[199, 200] 
Peripheral 
tissue 
tropism 
 Lymphoid tissues  
 Kidneys  
[28, 31]  
 Kidneys 
 Spleen and lungs 
(occasionally) 
[201-203] 
  Rare  
[204] 
 Testicular tissue  
 Urine  
 Kidney & urine 
 Spleen 
[205-207] 
Distribution 
of CNS 
Lesions  
Widespread: 
- cerebral 
cortex 
- hippocampus 
- brainstem 
- spinal cord  
(e.g. [28]) 
Widespread: 
- cerebral 
cortex 
- basal ganglia 
- hippocampus 
- cerebellar 
cortex 
- brainstem 
[197] 
Commonly: 
- hindbrain 
- spinal cord 
Rarely: 
- cerebral 
cortex 
- cerebellum 
[21, 49] 
Commonly: 
- mid-brain 
- brainstem 
- spinal cord 
Occasionally: 
- cerebral 
cortex 
- hippocampus 
- cerebellum 
[20, 87, 207, 208] 
WNV 
infection in 
the brain  
High level 
(~10
5-7
 PFU/g) 
[28, 31, 69] 
High level 
(IHC) 
[197] 
Low level to absent 
(IHC) 
(Bielefeldt-Ohmann 
et al., 2016, 
unpublished data) 
[21, 49] 
Low level 
unless immuno-
compromised 
(IHC) 
[87] 
Mortality 
rate  
 35 to 45% of 
infected (C57BL6) 
[31] 
 100% of infected 
(CD1 Swiss) [100] 
 ~40%  of infected 
[197, 203] 
 ~10 to 57%$ of 
clinical cases 
(WNV strain 
dependent) 
[21, 49, 100] 
 ~10% of 
neuroinvasive 
cases accounting 
for less than 1% 
of  infected 
persons 
[209, 210] 
$
 The mortality rate in the horse does not distinguish the number of cases euthanatised or died naturally.  Euthanasia 
may potentially end a recovering infection prematurely, thus artificially increasing the mortality rate.  The magnitude of 
this bias has not been assessed. 
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The relevance and implications of these differences may be profound.  One may contend that if the 
viraemia is different between rodents and the incidental hosts, the route of viral entry into the CNS 
may differ, as different quantities of haematogenous virions will be delivered to the various organs 
(e.g. olfactory bulb, spinal cord, peripheral nerves) thereby affecting the likelihood of crossing of 
CNS barriers.  The contrasting character of CNS infection and the associated neuropathology (Table 
1-6) may be, at least in part, attributed to this feature.  Along the same line, the higher susceptibility 
of the rodent hosts to WNV infection may imply a different pathogenesis and immune response to 
WNV in these species, as compared to humans and possibly horses.   
Given the discrepancies mentioned above, an alternative small animal pathogenesis model should 
be sought.  Rabbits may be a promising alternative model for studying the pathogenesis and 
immune response to WNV challenge, since previous experimental studies using cottontail rabbits 
have found a moderate acute viraemia, but with no morbidity or mortality [211].  Similar findings 
were observed when New Zealand White rabbits (NZWRs) were infected with a closely related 
flavivirus, MVEV [212].  Other possible alternatives for investigation include guinea pigs and 
ferrets, which have been used as small animal models for immunologic investigation with JEV 
[213] and other infectious agents such as influenza [214]. 
1.6 West Nile virus in the Australian context 
Prior to 2011, Australian WNV strains, also called Kunjin virus, were typically low in virulence in 
humans and horses, with clinical disease reported on rare occasions [215].  However, following 
heavy rainfall and extensive flooding throughout much of eastern Australia, a large-scale arboviral 
epizootic of equine encephalitis occurred in south-eastern Australia in 2011 [100, 216, 217].  
During this outbreak, a novel virulent WNV strain, WNVNSW2011, was isolated from the brain of an 
encephalitic horse in the state of New South Wales [100].  The virulence of this strain was 
identified as intermediate, with in vitro growth kinetics, plaque morphology, and in vivo survival 
characteristics in mice being less dramatic than those associated with the North American WNVNY99 
strain, but more virulent than the prototype Kunjin virus, WNVKUNMRM61C [100].  Other WNV 
isolates from deceased encephalitic horses in the states of Victoria and South Australia during the 
2011 outbreak were also reported to produce an intermediate disease phenotype in 18-20 day-old 
Swiss mice [218].  In the following year, another WNV strain, WNVNSW2012, with similar genetic, 
antigenic and mouse-survival profiles to WNVNSW2011, was isolated from Culex annulirostris 
mosquitos in New South Wales [219].  While no associated fatal equine cases were reported in the 
region in 2012, the existence of a WNV strain that has similar characteristics to the outbreak strain, 
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WNV2011, could pose a risk of future outbreaks.  Therefore, continual research into the pathogenesis 
of WNV is important in the Australian context. 
 
1.7 Discussion 
Since the incursion of WNV into North America in 1999, a vast amount of investigation has taken 
place in characterising the virological and immunological aspects of WNV neuroinvasion.  
However, several gaps in the current state of knowledge about the route and mechanisms of WNV 
neuroinvasion remain (Table 1-7).  As discussed here, clear evidence for certain haematogenous 
routes, such as the paracellular migration of WNV virions across the BBB, is not available.  While 
BBB permeability appears to be associated with neuropathogenesis, its precise role is blurred by the 
fact that CNS infection can, in return, cause BBB disruption via the resultant cytokine release by 
infected neurons [64, 65].  Appropriate delineation of the cause and effect role of the BBB and 
neuroinvasion is therefore an important issue to address.   
Transneural invasion by WNV also requires a closer examination, especially when there is growing 
evidence from in vivo experiments to support this [69, 79, 81].  However, methodological (route of 
inoculation), virological (strain, dose) and host (age, breed, species) variability continues to be a 
factor that gives rise to varying and sometimes contradicting results.  This also applies to research 
efforts into the mechanisms of virus control.  The lack of consistent tissue sampling, such as the 
olfactory bulb and spinal cord, also obscures the overall picture of WNV neuropathogenesis, which 
may involve multiple routes depending on the time post-infection.  This inconsistency also impedes 
the exploration of less well characterised barriers of the CNS, such as the BSCB.  Indeed, the 
remaining barrier mechanisms of the brain, namely the blood-CSF and CSF-brain barriers, have not 
received enough attention.  Recent advances in ex vivo methods, such as the brain slice culture, may 
provide new tools for investigating these avenues [220], though not without its intrinsic limitations.  
While the complex nature of some of these barriers, such as the arachnoid (meningeal) barrier, will 
present challenges for investigators to study, the shift of attention away from the singular focus on 
the BBB will undoubtedly lead to new insights into the neuropathogenesis of WNV. 
Similarly, while the virus-encoded molecular determinants for WNV neurovirulence and 
neuroinvasiveness have been studied extensively, their mechanism in aiding neuroinvasion is 
generally poorly understood.  The over-reliance on lethality studies in characterising viral 
neuroinvasiveness or neurovirulence also lacks specificity.  Death that follows peripheral viral 
challenge could be attributable to a variety of extraneural causes, such as multi-systemic organ 
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failure independent of CNS disease.  While brain viral load does indicate the success of viral 
neuroinvasion, the correlation between brain viral load and mortality may not always be consistent.  
The evidence that BSCB is more permeable than BBB to potentially neurotoxic cytokines may even 
cast doubt on the need for viral neuroinvasion for neuropathy and death to ensue.  This highlights 
the need for routine examination of the pathological, virological and immunological outcomes at 
death in infected mice.  Ultimately, the limitations associated with lethality studies have great 
implications on the validity of both pathogenesis and virulence determinant studies, especially when 
the commonly used rodent model does not represent the disease in the target hosts, horse and 
human.  Until a robust animal model with a more representative disease profile is identified, 
translation of pathogenic mechanisms and WNV-induced immune processes from the existing 
rodent models should be performed with caution.  As made evident in Table 1-7, the 
characterisation of the mechanism(s) of WNV neuroinvasion and control requires further research.  
With new outbreaks of WNV continuing to emerge worldwide, there is an urgency to address these 
gaps in knowledge in order that appropriate therapeutic and preventative strategies can be devised. 
Table 1-7 Unanswered questions in the field of WNV neuroinvasion 
Aspects of WNV neuroinvasion 
and virus control 
Current limitations and unanswered questions 
Transcytosis of virions across 
endothelium 
Lack of in vivo evidence for endothelial infection by WNV 
BBB Permeability Unknown whether increased permeability in the BBB precedes viral 
neuroinvasion or vice versa 
Paracellular neuroinvasion by 
diffusion across endothelial 
junctions 
Lack of evidence 
Paracellular neuroinvasion by 
“Trojan Horse” method 
Unknown function and trafficking behaviour of WNV infected 
leucocytes 
Transneural neuroinvasion from 
peripheral somatic nerves 
Use of artificial route of inoculation; Unknown whether virus can 
successfully reach the brain by this route; 
Transneural neuroinvasion from 
olfactory nerves 
Use of artificial intranasal inoculation 
Blood-CSF barrier (choroid plexus 
and CVOs) 
Unknown role in WNV neuroinvasion 
CSF-brain barrier Unknown role in WNV neuroinvasion 
Arachnoid (Meningeal) barrier Unknown role in WNV neuroinvasion 
BSCB Unknown role in WNV neuroinvasion 
Molecular determinants for the 
mechanism of WNV 
neuroinvasion 
In vivo validation of suggested mechanisms is deficient. 
Immune response The in vivo role of NK cells and PMNs in WNV control 
Rodent models Viraemia, pattern of brain infection and mortality are not representative 
of target hosts (human and horse).  Alternative pathogenesis and virus 
control model is required. 
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1.8 Project Proposal 
Goal:  To investigate the pathogenesis of the equine pathogenic Australian WNV strain, 
WNVNSW2011, in an established Swiss white (CD1) mouse model, as well as in a novel rabbit model. 
Hypothesis 1:   
a) Given the susceptibility of Swiss mice to WNVNSW2011, I hypothesise that this animal model 
may allow investigation into the mechanism of viral neuroinvasion. 
b) Since the hypothesis of haematogenous viral neuroinvasion is not well supported by the 
literature (see Chapter 1), I hypothesise that WNVNSW2011 neuroinvasion in infected Swiss 
mice takes place via the transneural or the CSF route. 
Aim 1.1.  To explore the suitability of the Swiss white (CD1) mouse model for studying mechanism 
of WNV neuroinvasion, by a pilot time-point challenge study examining the tissue viral load and 
neuropathology. 
Aim 1.2:  To characterise the neuropathogenesis of WNVNSW2011 infection in the young-adult Swiss 
white (CD1) mouse model. 
Objective 1.1:  To perform experimental intraperitoneal infection of WNVNSW2011 in young adult 
Swiss mice, with scheduled sacrifice on day 3 and 7 pi, as a pilot study.  Comparative experimental 
infection will be performed using closely related WNVKUN strains (WNVK68967 and WNVGu1009). 
Objective 1.2:  To establish the kinetics of pathology and in vivo virus replication associated with 
WNVNSW2011 and WNVKUN infection, by: 
a)  examining histopathology of peripheral tissue (lymph node, spleen, liver, kidneys, heart and 
lungs) and the nervous system (brain and spinal cord) 
b) localisation of WNV antigen in brains using immunohistochemical (IHC) labelling of viral 
non-structural protein 
c) virus isolation using the 50% tissue culture infective dose (TCID50) from serum, spleen, 
liver, kidneys and brain. 
- These objectives are addressed in Chapter 3. 
Objective 1.3:  To investigate the spectrum of lethal disease outcomes associated with WNVNSW2011 
by investigating the neuropathology, neural infection (by IHC) and glial cell activation (by IHC) in 
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moribund or dead, as well as surviving mice, post-infection.  Comparative experimental infection 
will be performed using closely related highly virulent MVEV strains (MVE1-51 and MVEK68838). 
- This is addressed in Chapter 4. 
Hypothesis 2:  Experimental WNV-infection of New Zealand White rabbits (NZWRs) has not been 
performed prior to this project.  However, based on the moderate viraemia observed in North 
American cottontail rabbits (CTRs) infected with WNV in a previous investigation by other 
researchers, I hypothesise that NZWRs may be a suitable animal species for studying the kinetics of 
in vivo virus replication, pathology and immune response against virus challenge. 
Aim 2.1:  To explore the suitability of NZWRs as an animal model for studying pathogenesis of 
WNVNSW2011 infections in a pilot challenge trial.   
Aim 2.2:  To characterise the acute and subacute in vivo kinetics of virus infection, immune 
response and pathology in NZWRs infected with WNVNSW2011. 
Aim 2.3:  To compare the pathogenesis of WNVNSW2011 infection in NZWRs with infection in 
CTRs, in order to identify potential species-specific differences. 
Aim 2.4:  To compare the pathogenesis of WNVNSW2011 infection against that of virulent flavivirus 
challenge in rabbits, in order to identify potential virus-specific differences. 
Aim 2.5:  To characterise age-dependent susceptibility profile of NZWRs to WNVNSW2011 infection.   
Objective 2.1: To characterise the clinical, pathological, virological and immunological outcomes 
associated with WNVNSW2011 infection (for Aims 2.1-2.5), by: 
a) daily clinical and neurological examination 
b) examination of gross pathology and histopathology of peripheral (lymph nodes, spleen, 
thymus, liver, kidneys, heart, and lungs) and nervous tissues (sciatic nerves, spinal cord 
and brain). 
c) virus isolation by TCID50 or plaque assay from serum, lymph nodes, spleen, liver, 
kidneys and brain. 
d) IHC labelling of viral antigen in brain and lymph node sections. 
e) characterisation of the general and neutralising antibody response, by blocking enzyme-
linked immunosorbent assay (ELISA) and virus neutralisation assay.  
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f) IHC labelling of leucocyte phenotypic markers in brain sections, in order to identify any 
infiltrating leucocytes. 
g) cytokine and chemokine transcriptional profiling (qRT-PCR) of the draining and non-
draining popliteal lymphoid, spleen and brain. 
h) IHC labelling of transcription factors pivotal for signalling of pro- and anti-
inflammatory response (e.g. NF-kB, STAT1 and STAT3) in the brain. 
Comparative investigation of the above outcomes in MVEV-infected NZWRs, as well as CTRs 
infected with a virulent North American WNV strain (WNVTX8667) will be performed. 
Objective 2.2:  To characterise age-dependent susceptibility profile of NZWRs to WNVNSW2011 
infection (for Aim 2.5), by assessing the clinical, pathological, virological, and immunological 
outcomes between 4-5 week old and > 3 month old NZWRs.  Comparative challenge with the 
highly virulent MVEV will be performed. 
- These objectives are addressed in chapters 5 and 6. 
1.8.1 Significance 
The significance of this project lies in five aspects: 
1) Investigation into the mechanism of WNV neuroinvasion in the Swiss mouse model will 
address the current gap in knowledge in this area, as highlighted in the literature review. 
2) The establishment of a novel rabbit model will provide an alternative option for 
investigating pathogenesis of WNV and other flavivirus strains (e.g. MVEV). 
3) The mechanistic investigation of the interaction between rabbits and WNV may identify 
some key host and viral factors that can be used to inform improved therapeutic and/or 
preventative strategies for equine and human WNV encephalitis. 
4) The clinical, pathological, virological and immunological data, to be generated from the 
rabbit challenge trials, will be used as reference data for any future treatment/vaccine 
efficacy trials. 
5) The viraemia data will provide information regarding the potential ecological role of rabbits 
in transmitting WNVKUN and MVEV in Australia.  
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Chapter 2. Preparation of virus stock 
2.1 Introduction 
In preparation for the mouse and rabbit challenge trials, various virus strains were required to be 
amplified to an amount that would sufficiently cover the entire project.  This would allow 
consistency of methods between the experiments and allow valid comparison of results between 
trials.  Strains to be amplified included the current strain of interest WNVNSW2011, various Kunjin 
strains and the prototype MVEV strain 1-51 (MVE1-51).  Validation of the identity of these 
amplified stocks was performed by characterising the genomic and antigenic profile. 
2.2 Materials and methods 
2.2.1 Virus passage history 
The virus of interest, the equine virulent WNVNSW2011, was obtained from the virology laboratory at 
Elizabeth Macarthur Agriculture Institute (Menangle, NSW, Australia) courtesy of Dr. Peter 
Kirkland.  Initial preparation of virus stock at Elizabeth Macarthur Agriculture Institute was 
described in [100].  Briefly, WNVNSW2011 was isolated from the brain of an encephalitic horse 
during the 2011 outbreak in NSW.  A 10 % w/v homogenate of brain was passaged on a monolayer 
of the Aedes albopictus C6/36 mosquito cell line, before being sent to the University of Queensland 
(UQ), St. Lucia campus, where one additional passage in African green monkey kidney cells (Vero) 
was performed to create the initial stock. 
MVE1-51 is the prototype strain, originally isolated during the 1951 outbreak [221, 222]. Its passage 
history has been outlined in Dalgarno et al. [221], and involved multiple suckling mouse brain 
passages.  Since 2001, the stock has been passaged once in Vero cells and then twice in C6/36 cells 
at UQ. 
The KUN strains chosen to be amplified were WNVK68967, WNVGu1009 and WNVGu0631, with 
WNVK68967 being the most attenuated in terms of neuroinvasiveness as characterised by in vivo 
intraperitoneal (IP) challenge of mice [219].  WNVGu1009 and WNVGu0631 exhibited comparable 
levels of neuroinvasiveness to WNVNSW2011 in the young adult Swiss white CD1 mouse model (also 
via IP challenge) [219].  These three WNVKUN strains were all passaged on C6/36 twice after initial 
isolation from mosquitoes, followed by one more passage on Porcine-Stable Equine Kidney (PSEK) 
cells. 
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2.2.2 Amplification of virus stock  
All initial virus stocks used to infect monolayers of C6/36 cells for virus stock amplification 
consisted of 50μL of initial stock virus, mixed with either 2mL or 5mL of maintenance Roswell 
Park Memorial Institute (RPMI) media (HyClone), supplemented with 2% foetal bovine serum 
(FBS) and 10 units/mL of penicillin/streptomycin/L-glutamine (P/S/G).  The inoculum was 
incubated on the cells in a 75 cm
2
 flask (Corning) for 1-2 hours at 28C to allow for virus 
attachment.  After such time, the inoculum was removed and replaced with maintenance RPMI 
media (as prepared above).  Amplified virus stock was harvested on day 5.  Harvested virus 
supernatant was clarified for 10 minutes by centrifugation at 4°C at 1800 x g and 10mL of this 
supernatant was recovered.  FBS concentration was adjusted to 10%. and the supernatant was 
subdivided into 300-500 μL aliquots for storage at -80°C. 
2.2.3 RNA extraction 
Following collection of virus-containing spend medium from the cell culture flasks, the remaining 
cells (C6/36) were incubated with 3.5mL of TRI reagent (Sigma-Aldrich) for a few minutes until 
cells were detached from the flask.  The cell lysate was stored at -80C until RNA isolation was 
performed according to the manufacturer’s protocol (Sigma-Aldrich).  Briefly, phase separation was 
performed with 0.2mL chloroform per mL of TRI reagent mixture, followed by vigorous agitation 
and centrifugation at 12,000 x g, for 15 minutes at 4C.  The aqueous RNA phase was extracted and 
mixed with 0.5mL of 2-propanol per mL of the initial TRI reagent mixture for RNA precipitation.  
The RNA pellet was then washed with 1mL of 75% ethanol per mL of the initial TRI reagent.  The 
pellet was then resuspended with 20μL of RNAse free water and store at -80C. 
2.2.4 Reverse transcriptase polymerase chain reaction (RT-PCR) 
A standard two-step reverse-transcriptase polymerase chain reaction (RT-PCR) was performed on 
the isolated RNA, according to the New England BioLabs (NEB) protocol for both first strand 
synthesis and PCR.  Forward and reverse primers used for characterising the viral genomes are 
detailed in Table 2-1:  
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Table 2-1  Details of the primers used. 
Set Primers Genomic 
Position 
Virus 
Strains 
Product 
Length 
(bp) 
Sequence (5’3’) Reference 
1 KUNF 
(F) 
445-466 
(prM) 
Kunjin 
/WNVNSW2011 
1240 Gtcactctctccaactttcaag [223] 
KUN527
6 (R) 
1685-1664 
(E) 
Gcgtgtggttcttcaaactcca 
2 MVE122
8s (F) 
1229-1250 
(E) 
MVEV 954 Gggagtcacacaacacgaagc [224] 
MVE218
2 (R) 
2183-2161 
(E) 
Ggtgattgatctgcttgtctcc 
3 FU2 (F) 9233
a
 
(NS5) 
Flavivirus 844 Gctgatgacaccgccggctggga
cac 
[225] 
cFD3 (R) 10077
a
 
(NS5) 
Agcatgtcttccgtggtcatcca
 
a, genomic position in Yellow Fever virus [225]; (F), Forward primer; (R), Reverse primer. 
In generating the first stand cDNA, 0.5 to 2g of RNA template was mixed with 2L of the 
appropriate reverse primer, 4L of 10mM dNTP mix and nuclease free water to make up a volume 
of 16L.  An initial five-minute incubation at 65-70°C was carried out on PCR Express PCR 
thermocycler. 
The reaction mixture was then added with 2μL of 10x RT buffer, 1μL of murine RNase inhibitor 
(40U/μL) and 1μL of M-MuLV Reverse Transcriptase (200U/μL) to make up a 20μL reaction to 
complete the first strand synthesis with a 42°C incubation step for one hour, followed by an enzyme 
inactivation step at 80°C for 5 minutes. 
Complementary DNA (cDNA) products were amplified, using PCR Express PCR thermocycler, as 
a 50μL PCR for each stock virus.  Each PCR consisted of 1ng to 1g of DNA template,  5μL of 10x 
ThermoPol Buffer, 1μL of 10mM dNTP mix, 0.25μL Taq Polymerase, 1 μL of both forward and 
reverse primers, and an appropriate volume of nuclease free water to make a total volume of 50 L.  
PCR thermocycling steps involved an initial denaturation cycle of 94C for 2 minutes, followed by 
30 amplification cycles of 94C for 30 minutes, 50C for one minute and 68C for two minutes.   A 
final extension cycle of 68C for 5 minutes completed the PCR.  In each PCR run, a no template 
control was employed to detect any contamination in the PCR reagents. 
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2.2.5 Gel electrophoresis 
Gel electrophoresis of the PCR amplicons was performed to visualise the fragment size and for gel 
purification.  For gel electrophoresis, 5L of the PCR product was mixed with 1.5μL of loading 
dye.  Five μL of this mixture was then added into lane wells in a 1% w/v agarose gel (Seakem LF 
Agarose in 0.5% Tris-Borate-EDTA (TBE) buffer), which contained 1μL RedSafe per gel block.  
Gel electrophoresis was run at 110 volts for 35 minutes, in 0.5% TBE solution.  Visualisation of gel 
bands was achieved with a Gel Logic 212 Pro UV illuminator, with photos taken with Carestream 
software. 
2.2.6 Gel purification and sequencing 
Amplified PCR products were cut out from the agarose gel, and DNA purification was performed 
using the IBI gel purification kit, according to manufacturer’s protocol.  Briefly, the steps involved 
gel dissolution in DF buffer, followed by two wash steps and finished with an elution step.  Final 
elution was performed with 20μL of Elution buffer.  Routine Sanger sequencing of both the forward 
and reverse strands of the purified DNA products was carried out at the Australian Genome 
Research Facility (AGRF) at UQ, St Lucia campus. 
2.2.7 Fixed cell enzyme-linked immunosorbent assay   
Fixed cell enzyme-linked immunosorbent assay (ELISA) involved a one-hour blocking step with 
TENTC blocking buffer, consisting of 100mM Tris, 2.0M NaCl, 10mM EDTA, 2% w/v casein and 
Tween-20, with a final pH adjusted to 8.0.   Fifty μL per well of primary monoclonal antibodies 
(mAB) at two-fold serial dilutions in duplicate wells at each dilution, was incubated on both an 
infected and uninfected plate for one hour.  HRP-conjugated goat-anti-mouse IgG antibody (Dako), 
used at 1:5000 dilution, was then incubated for one hour, before 100μL of ABTS substrate 
(consisting of 200L ABTS (2.8% weight/vol): 200L H2O2 (0.38% vol/vol):  10mL substrate 
buffer [200mM phosphate solution mixed with 100mM citric solution]) was incubated for another 
hour.  Alternating wash steps with PBST (1x concentration) was performed after the primary and 
secondary antibody incubations.  The optical density (OD) was read on LabSystem Multiskan EX 
plate reader at 405nM wavelength.  Positive immunoreactivity was considered when an OD reading 
was double that of the negative control.  
2.2.8 Antigenic characterisation of virus stocks 
For antigenic analysis of the stock viruses, monolayers of C6/36 cells in flat bottom 96 well plates 
were first infected with each of the amplified stock virus per plate, at 1/100 dilution and 50μL per 
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well.  Plates were incubated for 5 days at 28C, followed by 20% acetone (with 0.02% Bovine 
Serum Albumin (BSA) added) fixation at 4°C for 12-24 hours and air drying at room temperature.   
Fixed cell ELISA [226] was carried out with the following primary mABs:  4G2, 4G4, 2B2, 10A1, 
5H1, 10C6, 3.101C, 17D7, 3.67G, 4F11, 5E9, 995 (see Table 2-2 for details) .  The choice for this 
combination of mABs was to ensure our stock viruses possessed the appropriate binding patterns, 
specific for the strain of virus as previously established.  Table 2-2 summarises the expected 
binding pattern, virus specificity, the start dilution used and the references for the mABs used. 
Table 2-2  Monoclonal antibodies used for antigenic analysis of amplified virus stock. 
 mAB Start Dilutions Specificity (Virus) Target Antigen References 
4G2 1/10 Pan-flavivirus E  [227] 
4G4 1/10 Most flavivirus
* 
NS1 [228] 
2B2 1/10 WNV group E [229] 
10A1 1/10 Specific for KUN E [230] 
5H1 NEAT Specific for KUN NS5 [100] 
10C6 1/10 Specific for MVEV  NS1 
[100] 
3.101C NEAT Specific for KUN Unglycosylated E [230] 
17D7 1/1000 Flavivirus with glycosylated E Glycosylated E [231] 
3.67G 1/10 Specific for KUN E [230] 
4F11 1/10 Specific for MVEV NS1 [228] 
5E9 1/10 Specific for MVEV NS1 [228] 
995 1/10 Specific JEV E [232] 
*
, exceptions include Bamaga virus and Fitzroy river virus; E, envelope; NS1, non-structural protein 
1. 
2.2.9 TCID50 
For TCID50 assay, 50μL of serial 10-fold dilutions of virus stock was inoculated on monolayers of 
Vero cells which had reached 70-80% confluency, in flat-bottom 96-well plates (Corning, Costar).  
All dilutions were performed in 24-well plates (Corning, Costar) on ice with Dulbecco Modified 
Minimum Essential Media (DMEM) (In Vitro Technologies), supplemented with 2% FBS and 
10units/mL P/S/G mixture.  Ten replicate wells per dilutions were used to determine the 50% 
endpoint.  Two columns of uninfected negative control were used for each 96-well plate.  An 
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equivalent amount (50μL) of media was added to each well in these two columns.  Infected plates 
were incubated at 37 ˚C and 5% CO2 for five days.  Confirmation of cell infection was performed 
with fixed cell ELISA [226], employing the flavivirus envelope-specific monoclonal antibody, 4G2 
[227].  The plates’ optical density (OD) was read with LabSystems Multiskan EX plate reader, 
reading at 405nM wavelength.  Final titre was expressed as TCID50/mL, and calculated by the Reed 
and Meunch method [233]. 
2.2.10 Plaque Assay 
Monolayers of Vero cells, seeded onto six-well plates (Corning, Costar) 24 hours previously, were 
infected with 300μL of 10-fold serial dilutions of each stock virus, ranging from 10-3 to 10-7.  All 
dilutions were performed on ice with DMEM, supplemented with 2% FBS and 10 units/mL P/S/G 
mixture.  The remaining well per plate was used as an uninfected negative control, with 300μL of 
media added.  Two hours’ incubation at 37°C and 5% CO2 with gentle agitation every 20 minutes 
allowed even attachment of virus to the monolayer of Vero cells.  For the overlay, two mL per well 
of 0.5% low melting point (LMP) agarose, diluted 1:4 from 2%, with DMEM (prepared as above) 
were used.  On day three post-infection, the plaque assay plates were fixed with 2mL per well of 
10% formaldehyde for 30 minutes.  After removing the overlay plug, 1-2mL of 0.2% Crystal Violet 
stain was applied per well.  Plaques were read and reported as plaque forming units/mL (PFU/mL).  
2.3 Results 
2.3.1 Genomic characterisation 
The amplicon sizes of each RT-PCR suggest that all virus stocks amplified the appropriate 844base 
pairs (bp) NS5 region of flavivirus genome (Figure 2-1, lane 1, 3, 5, 7, and 9), that WNVNSW2011 and 
WNVKUN stocks amplified the 1240 bp prM/E region of WNVKUN genome (Figure 2-1, lane 2, 4, 8, 
and 10), and that MVE1-51 stock amplified the 954 bp E region of MVEV genome (Figure 2-1, lane 
11 and 12) 
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Figure 2-1 Inverse image of RT-PCR products of the conserved regions in the prM-E and NS5 
coding sequence of stock virus.  Gel electrophoresis carried out on standard 0.5% agarose gel.  
Lane 1: WNVK68967 (FU2/cFD3 primers [844bp]);  Lane 2: WNVK68967 (KUNF/KUN5276 primers 
[1240bp]);  Lane 3: WNVNSW2011 (FU2/cFD3 primers);  Lane 4: WNVNSW2011 (KUNF/KUN5276);  
Lane 5: MVE1-51 (FU2/cFD3 primers);  Lane 6: MVE1-51 (MVE1228s/MVE2182 primers [954bp]) 
first failed attempt;  Lane 7: WNVGu1009 (FU2/cFD3 primers);  Lane 8: WNVGu1009 
(KUNF/KUN5276 primers);  Lane 9: KUNGu0631 (FU2/cFD3 primers);  Lane 10: KUNGu0631 
(KUNF/Kun5276 primers);  Lanes 11 & 12: MVE1-51 (MVE1228s/MVE2182 primers) second 
attempt with increased RNA template (4 µL).  HL, hyperladder I (Bioline).  bp, base-pairs.   Note: 
For MVE1-51, RT-PCR with the primer set, MVE1228s/MVE2182, failed to produce a visible band 
at its appropriate size level (954 base-pairs) on the first attempt (lane 6).  Even on the second 
attempt, the bands were still faint (lanes 11 and 12).  However, on gel purification, the faint bands 
contained enough DNA amplicons for sequencing to confirm its identity as MVE1-51.  In lane 8, 
three distinct bands were produced for WNVGu1009 with the primers KUNF/KUN5276.  Excision, 
purification and sequencing of the band, indicated by box (black), revealed an appropriate segment 
in KUN genome, encoding the prM-E.  
2.3.2 Sequence analyses 
The forward and reverse sequences for each of the amplicons generated by RT-PCR, as described in 
Section 2.3.1, was obtained by Sanger Sequencing.  Alignment analysis of each sequence was 
performed using the BLAST database (NCBI) to identify the virus strain with highest identity.  The 
forward and reverse sequences of the stock viruses align most closely to sequences of WNVNSW2011, 
WNVK6453 or MVE1-51 (Table 2-3). 
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Table 2-3  Alignment of the sequences of RT-PCR products, using BLAST database. 
Product Primers BLAST result (highest identity) Identity 
WNVNSW2011 FU2 WNVNSW2011 99% 
cFD3* WNVNSW2011 90% 
KUNF WNVNSW2011 98% 
KUN5276 WNVNSW2011 99% 
WNVK68967 FU2 WNVNSW2011 99% 
cFD3* WNVNSW2011 95% 
KUNF WNVNSW2011 97% 
KUN5276 WNVNSW2011 97% 
WNVGu1009 FU2 KUNK6453 96% 
cFD3* KUNK6453 86% 
KUNF KUNK6453 98% 
KUN5276 KUNK6453 98% 
WNVGu0631 FU2 KUNK6453 97% 
cFD3* KUNK6453 73% 
KUNF KUNK6453 96% 
KUN5276 KUNK6453 97% 
MVE1-51 FU2 MVE1-51 98% 
cFD3* MVE1-51 94% 
MVE1228s MVE1-51 99% 
MVE2182 MVE1-51 99% 
The above alignments were performed on the 4-29
th
 October 2012.  The entire unedited sequence 
received from AGRF was used for the alignments.  * These sequences are unreliable due to the 
presence of unevenly spaced peaks, and prominent baseline (or “noise”) peaks in their respective 
chromatograms. 
 
2.3.3 Antigenic characterisation 
Fixed-cell ELISA of C6.36 cells infected with the various stock viruses confirmed the identities.  
Table 2-4 summarise the monoclonal antibody binding pattern for each virus stock. 
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Table 2-4  Results of monoclonal antibody (mAB) binding patterns for each stock virus 
 Monoclonal 
antibodies 
4G2 4G4 2B2 10A1 5H1 10C6 3.101C 17D7 3.67G 4F11 5E9 995 
 Binding 
specificity 
E (pan-
flavivirus) 
NS1 (pan-
flavivirus) 
E (WNV) E (KUN 
specific) 
NS5 
(KUN 
specific 
for 
strains 
before 
2009) 
NS1 
(MVEV 
specific) 
Unglycosylated 
E 
Glycosylated 
E 
E (KUN 
specific) 
NS1 
(MVEV 
specific) 
NS1 
(MVEV 
specific) 
 JEV 
specific 
WNVNSW2011 + (1280) + (160) + 
(1280) 
+ (160) - - - + 
(128000) 
+ (1280) - - - 
WNVK68967 + (1280) + (160) + 
(1280) 
+ (320) - - - + 
(128000) 
+ (1280) - - - 
WNVGu0631 + (1280) + (320) + 
(1280) 
+ (320) + (8) - - + 
(128000) 
+ (1280) - - - 
WNVGu1009 + (1280) + (320) + 
(1280) 
+ (320) + (64) - - + 
(128000) 
+ (1280) - - - 
MVE1-51 + (1280) + (80) - - - + (640) - + 
(128000) 
- + (640) + (1280) - 
+, indicates positive binding of mAB.  Dilution endpoints of positive wells are indicated as their inverse within brackets.  -, indicates negative binding of mAB.
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2.3.4 Virus titration 
The titre of the amplified virus stock was determined by two methods, TCID50 and plaque assay, 
both performed on Vero cells.  Table 2-5summarises the titre of the virus stock. 
Table 2-5  Titres for virus stock used in this thesis 
Virus strains TCID50/mL PFU/mL 
WNVNSW2011 10
9.7
 10
8.8 
MVE1-51 10
8.5 
10
6.8 
WNVGu0631 10
8.7 
10
5.5 
WNVGu1009 10
7.3 
10
6.7 
WNVK68967 10
9.0 
10
7.5 
 
2.4 Conclusions 
In this chapter, I have amplified and characterised the genomic and antigenic profile of several of 
the virus strains to be used in the experiments in subsequent chapters of this thesis.  In general, 
these amplified virus stocks appear to have retained the appropriate genomic and antigenic 
properties of their respective strain.  However, there are some limitations applicable to the 
interpretations of this characterisation.   
The alignments performed are of the forward and reverse sequences of the amplicons generated 
from the two primer sets targeting the NS5 and prM/E region of the viral genome (i.e. FU2/cFD3 
and KUNF/KUN5276 for WNV strains and FU2/cFD3 and MVE1228/2182 for the MVEV strain).  
Therefore the degree of similarity between the sequence of the amplified virus and that of their 
respective strains in other regions of the genome is unknown.  Full length sequence analysis would 
allow a comprehensive comparison of the virus stocks amplified here.  However, this work is 
beyond the scope of the thesis. 
At the time of the BLAST analyses outlined in Table 2-3, the forward and reverse sequences of the 
amplicons did not allow differentiation between WNVNSW2011 and WNVK68967, nor between the 
different WNVKUN strains.  A later study by Prow et al. extensively characterised the genomic and 
antigenic profile of these WNVKUN strains and published their full length sequences on the 
GenBank database [219].  A repeat of the BLAST analyses on the 4
th
 December, 2016 (Appendix 
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1), using the FU2 forward sequences of each of the strains, confirmed the identity of the respective 
WNVKUN strains, thus resolving this limitation. 
The virus titre for each of the virus stock is of a sufficient titre ready for use in subsequent in vivo 
challenge trials.  The comparison between the two titration methods shows that there are minimal 
differences between TCID50 and PFU titre for WNVNSW2011, thus the use of either titration method 
would be appropriate in subsequent viral load investigations.  However, it is of note that the two 
different titration methods yielded moderately different titres for the remaining strains.  This likely 
reflects the intrinsic differences in the assays and their respective sensitivity limit.  The plaque assay 
used for titration here measures the number of lytic foci within a monolayer of Vero cells after 
inoculation with titrated volumes of the stock virus, whereas the TCID50 method measures the 
presence of NS1 antigen in monolayers of Vero cells by fixed cell ELISA.  Therefore the latter 
method measures the presence of productive infection in Vero cells, and thus may be more sensitive 
than detecting macroscopically visible lytic foci as performed in plaque assays.  This may explain 
the consistently higher TCID50 titres relative to PFU observed here.  However, to prove this 
hypothesis, one would require concurrent titrations of the same vial of virus stock by both TCID50 
and plaque assay.  This work, while interesting to pursue, is beyond the scope of this thesis. 
In this chapter, I have not included the details of the amplification and characterisation of some of 
the virus strains used in later chapters, such as WNVNSW2012, WNVTX8667, and MVEVK68838, since 
the preparation of these stock viruses was performed elsewhere.  Details of these virus strains and 
references of their sources have been included when first mentioned in subsequent chapters. 
 
 
  
48 
 
Chapter 3. Neuropathogenesis investigation of WNVNSW2011 in 
Swiss white CD1 mice    
3.1 Introduction 
As highlighted in the literature review chapter (Chapter 1), the mechanism of WNV neuroinvasion 
requires further investigation.  The emergence of the novel Australian equine-virulent WNV strain, 
WNVNSW2011, presented a unique opportunity to examine the mechanism of WNV neuroinvasion in 
the established Swiss white CD1 mouse model.  The initial virulence characterisation of the 
outbreak strain, WNVNSW2011, was performed in the Swiss white CD1 mouse model [100].  
Intraperitoneal infection of WNVNSW2011 in weanling (18-19 day old) and young adult (4 week old) 
Swiss mice at various doses determined that its 50% lethal dose end-point (LD50) was lower than 
that of the naturally attenuated Australian WNVKUN strain, but higher than that of the highly 
virulent North American WNVNY99 strain [100].  With supporting evidence from the in vitro 
replication profile, WNVNSW2011 was identified as a WNV strain of intermediate virulence [100]. 
 
In this study, I aimed to conduct a preliminary assessment of the mechanism of WNV 
neuroinvasion using WNVNSW2011 in the established young adult Swiss white CD1 mouse model 
[100].  A pilot time-course sacrifice experiment was performed, in order to assess the general 
kinetics of pathological and virological outcomes in various peripheral and nervous tissues.  An 
inoculation dose of 1000 PFU was selected since this dose resulted in high morbidity and mortality 
in the young adult model [100].  Sacrifice time-points on day 3 and 7 post-infection (pi) were 
chosen, in order to assess the disease profile at the early infection phase, as well as during the time 
just prior to when we generally expect mortality from WNV infection in mice [100].  The survival 
curve of WNVNSW2011 challenge in this model further suggested that the first death would occur on 
day 7 pi, hence justifying this time-point as a potentially appropriate snapshot of the phase during 
viral neuroinvasion.  Comparative experimental infections with closely related WNV-Kunjin 
strains, WNVK68967 and WNVGu1009, were conducted.  WNVK68967 had a low virulence profile (LD50 
of 10 PFU), while WNVGu1009 had a comparable virulence profile as WNVNSW2011 (LD50 of 0.4 PFU, 
as compared to LD50 of 0.5 PFU for WNVNSW2011) in weanling Swiss mice challenge experiments 
(Technical appendix of [219]).  Through this investigation, I found that the pathological and 
virological outcomes on both day 3 and 7 pi were generally benign, contrary to my hypothesis. 
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3.2 Methods and materials 
3.2.1 Virus 
The passage history of WNVNSW2011, WNVK68967 and WNVGu1009 has been fully described in Section 
2.2.1.  Table 3-1 recapitulates these details. 
Table 3-1  Summary of the WNV strains used in this experiment 
 WNVNSW2011 WNVK68967 WNVGu1009 
Time isolated 2011 2009 2000 
Region isolated 
from 
New South Wales Kimberley Gulf of 
Carpentaria 
Species isolated 
from 
Infected horse brain Culex annulirostris Culex 
annulirostris 
Passage History (no. 
time and cell type) 
1xC6/36 
1xVeros 
1xC6/36 (at UQ) 
2xC6/36 
1xPSEK 
1xC6/36 (at UQ) 
2xC6/36 
1xPSEK 
1xC6/36 (at UQ) 
3.2.2 Animals and Experiment Design 
With the approval of the UQ Animal Ethics Committee (permit number 
SCMB/196/11/NHMRC(NF)), a total of eighteen female and three male 28 day-old Swiss outbred 
CD1 mice were sourced from the UQ Biological Resources (UQBR) breeding colony for an 
intraperitoneal-challenge time-course experiment (see Table 3-2 for assignment of mice into 
groups).  Mice are inoculated with 1000 PFU of the WNV strains intraperitoneally.  Time-points of 
day 3 and 7 pi were chosen to study the peripheral replication profile of WNVNSW2011 (at day 3 pi) 
and its neuroinvasive profile (at day 7 pi).   
Table 3-2 Assignment of mice into virus and time-point groups 
Sacrifice 
time-points 
WNVNSW2011 WNVGu1009 WNVK68967 Sham-
inoculation 
control 
3 dpi 3 3 3 3 (males) 
7 dpi 3 3 3 
dpi, days post-infection 
3.2.3 Tissue Sampling 
At each designated time-point or if signs of severe neurological disease were exhibited, mice were 
euthanatised with a lethal dose of ketamine (100mg/kg), xylazine (20mg/kg) and phosphate 
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buffered saline mixture.  Intracardiac bleed was performed at the time of deep anaesthesia just prior 
to death, followed by post mortem intracardiac perfusion with up to 10ml of sterile PBS.  All post-
mortem procedures were carried out in a PC2 biosafety cabinet.  Tissues sampled included liver, 
spleen, kidneys, tracheal lymph nodes, heart, lungs, spinal cord and brain.  Half of the liver, spleen, 
kidneys and brains were assigned for virus assays (see below) and were snap frozen on dry ice and 
stored at -80ºC.  The remaining samples were fixed in 10% neutral buffered formalin for 
downstream histopathological and immunohistochemical processing. 
3.2.4 Histopathology 
Tissue samples were fixed in 10% neutral buffered formalin solution for 48-72 hours.  In order to 
minimise aldehyde-induced cross-linking of epitopes by formalin (for immunohistochemistry), 
samples were then placed in 70% ethanol for further fixation and preservation.  For the brains, nasal 
cavity (for the olfactory bulb) and spinal cord, samples were placed into 8% formic acid 
decalcifying solution for 3-7 days after formalin fixation.  The head, from the level of the cribiform 
plate to the foramen magnum, was sectioned to allow examination of the brain at the level of the 
olfactory bulb, two levels encompassing the hippocampus, thalamus and hypothalamus, and two 
levels encompassing basal ganglia, cerebellum and brainstem [234]. The spinal cord was sectioned 
transversely into 2-3 mm thick segments and all processed in the same cassette. Extraneural tissues 
sampled with variable frequency included eyelids, salivary glands, bone marrow, blood vessels, 
thymus, spleen, lymph nodes, gastrointestinal tract, skeletal muscles, kidneys, heart and lungs.  
These samples were fixed in the same manner, followed by storage in 70% ethanol until processing 
for histopathology examinations.  All samples were processed and analysed, as previously described 
[235].  Severity of histopathological lesions was scored semi-quantitatively on a scale of zero to 
five,  by an observer blinded to the group and clinical outcome (HBO), as follows: zero = no 
apparent lesions, 1 = minimal to mild, focally restricted leucocyte infiltration and/or microgliosis, 2 
= scattered foci of mild leucocyte infiltration with or without apparent neuronal changes 
(degeneration, apoptosis/necrosis or neuronophagia), 3 = scattered foci of moderate leucocyte 
infiltration and neuronal changes, 4 = multifocal, marked leucocyte infiltration and neuronal 
changes, 5 = multifocal to diffuse, severe leucocyte infiltration and neuronal changes 
(representative illustrations are depicted in Figure 3-1).  
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Figure 3-1 Representative illustrations for each neuropathology score.  (A) Score of 1 to 2, (B) 
Score of 2, (C) Score of 3, (D) Score of 4, (E and F) Score of 5.  Please refer to the methods section 
for detailed description of each score.  
All trimmed tissue samples were paraffin embedded in a Thermo Scientific Excelsior ES processor.  
Five µm thick sections were then prepared from the paraffinised tissue block on a microtome (Leica 
RM2255) and subsequently mounted on glass slides.  Routine haematoxylin and eosin (H&E) stain 
was applied to one section per block. 
  
52 
 
All H&E sections were read on either a Nikon YS100 or an Olympus BX41 microscope.  
Photomicrographs were taken on Q-imaging MicroPublisher 5.0 RTV camera using the Q-Capture 
6.0 software, with pixel setting at 2560 x 1920 in .tiff format.  No post-capture modification of the 
pictures was performed, except for cropping to areas of interest and addition of indicators where 
necessary. 
3.2.5 Immunohistochemistry (IHC) 
The tissue sections were de-paraffinised and rehydrated in a Leica ST5020 robotic staining 
machine.  Antigen retrieval was achieved by placing slides in Target Retrieval pH 9 solution 
(Dako), for 25 minutes in ~96ºC water bath, and a further 20 minutes cooling at room temperature.  
Ten minute blocking steps with 0.6% hydrogen peroxide (peroxidase block), 0.05M glycine 
solution in PBS (aldehyde blocking) and 30 min antibody diluent with background control (DAKO) 
(general blocking including Fc receptors) were performed with alternating steps of a TBST (1x) 
rinse.  Slides were then incubated for 2 hours at room temperature with undiluted hybridoma spend-
medium containing the flavivirus NS1-specific mAB, 4G4 [228], a reliable indicator of viral 
infection [236].  After thorough TBST washing, the EnVision+ System-HRP (AEC) kit (Dako) was 
used.  Its protocol involved a 30-minute anti-mouse secondary antibody incubation, followed by 
multiple TBST rinses, before the application of AEC chromogen, incubated for approximately 7-8 
minutes and stopped before the negative uninfected control exhibited background staining.  Slides 
were counter stained with Mayer’s haematoxylin and cover slips were mounted with Faramount 
(Dako).  In each IHC staining session, an infected positive tissue control and an uninfected negative 
tissue control were employed. 
3.2.6 Quantitation of IHC antigen in tissue sections 
All IHC-stained slides were scanned at 10-20x light microscope objectives, on an Olympus BX41 
light microscope, for red stained WNV-NS1 positive cells.  Sections that were positive went 
through a second stage of semi-quantitation.  The overall aim of this step was to obtain an 
approximate positive cell count per specified area (mm
2
).  
3.2.6.1 Photomicrographs and positive cell count 
Slides with low density of positive cells were photographed at lowest magnification (2x).  Slides 
with moderate density of positive cells were photographed at 4-10x magnification. For slides with 
high density of positive cells, 10-15 photomicrographs were taken of 2-3 defined zones on the 
section at 40x magnification.  Positive cell count (PCC) was performed on photomicrographs taken, 
using Image J software.  An average number of positive cells per 40x field were used for 
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approximation of the number of cells per mm
2
.  For slides with low and moderate density of 
positive cells, complete PCC were performed on the whole section.  
3.2.6.2 Calculating positive cell density (per mm
2
) 
Reference area of each objective, as viewed through the Q-imaging MicroPublisher 5.0 RTV 
camera attached on the Olympus BX41 microscope, was measured using a haemocytometer.  
Reference areas were calculated for each objective of the microscope (Table 3-3). 
Table 3-3 Reference area for each objective on Olympus BX41 microscope, as viewed through 
Q-imaging MicroPublisher 5.0 RTV camera with Q-capture 6.0 software. 
Magnification (x) Width (mm) Height (mm) Area (mm2) 
2 4.409 3.306 14.576 
4 2.158 1.618 3.492 
10 0.862 0.646 0.557 
20 0.416 0.312 0.130 
40 0.219 0.164 0.036 
 
The density of positive cells was expressed as the number of positive cells per mm
2
. This was 
calculated by converting the PCC per objective field to PCC per its corresponding area, using the 
reference area detailed in Table 3-3. 
3.2.7 Cell Culture, virus isolation and titration 
A 10% w/v homogenate of each of the harvested tissues was made by using a mortar and pestle 
device (Kontes pellet pestle motor).  All tissue samples for virus isolation were homogenised in 
DMEM (In Vitro Technologies) containing 2% FBS and 10 units/mL penicillin/streptomycin/L-
glutamine mixture.  Homogenate was clarified at 3000 rpm, for 10 min at 4 °C, with supernatant 
extracted for downstream procedures.  All homogenisation steps were carried out on wet ice. 
For virus isolation and titration, TCID50 assay using Vero cells, as detailed in Section 2.2.9, was 
employed for each tissue homogenate.  Eight to ten wells per dilution were used. 
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3.3 Results 
3.3.1 Histopathology 
No apparent clinical signs were observed for any of the mice infected with any one of the three 
WNV strains.  However, neuropathology was observed in the brain of 3/3 mice inoculated with 
WNVGu1009, 2/3 with WNVK68967 and 1/3 with WNVNSW2011 at day seven post-infection (pi) (Figure 
3-2A and B).  On day 3 pi, neuropathology was only observed in the olfactory bulb of one mouse 
infected with WNVGu1009 (Figure 3-2C), exhibiting as mild focal meningitis. 
While the frequency of neuropathology in the brains of WNVGu1009 infected mice was the highest of 
the three day 7 pi groups, the most severe and extensive meningo-encephalitis was observed in one 
of the three mice infected with WNVK68967.  In this mouse, a moderate multifocal mononuclear 
meningo-encephalitis was observed distributed across all areas of the brain, except for the 
cerebellum (Figure 3-3B, E and H).  Pathology was mainly exhibited as moderate leukocytosis in 
the Virchow-Robin space (perivascular cuffing), with minimal infiltration into the neuropil (Figure 
3-3B and H inset).  Neuronophagia or apoptosis was not observed.  For the remaining animals with 
neuropathology on day 7 pi, the mononuclear meningitis or meningo-encephalitis was mainly 
confined to the mid-brain to brainstem, as in the case for mice infected with WNVGu1009 (Figure 
3-3I) or confined to the olfactory bulb, as in the case for the mouse infected with WNVNSW2011 
(Figure 3-4A).  Within the olfactory bulb, occasional PMNs were seen infiltrating the meninges.  
Mild multifocal mononuclear spinal meningitis was observed in 2/3 of the WNVK68967-infected 
group at day 7 pi (Figure 3-2B and Figure 3-4E).  No pathology was observed in the spinal cords of 
the remainder of the mice. 
In extra-neural tissue, lymphoid activation was observed in most mice (Figure 3-2).  It was evident 
from the formation of secondary follicles in spleens and lymph nodes, hypertrophy of the splenic 
periarteriolar lymphoid sheath (PALS) and hypertrophy of the paracortical zone (PCZ) of lymph 
nodes.  Figure 3-5A-C details the histopathology score of splenic and lymph node activation in the 
six groups of mice according to the scoring system outlined in Section 3.2.4.  From Figure 3-5A-C, 
there does not appear to be an obvious pattern to the temporal activation of the lymphoid system 
associated with the three strains of virus. 
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Figure 3-2 Proportion of mice with pathology in extra-neural tissues.  Panel A, B and C 
compare the proportion of mice with pathology in relation to time points (3 and 7 days post-
infection) in mice infected with WNVNSW2011, WNVK68967 and WNVGu1009, respectively.  kidneys 
(K), liver (Lr), spleen (Sp), mesenteric lymph nodes (MesLN), thymus (Thy), tracheobronchial 
lymph nodes (Trach LN), heart (He) and neural tissues (brain (Br), olfactory lobe (OL), spinal cord 
(SC).   
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Figure 3-3 Comparison of neuropathology in the brains of mice infected with WNVNSW2011 
(left column), WNVK68967 (middle column), WNVGu1009 (right column) on day 7 pi.  Areas 
compared include the cerebral cortex (top row), meninges (middle row), brainstem (bottom row).  
Panel A: Normal cerebral cortex; Panel B: Moderate encephalitis in cerebral cortex, with 
mononuclear perivascular cuffing (inset); Panel C: Normal cerebral cortex; Panel D: Normal 
meninges; Panel E: Moderate multifocal meningitis with mononuclear leucocytes (inset); Panel F: 
Minimal-mild multifocal mononuclear meningitis; Panel G: Normal brainstem; Panel H: Moderate 
multifocal encephalitis in brainstem with moderate perivascular cuffing (inset); Panel I: mild 
encephalitis in brainstem with mild perivascular cuffing (inset).  Arrows indicate areas of 
mononuclear leukocytic infiltration.  All photomicrographs were taken at 10x magnification.  , 
Applicable to all panels, the scale bar in Panel I represents 140μm .  All sections were stained with 
H&E.  
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Figure 3-4  Comparison of pathology in the olfactory bulb (top row), spinal cord (middle row) 
and heart (bottom row) between mice infected with WNVNSW2011 (left column), WNVK68967 
(middle column) and WNVGu1009 at day 7 pi (right column).  Panel A: Mild meningitis (arrow), 
with mild degree of neuropil infiltration (arrowhead); Panel B: Mild meningitis (arrow), with 
minimal perivascular cuffing (arrowhead); Panel C: Normal olfactory bulb; Panel D: Normal spinal 
cord; Panel E: Mild spinal meningitis (arrows); Panel F: Normal spinal cord; Panel G: Mild focal 
myocarditis  (arrows) with mononuclear infiltrate (inset);  Panel H: Normal myocardium; Panel I: 
Mild focal myocarditis (arrows) with mononuclear infiltrate (inset).  Magnifications: A and B at 
20x, C to I at 10x.  The scale bars in Panel A and B represent 80μm , while those in Panels C to I 
represent 140 µm.  All sections were stained with H&E. 
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Figure 3-5 Lymphoid activation in spleen (panel A), tracheobronchial lymph node (Panel B) and mesenteric lymph node (Panel C). 
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In other extra-neural tissue, occasional focal to multifocal infiltrates of mononuclear leucocytes, 
predominantly lymphocytes, were seen in the myocardium of the heart (Figure 3-4G and I), kidney 
and liver. 
3.3.2 Immunohistochemistry 
Immunohistochemistry (IHC) using flavivirus NS1-specific mAB 4G4 was performed on selected 
tissue sections from mice culled at day three and seven pi.  Detection of NS1 antigen is suggestive 
of active viral replication, as it is an essential co-factor for replication [237].  No NS1 antigen was 
detected in any nervous tissue on day three pi.  On day seven pi, NS1 antigen was detected almost 
exclusively in neurons in the brain, olfactory bulb and/or spinal cord from mice infected with 
WNVK68967 (Figure 3-6A, B, C and E) and to a lesser extent from mice infected with WNVGu1009 at 
day seven pi.  Semi-quantitative count of infected neurons in nervous tissue showed that WNVK68967 
infection was associated with markedly higher numbers of infected neurons than WNVGu1009 
infection.  Table 3-4 details the number of infected neurons per mm
2
 in neural tissue sections.  
Unexpectedly, infection with the equine virulent WNVNSW2011 was not associated with detection of 
viral antigen in any of the neural tissue.   
Leucocytes in the spleen and lymph nodes also appeared to be sites where WNV NS1 antigen could 
be located on day 7 pi (See Figure 3-6D and Table 3-5).  While low intensity staining of some 
leucocytes may suggest non-specific immunoglobulin binding during IHC steps, stronger intensity 
staining in other leucocytes suggested genuine detection of NS1 antigen.  However, validation with 
other viral assays, such as TCID50 and/or reverse-transcriptase polymerase chain reaction (RT-
PCR), will be required to support presence of viral particles in these cells. 
IHC was performed on sections of kidney, liver and heart (selected sections).  No antigen was found 
in any of the kidney and liver section.  But one heart section (from a WNVK68967 infected mouse) 
stained positive for NS1 antigen in the myocardium (Figure 3-6F).  In this section, no myocardial 
pathology was associated with the presence of viral antigen. 
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Figure 3-6 Detection of flavivirus replication by IHC (red stain) with flavivirus NS1-specific 
monoclonal antibody.  Left column contains photomicrographs of the brain, olfactory bulb and the 
spinal cord of a mouse infected with WNVK68967 at day 7 pi.  Panel B: moderate density of infected 
neurons in the brain of another mouse infected with WNVK68967 at day 7 pi.  Panel D: infected 
mononuclear leucocytes (red) in the spleen of a mouse infected with WNVNSW2011 at day 7 pi.  
Panel F: infected myofibre of the heart of a mouse infected with WNVK68967 at day 7 pi.  
Magnifications:  A to D and F at 40x; E at 10x.  Scale bar represents 40 µm for A to D and F, and 
160 µm for E.  All sections were counterstained with Mayer’s haematoxylin.  
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Table 3-4  Quantitation of infected neurons in neural tissue at day seven pi.   
Virus Inoculated Animal ID OL Br SC(a) SC(b) 
WNVNSW2011 4 0 0 0 0 
5 0 0 0 0 
6 0 0 0 0 
WNVK68967 10 0 0 0 0 
11 487 510 18 0 
12 0 278 0 0 
WNVGu1009 16 0 8 0 0 
17 0 3 0 0 
18 0 0 0 0 
Counts are expressed as the number of infected neurons per mm2.  OL, olfactory lobe; Br, brain; SC(a), spinal cord (cranial half); 
SC(b), spinal cord (caudal half). 
Table 3-5  Quantitation of infected cells in extra-neural tissue at day seven pi.   
Virus Inoculated Animal ID LK Lr SP Trach 
LN 
WNVNSW2011 4 0 0 0 0 
5 0 0 97 3 
6 0 0 1 0 
WNVK68967 10 0 0 0 0 
11 0 0 1* 0 
12 0 0 58 0 
WNVGu1009 16 0 0 84 0 
17 0 0 na 0 
18 0 0 0 np 
Counts are expressed as the number of infected cell per mm2.  LK, left kidney; Lr, liver; SP, spleen; Trach LN, tracheobronchial 
lymph nodes; na, not analysed; * count was affected by artefacts in section. 
 
3.3.3 TCID50 Results 
Monolayers of Vero cells were inoculated with day three pi sera and 10% w/v homogenates of 
brain, liver, spleen and kidney of all mice, in order to determine levels of infectious virus.  Low 
magnitude viraemia (10
2.8
 TCID50/mL) was observed in all mice infected with WNVNSW2011, 1/3 of 
mice infected with WNVGu1009 and none infected with WNVK68967 at day three pi (Table 3-6).  
Conversely, infection with WNVK68967 was associated with detectable viral load in the brain by day 
seven pi with viral titres as high as 10
10.05
 TCID50/g in one of these animals (Table 3-6).  The 
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remaining brain homogenates failed to elicit infection of Vero cells at any dilution (Table 3-6), 
suggesting either a failure of viral neuroinvasion or a viral titre that is below the detection limit of 
TCID50. 
For the extra-neural homogenates, infectious viral particles were not isolated from kidney 
homogenates, except for two samples, both derived from mice infected with WNVGu1009.  But the 
magnitude of these titres was approahing the limit of detection, with only a couple of positive wells 
at 10
-1
 dilution i.e. < 10
2.8
 TCID50/g  (Table 3-6).   
A few artefacts were encountered with plates inoculated with liver and spleen homogenates.   
Increased optical density reading was observed in wells inoculated with liver homogenates at 10
-1
 
dilution, even for the uninfected negative control.  While no infection was observed in wells at 10
-2
 
to 10
-4 
dilution (except for one mouse infected with WNVK68967, Table 3-6), the artefacts at 10
-1
 
dilution hindered interpretation of the viral load and a definitive titre could not be reached. 
In the case of splenic homogenates, a generally uneven and random distribution of positive wells 
was observed regardless of the dilutions of the homogenates inoculated.  For example, occasional 
positive wells were observed at high dilutions, such as 10
-3
, but without the presence of any positive 
wells at 10
-2
 dilution.  This variability may be either due to inhibitory factors in the homogenates or 
very low titres resulting in stochastic occurrence of infectious virus in the dilution series.  For both 
splenic and liver homogenates, validation of viral titres with highly sensitive quantitative RT-PCR 
(qRT-PCR) may be warranted. 
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Table 3-6  TCID50 titres from liver, spleen, kidney and brain homogenates and sera.   
Day 
post-
infection 
 Virus 
Inoculated 
Animal 
ID 
Liver Spleen Kidney Brain Sera 
3 WNVNSW2011 
  
  
1 0 0 0 0 2.8 
2 0 + 0 0 2.8 
3 0 0 0 0 2.8 
WNVK68967 
  
  
7 0 # 0 0 0 
8 0 + 0 0 0 
9 0 # 0 0 0 
WNVGu1009 
  
  
13 0 # 0 0 2.8 
14 0 + 0 0 0 
15 0 + 0 0 0 
                
7 WNVNSW2011 
  
  
4 0 0 0 0 nd 
5 0 0 0 0 nd 
6 0 0 0 0 nd 
WNVK68967 
  
  
10 0 0 0 0 nd 
11 + + 0 10.05 nd 
12 0 # 0 6.3 nd 
WNVGu1009 
  
  
16 # # <2.8 0 nd 
17 # # <2.8 0 nd 
18 # # 0 0 nd 
Titre is expressed as log10 TCID50 per gram of tissue or per mL of serum.  +, likely positive results but unable to obtain titre due to 
“spotty” results;  #, unable to obtain a reliable titre, due to presence of artefacts (see text for details);  nd, not done. 
3.4 Discussion 
In an attempt to follow the extraneural and neural viral kinetics and distribution of pathology, I have 
employed three main methods: 1) histopathological examination, 2) immunohistochemistry for viral 
antigen detection and 3) TCID50 for virus titration.  Overall, I did not achieve expected results for 
the WNVNSW2011 and the WNVK68967 groups, and only partially for the WNVGu1009 group. 
In a previous survival study, challenging four week old CD1 Swiss outbred mice with 1000 PFU of 
WNVNSW2011, an average survival time of 10.7 days was reported [100].  The first death occurred 
around day 7 pi [100].  Since the experiment conducted for this chapter replicated the experimental 
methods of the study performed by Frost et al. [100], my initial expectation was to observe 
WNVNSW2011 neuroinvasion to have occurred by day 7 pi.  While mild meningitis was present in 1/3 
of WNVNSW2011 challenged mice at day 7 pi, neither infectious virus nor virus antigen was observed 
in any nervous tissue from this group, which may suggest a failure of viral neuroinvasion.  
However, this finding may also be attributable to a relatively low sensitivity in both the IHC and 
TCID50 assay.  Validation of these negative results with qRT-PCR is therefore warranted.  Should 
  
64 
 
these negative results be valid, however, a time point later than 7 days pi should be considered for a 
repeat of the experiment. 
In contrast, the WNVK68967 isolate, expected to be attenuated based on a previous survival challenge 
experiments [219], had invaded the CNS by day 7 pi in the present study.  In particular for one 
mouse, the challenge with WNVK68967 resulted in an unexpectedly high magnitude viral load 
(10
10.05
TCID50/g) in the brain.  However, it is possible that host factors in this particular case have 
allowed a higher than expected level of neuroinvasion.  Furthermore, it is unclear how significant 
this result is, given the low sample size used.  Repeat of the experiment with a larger sample size 
may be of value. 
Furthermore, observing infected neurons may not necessarily translate to higher mortality, 
especially when none of the mice infected with WNVK68967 showed any clinical symptoms at day 7 
pi.  Studies, such as those by Appler et al. [114]  and Brown et al. [27], have shown that WNV 
persistence can occur in the brain, spinal cord and other tissue without causing noticeable clinical 
signs.  Furthermore, the associated neuropathology was not proportional to the viral load for mice 
infected with WNVK68967 (i.e. only moderate pathology as compared to the high density of infected 
neurons).  This, as well as the scenario for WNVNSW2011, may be highlighting the occasional 
discrepance between results obtained from survival studies and ones from pathogenesis studies.  In 
this sense, neuroinvasion (i.e. the invasion of virus into the CNS) may not always correlate with the 
broadly defined term, “virulence”, as characterised by lethality studies.  A repeat of the challenge 
experiment with terminal end-points or with end-points at development of severe clinical disease 
may be warranted, in order to investigate this relationship between neuroinvasion and mortality, 
specifically applicable for WNVKUN virus. 
WNVGu1009 is a strain with similar virulence in mice as compared to WNVNSW2011 [219].  The 
present findings at least partially corroborate the earlier observations.  The low level of brain viral 
load (only detected by IHC) and neuropathology suggested successful viral neuroinvasion.  But, 
perhaps, as for WNVNSW2011, the time-point of seven days pi was too early relative to the peak of 
both virus entry into the CNS and its associated pathology. 
While the observation of a general lymphoid activation was not unexpected, the observed 
myocarditis was interesting for mice infected with WNVNSW2011 and WNVGu1009.  It is a condition 
that has been reported in WNV infected human [108, 109, 207], birds [110-113, 238], dogs [239, 
240] and horses [49].  Associated cardiac arrhythmia, as described in some human case reports 
[108], may contribute to the overall morbidity of mice.  The lack of viral antigen (by IHC) in this 
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area for these mice may potentially suggest a resolving lesion or an underlying immunopathological 
mechanism.  The converse situation was also noted, where virus antigen was detected in the face of 
a lack of myocarditis, as in the case for the mouse infected with WNVK68967.  This demonstrates the 
occasional lack of correlation between the level of viral load and pathology, and may be depending 
on timing, although the viral load may be influenced by the detection limit of the method used.  
Unfortunately, heart was not sampled consistently for histopathology, IHC and TCID50 assay in this 
experiment, as I was not anticipating pathology or virus particles to be present in this tissue at the 
beginning of this trial. 
For the rest of the extra-neural tissues, the rare focal nephritis and mild lymphocytic hepatic 
infiltration should be noted.  But given the low degree of pathology in these fairly resilient organs, 
as well as the lack of associated virus particles in these tissues, the relevance of these lesions may 
be minor, although it should be noted that both organs are major targets for the non-arthropod borne 
flaviviruses – the liver in case of hepatitis C virus [241], and the kidney in case of the pestiviruses 
[242, 243].  Of note, background lesions are common in the liver of mice, especially 
lymphocytic/leukocytic infiltration associated with piecemeal necrosis from retrograde ascension of 
gut bacteria and/or extramedullary haematopoeisis [244]. 
Overall, the unexpected results obtained from this study have indicated that further validation 
assays, such as the highly sensitive qRT-PCR, will be needed to confirm the absence/undetected 
levels of WNVNSW2011 in the brain.  A repeat of the experiment with investigation of the disease 
profile when moribund or dead may characterise the end-point neuroinvasive potential of these 
WNVKUN strains.  Without evidence of neuroinvasion by the WNVNSW2011 strain, my initial aims 
will need to be adjusted accordingly.  In this scenario, neuronal dropout may play a significant role 
in contributing to mortality [245].  Further investigation is required to delineate the exact relevance 
of neuroinvasion to mortality. 
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Chapter 4. End-point disease investigation for virus strains of 
intermediate virulence as illustrated by flavivirus infections 
 
4.1 Manuscript information 
The content of this chapter has been included in my publication [246].  In this chapter, I examined  
the disease phenotype, neuropathology, neural infection and glial cell activity in moribund/dead and 
surviving Swiss white (CD-1) mice after intraperitoneal infection with various Australian 
flaviviruses, including West Nile virus (WNV) strains of intermediate virulence (WNVNSW2011 and 
WNVNSW2012), and highly virulent Murray Valley encephalitis virus (MVEV) isolates.  Hence, this 
chapter addressed objective 1.3 (Section 1.8), and troubleshoots the issues raised in Chapter 3.   The 
experiments conducted for this chapter identified notable intragroup variation in the end-point 
disease in mice infected with either WNVNSW strain, but to a lesser extent in mice infected with 
MVEV strains.  The variable outcomes associated with WNVNSW infection suggest that 
pathogenesis investigations using time-point sacrifice of WNVNSW- infected mice may not be the 
best approach, since the assumption of uniformity in outcomes is violated.  This chapter has 
therefore highlighted a previously unacknowledged challenge to investigating pathogenesis of virus 
isolates of intermediate virulence.  I have also set a precedent for routine examination of the disease 
phenotype in moribund/dead and surviving mice, during survival challenge experiments. 
4.2 Introduction 
Time-course sacrifice experiments have been the conventional approach for viral pathogenesis 
studies.  Post-challenge with the virus of interest, a number of animals are sacrificed randomly at 
various time-points, in order to establish the in vivo kinetics of pathology, virological and 
immunological outcomes associated with the infection (e.g. [28, 247, 248]).  The principle of this 
approach relies on the assumption that all infected animals would reach a similarly timed fate after 
infection.  Hence, it has been an aim for many research groups to achieve a uniform outcome (e.g. 
uniformly lethal) in experimentally infected animals (e.g. [249, 250]).  This uniformity allows 
random samples at various time-points to reliably represent the pathogenic processes toward a 
particular end-point, which in turn helps establish the pathogenesis of the virus of interest. 
However, it is common to observe incomplete morbidity and mortality in a group of virus-
challenged animals, particularly in strains of intermediate virulence, where neither 100% mortality 
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nor 100% survival occurs (e.g. [100, 251]).  Furthermore, it is also common to observe variability in 
the time from infection to death in animals challenged with virus strains of intermediate virulence 
(e.g. [100]).  This suggests a potential variability in the balance between host restriction and in vivo 
virus replication.  However, thorough examination of pathological, virological and immunological 
outcomes in moribund or dead (also collectively designated as “fatalities” or “fatal/lethal end-
points” in this manuscript) and surviving mice during survival challenge experiments is not 
routinely performed.  When investigated, the disease phenotypes were often pooled according to the 
two survival outcomes: moribund/dead vs survivors (e.g. [252]).  Variability in disease phenotype 
within fatal end-points and its implications for downstream pathogenesis investigations have not 
been discussed [252].    
In the current study, we investigated the spectrum of end-point disease associated with infection 
with two Australian West Nile virus (WNV) strains of intermediate virulence (WNVNSW2011 and 
WNVNSW2012) in an established intraperitoneal infection model in female young adult Swiss white 
(CD-1) mice.  In this outbred mouse model, these two virus strains have been shown to produce 
intermediate levels of mortality [100, 219].  We examined the end-point histopathology, virus 
infection in the nervous system and glial cell activation in moribund/dead mice.  Surviving mice at 
the end of the trial were also included as part of the disease spectrum assessment.  As a comparison, 
we characterised the neuropathology in mixed gender weanling Swiss white mice infected with the 
highly virulent Australian Murray Valley encephalitis virus (MVEV), which typically causes a high 
degree of morbidity and mortality in this model [84, 222].  This model system is a valid comparison 
to WNVNSW2011 in an Australian context, since MVEV is the one of most virulent flaviviruses found 
in Australia and it produces almost identical rate of and time to mortality in weanling Swiss white 
mice, as those observed in infection with virulent North American WNV strains, such as WNVNY99 
[100]. 
The outcome of our studies shows that despite challenge with the same virus strain at the same dose 
and route, there is considerable intragroup variability in the end-point disease phenotype in 
WNVNSW-infected mice, and to a lesser degree in MVEV-infected mice.  This difference in 
variability between WNVNSW- and MVEV-infected mice may be correlated to the difference in the 
levels of mortality (“virulence phenotype”) and the variability of time to mortality between the two 
model systems.  This comparison highlights the importance of various virus (family, strain), host 
(species, strain, age, gender, immune status and homogeneity of genetic background) and 
experimental factors (dose and route of inoculation) in contributing to the “virulence phenotype” 
and its associated disease phenotypic spectrum.  Therefore, it is paramount to characterise the end-
  
68 
 
point disease spectrum for new or existing virus isolates in any animal model system to be 
employed for pathogenesis studies.  Furthermore, we propose that it may be inappropriate to 
investigate pathogenesis using time-point sacrifice in a model system that produces notable 
variability in the end-point disease phenotype of interest, since the assumption of uniformity in 
outcomes is violated.  The present study therefore sets a precedent for routine evaluation of end-
point disease variability, which in turn can help determine the experimental design of downstream 
pathogenesis investigations. 
4.3 Methods 
4.3.1 Virus strains, animals and experimental design 
The 2012 Australian WNV strain, WNVNSW2012, was isolated from Culex annulirostris mosquito 
pools sourced from the state of New South Wales [219].  The isolation and propagation of the 
outbreak strain, WNVNSW2011, has been previously described [100].  These two strains were titrated 
by plaque assay on African green monkey kidney (Vero) cells [235] and the virus stock titres were 
expressed as PFU.  Multiple survival challenge experiments involving female 24-28 days-old CD-1 
Swiss outbred mice were conducted, as previously described [235].  Ten mice were randomly 
assigned to each virus challenge group.  Mice were challenged intraperitoneally with either 100 or 
1000 PFU in 100 L of Roswell Park Memorial Institute (RPMI) media, supplemented with 2% of 
foetal bovine serum [253].  To investigate the end-point phenotype in a highly virulent Australian 
flavivirus strain, we used two strains of MVEV:  a contemporary MVEV isolate (MVEK68838) and 
the prototype (MVE1-51).  Isolation of MVE1-51 has been described previously [254].  MVEK68838 
was isolated from mosquitoes trapped in Western Australia in 2012 and was kindly provided by Dr. 
Cheryl Johansen (University of Western Australia).  MVEV strains were additionally passaged once 
on insect Aedes albopictus cells (C6/36), and titrated by a tissue culture infective dose (TCID50) 
assay on Vero cells prior to use [224].  MVEV strains were inoculated intraperitoneally in the 
established 18 day-old mixed gender Swiss CD-1 outbred mouse model at doses of 10 and 1000 
TCID50 with ten mice randomly assigned to each challenge group [84, 254]. 
All animal experiments were conducted under Physical Containment level 2 condition with ethics 
approval from the University of Queensland Animal Ethics Committee (permit number 
SCMB/196/11/NHMRC(NF)).  Twice daily monitoring for clinical and neurological signs was 
conducted.  A score of zero to four was assigned to each mouse, where score zero signifies normal 
behaviour, and score three indicates state of moribund or exhibition of severe clinical signs, such as 
seizure and paralysis.  Mice with a score of three were euthanatised on humane grounds with an 
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overdose of ketamine (100mg/kg), xylazine (20mg/kg) and phosphate buffered saline mixture.  A 
score of four was assigned to mice that died naturally due to unexpected rapid deterioration.  Fatal 
end-point was defined as a mouse that reached a clinical score of three or four.  Survivors at day 20-
22 pi were humanely euthanatised, as described above, following a cardiac bleed under deep 
anaesthesia, for serum procurement. 
4.3.2 Histology 
At either time of end-point euthanasia or discovery of carcass, samples of the neural and extra-
neural tissues were taken for histopathological and immunohistochemical analysis [235].  The entire 
head, with skin and calvarium removed, along with the entire length of the vertebral column were 
fixed in 10% neutral buffered formalin for 48 to 72 hours, followed by de-calcification in 8% 
formic acid for three to four days.  Histopathology processing and scoring are described in detail in 
Section 3.2.4.    
4.3.3 Immunohistochemistry 
The IHC-protocol for detection of flaviviral non-structural protein 1 (NS1) antigen has been 
previously described in detail [235].  Anti-flavivirus NS1-specific monoclonal antibody, 4G4 [228] 
was used for detection of WNV and MVEV infection in neural and extraneural tissues.  Rabbit anti-
GFAP (DAKO) and goat-anti-Iba-1 (Abcam) antibodies were used to assess astrocytic and 
microglial activation in brain and spinal cord sections, using a previously described protocol [255].  
The degree of viral antigen load and glial cell activation was scored semi-quantitatively as 
previously described [72, 256] by an observer (HBO) blinded to the group allocation.  Viral antigen 
load was scored on a scale of zero to three (zero = no viral antigen apparent; 1 = rare, scattered 
positive cells or a few positive cells limited to a single focus; 2 = moderate numbers of scattered or 
positive cells or focally extensive occurrence; 3 = widespread in all parts of brain/spinal cord), 
while glial cell activation was scored on a scale of zero to five (zero = normal GFAP/Iba-1 pattern; 
1 = minimal to mild increase in cell sizes and signal intensity in a single region of the brain; 2 = 
mild increase in cell sizes and signal intensity  in several regions of the brain; 3 = moderate increase 
in cell sizes and signal intensity in several regions of the brain; 4 = marked increase in cell sizes and 
signal intensity in several regions of the brain; 5 = diffuse, severe increase in cell sizes and signal 
intensity in several regions of the brain). 
4.3.4 Seroconversion 
At time of euthanasia, terminal cardiac bleed was performed on survivors at the end of the trial (day 
20-22 pi), and sera were extracted.  Antibody production against the WNVNSW and MVEV strains 
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was assessed in survivors by fixed cell enzyme-linked immunosorbant assay (ELISA) using 
WNVNSW or MVEV-infected C6/36 cells, as previously described [230]. 
4.3.5 Statistical analysis 
Time to fatal end-point data have a right skewed distribution pattern and were log10(Y+1) 
transformed before performing parametric tests.  All pathology and immunohistochemistry scores 
had a Gaussian distribution.  Two-way ANOVA with post-test Sidak or Tukey was performed to 
assess group differences.  For testing the equality of variance, we initially transformed the raw data 
to the absolute difference of the raw scores to the median of each group, before performing a two-
way ANOVA to identify variance differences between groups [257].  Post-hoc tests (Sidak) also 
allowed identification of specific group differences in variance [257].  This test is a modification of 
the Brown-Forsythe test of equality of variance [257].  Correlation was performed by a two-tailed 
Spearman correlation test.  Survival curve comparisons were performed by a log-rank (Mantel-Cox) 
test. All statistical analyses were performed in statistical software, Graphpad Prism 6 (Graphpad 
Software Inc., San Diego, CA). 
4.4 Results 
4.4.1 Time to fatal end-point 
Table 4-1 summarises the mortality rate and the day post-infection (pi) on which fatal end-points 
were observed for each virus-challenge group.  The variance of the time from infection to fatal end-
point was significantly larger in WNVNSW groups as compared to that of the MVEV groups at the 
low dose (Figure 4-1A, p = 0.0103).  However, the mean time to fatal end-point was not 
significantly different between the two WNVNSW strains at either dose.  As expected, the average 
time to fatal end-point in the MVEV groups were generally earlier than in the WNVNSW groups 
(Figure 4-1A, low dose: p < 0.0001; high dose: p = 0.0009).  Between the MVEV challenge groups, 
the survival curves differed significantly at both doses, with the more contemporary 2012 Western 
Australian strain (MVEK68838) producing a lower degree of mortality (Figure 4-2A and B; ten 50% 
tissue culture infective dose (TCID50): p = 0.0003; 1000 TCID50: p = 0.0450).  All survivors, except 
for one challenged with 1000 TCID50 of MVE1-51, at the end of the trial seroconverted.  The 
seronegative MVE1-51-challenged mouse was excluded from further analyses. 
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Table 4-1 Mortality rate and day of fatal end-points in mice challenged with WNVNSW and 
MVEV strains. 
Inoculation 
dose 
 Virus strain Mortality 
rate 
Day of fatal end-points (Day pi) 
100 PFU WNVNSW2012 4/10 8 (n = 1), 9 (n = 1), 10 (n = 1), 14 (n = 1) 
WNVNSW2011 8/10 8 (n = 3), 10 (n = 2), 11 (n = 2), 12 (n = 1) 
1000 PFU WNVNSW2012 7/10 6 (n = 1), 7 (n = 2), 8 (n = 1), 9 (n = 1), 10 (n = 1), 
11 (n = 1) 
WNVNSW2011 7/10 7 (n =1), 8 (n = 3), 10 (n = 3) 
10 TCID50 MVEK68838  9/10 7 (n = 3), 8 (n = 4), 9 (n = 1), 10 (n = 1) 
MVE1-51  10/10 6 (n = 6), 7 (n = 4) 
1000 TCID50 MVEK68838 9/10 7 (n = 7), 8 (n = 1), 9 (n = 1) 
MVE1-51 9/9
#
 6 (n = 5), 7 (n = 2), 8 (n = 2) 
#
 one mouse has been excluded from this group, due to seronegativity at the end of the trial.  pi, 
post-infection; n, number of moribund/dead mice; PFU, plaque forming units; TCID50, 50% tissue 
culture infective dose. 
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Figure 4-1 Time to fatal end-point (A) and severity of lethal neuropathology (B to D).  Each 
data point represents one fatal case.  Horizontal bars indicate the median and error bars represent 
the interquartile range. Low dose for WNVNSW was 100 PFU, and for MVEV was 10 TCID50.  
High dose for WNVNSW was 1000 PFU and for MVEV was 1000 TCID50.  The degree of variance 
between WNVNSW and MVEV groups were compared using a modified Brown-Forsythe test of 
equality of variance.  Symbol (*) represents statistical significance of this test: * p < 0.05, ** p < 
0.01, *** p < 0.001.  Appendix 2 to Appendix 5 tabulate the corresponding neuropathology for each 
individual mouse, infected with either of the WNVNSW or MVEV strains.  
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Figure 4-2 Survival curves of weanling Swiss white mice infected with 10 (A) and 1000 TCID50 
(B) of MVEK68838 and MVE1-51, and survival curves of 28 day-old Swiss white mice infected 
with 100 (C) and 1000 pfu (D) of WNVNSW2011 and WNVNSW2012.  Statistical significance was 
calculated by log rank Mantel-Cox algorithm.  Note that one animal has been excluded from the 
1000 TCID50 MVE1-51 challenge group, due to seronegativity to MVE1-51 at the end of the trial (see 
Table 4-1).  
 
4.4.2 Histopathology 
The severity and incidence of WNVNSW2012-induced lethal neuropathology were not significantly 
different to those of WNVNSW2011, regardless of dose (Figure 4-1B to D; Table 4-2).  Of the three 
aspects of neuropathology investigated, lesions in the neuropil of the brain (encephalitis) were 
generally more severe than those in the neuropil of the spinal cord (myelitis) (Figure 4-1C and D). 
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Table 4-2 Incidence of lethal neuropathology 
Inoculation 
dose 
Virus strain Meningitis Encephalitis Myelitis 
100 PFU WNVNSW2012 3/4  3/4  2/4  
WNVNSW2011 6/8  8/8  8/8  
1000 PFU WNVNSW2012 5/7  7/7  5/7  
WNVNSW2011 5/7  7/7  6/7  
The proportion of animals with neuropathology was not significantly different between the two virus challenge groups 
for each inoculation dose (Fisher’s exact test, p > 0.05 for all pairwise comparisons). 
 
There was no significant dose-dependent effect on the severity of lethal neuropathology in 
WNVNSW- and MVEV-infected mice (Figure 4-1B to D).  However, within each of the WNVNSW-
challenge groups, notable variability was observed.  The variance in the brain pathology scores of 
the WNVNSW groups was significantly larger than that of the MVEV challenge groups (Figure 4-1B 
and C; meningitis: at low dose: p = 0.0059; at high dose: p = 0.0207; encephalitis: at low dose: p = 
0.0049, at high dose: p = 0.0481).  The variability of myelitis severity was not significantly 
different between mice infected with WNVNSW and MVEV, regardless of the dose inoculated 
(Figure 4-1D). 
The scatterplots of the lethal neuropathology scores over time show that mild neuropathology 
(scores < 1) in the brain was only observed in fatal cases after day 9 pi (Figure 4-3A to D).  This 
trend was more evident in mice infected with WNVNSW2012 at either of the doses (Figure 4-3A and 
C).  A similar pattern was observed for the spinal cord of mice in these groups (Figure 4-4A to D). 
The features of neuropathology observed ranged from severe neuronal degeneration and necrosis 
typically in the cerebral cortex and hippocampus (Figure 4-5A and B) to milder lesions such as 
focal mononuclear leucocyte infiltrates in the thalamus or pons.  Hydrocephalus involving the 
lateral and third ventricle was observed in one mouse infected with 1000 PFU of WNVNSW2011 
(Figure 4-5C). Another mouse challenged with 100 PFU of WNVNSW2012 reached its lethal end-
point on day 14 pi without any observable central nervous system (CNS) lesions.  In contrast, a 
trend of low neuropathology scores in late lethal end-points was not as evident in the MVEV 
groups, since most mice reached their end-points before day 9-10 pi (Figure 4-6A to D). 
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Figure 4-3 Scatterplots of lethal events in the brain.  (A to D) Virus infection, neuropathology 
and glial activation in the brain of moribund/dead mice infected with WNVNSW2012 (A and C) 
and WNVNSW2011 (B and D).  Each data point represents one fatal case.  The demarcation between 
the shaded and non-shaded area represents the proposed demarcation of the early and late fatal end-
point phenotype at around day 9 pi.  Appendix 2 and Appendix 3 tabulate the corresponding 
neuropathology, CNS infection, and glial activation for each individual mouse, infected with either 
of the WNVNSW strains.  
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Figure 4-4 Scatterplots of lethal events in the spinal cord.  (A to D) Virus infection, 
neuropathology and glial activation in the spinal cord of moribund/dead mice infected with 
WNVNSW2012 (A and C) and WNVNSW2011 (B and D).  Each data point represents one fatal case.  
The demarcation between the shaded and non-shaded area represents the proposed demarcation of 
the early and late fatal end-point phenotype at around day 9 pi.  Appendix 2 and Appendix 3 
tabulate the corresponding neuropathology, CNS infection, and glial activation for each individual 
mouse, infected with either of the WNVNSW strains.  
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Figure 4-5 Severe lethal neuropathology and CNS infection.   (A and B) Extensive and severe 
neuronal necrosis, as characterised by fragmented neuronal nuclei (karyorrhexis; inset in (A) and 
arrow in (B)), in the hippocampus (A) and cerebral cortex (B), with severe infiltration of 
mononuclear leucocytes in the neuropil (C) Hydrocephalus, as characterised by severe dilation of 
the lateral ventricles (asterisk), in a fatal end-point challenged with WNVNSW2011 at 1000 PFU.  (d) 
Severe and extensive necrosis and mineralisation (arrows) in the cerebral cortex, with severe 
granulomatous inflammation in a MVEK68838-infected survivor.  Calcium deposition in mineralised 
foci has been confirmed with positive Von Kossa staining (black stain in D inset). (E and F) WNV 
NS1 antigen in intact (E; score of 3) or degenerating neurons (F; score of 3).  (F, arrow) Histiocytic 
phagocytosis of WNV-infected neuron (neuronophagia).  Magnifications: 10x (a), 40x cropped and 
resized (A inset), 40x (B), 2x cropped (C), 20x (D), 20x (E), and 40x (F).  Scale bar represents 
40μm for (B), 80μm for (A inset, D, and E), 140μm for (A), and 300μm (C).  
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Figure 4-6 (A to D) Scatterplots of lethal neuropathology score against time in moribund/dead 
MVEK68838- (A and C) and MVE1-51-infected (B to D) Swiss mice. Each data point represents one 
fatal case.  The demarcation between the shaded and non-shaded area represents the proposed 
demarcation of the early and late fatal end-point phenotype at around day 9 pi.  Appendix 4 and 
Appendix 5 tabulate the corresponding neuropathology for each individual mouse, infected with 
either of the MVEV strains.  
Mild to moderate neuropathology was also observed in WNVNSW2012 and WNVNSW2011 infected 
survivors (WNVNSW2012 at 100 plaque forming units (PFU): n = 3/6, at 1000 PFU: n = 1/3; 
WNVNSW2011 at 1000 PFU: n = 1/3).  Involvement of the basal ganglia, hypothalamus and/or 
cervical spinal cord was noted.  None of the three survivors from the 100 PFU WNVNSW2011 
challenge group had observable CNS lesions.  Of the two survivors from MVEV challenge groups, 
one mouse infected with 1000 TCID50 of MVEK68838 displayed severe granulomatous inflammation, 
mineralisation and malacia in the cerebral cortex and thalamus (Figure 4-5D), accompanied by 
hydrocephalus. 
The heart was also examined in a subset of dead/moribund and surviving mice.  Cardiac 
inflammation was consistently observed in one mouse per group.  The severity and character ranged 
from focal mild endocarditis to focal mild to moderate vasculocentric myocarditis.  No 
histopathological lesions were noted in any of the remaining extraneural tissues examined. 
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4.4.3 Virus infection 
In order to explain the relatively large variability of lethal end-point neuropathology induced by the 
two strains of WNVNSW, the severity and distribution of virus infection in the CNS were 
investigated by immunohistochemistry (IHC). 
The presence of viral antigen in the CNS of fatal cases was predominantly observed in mice with 
concurrent encephalitis and myelitis scores of 2 or greater (n = 18/19 brains and n = 16/16 spinal 
cords).  There was a significant positive correlation between the severity of brain lesions and virus 
infection (encephalitis: r = 0.8270, p < 0.0001; meningitis: r = 0.5254, p = 0.0058).  Only one virus 
positive brain from a mouse infected with 1000 PFU of WNVNSW2012 had a concurrent lethal 
encephalitis score of 1 on day 10 pi.  Similar to lethal neuropathology, low viral antigen load in the 
brain (<2) was only detected after day 9 pi (Figure 4-3A to D).  The variance in the severity of viral 
antigen load in the CNS was also large, similar to neuropathology (Figure 4-7A and B).  The 
median brain viral antigen scores were higher than those in the spinal cord for most groups, except 
for mice infected with 100 PFU of WNVNSW2012 (Figure 4-7A and B).  Notably, dead/moribund 
mice infected with 1000 PFU of WNVNSW2012 had a higher median brain viral antigen load than all 
other groups, though this difference was not statistically significant (Figure 4-7A). 
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Figure 4-7 Virus infection and glial activation in the CNS.  (A and B) Overall viral antigen load 
score in the brain (A) and spinal cord (B) of moribund/dead mice infected WNVNSW2012  and 
WNVNSW2011.  (C) Incidence of virus infection in different regions of the brain.  (d) Astrocytosis in 
the brain.  (E and F) Microgliosis in the brain (E) and spinal cord (F).  For panels (A, B, D, E, and 
F), each data point represents one fatal end-point.  For panel (C), each point represents the 
incidence of virus infection in each region of the CNS for each virus challenge group.  The number 
adjacent to these data point represents one challenge group: 1, WNVNSW2012 (100 PFU); 2, 
WNVNSW2011 (100 PFU); 3, WNVNSW2012 (1000 PFU); 4, WNVNSW2011 (1000 PFU).  All horizontal 
bars indicate the median and the error bars, where used, indicate the interquartile range.  Appendix 
2 and Appendix 3 tabulate the corresponding neuropathology, CNS infection, and glial activation 
for each individual mouse, infected with either of the WNVNSW strains.  
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There was a temporo-spatial trend in terms of the extensiveness of CNS infection and the timing of 
the fatal event.  Late fatal end-points typically had less widespread CNS infection than the earlier 
end-points (Figure 4-8A to D).  Common sites of lethal virus infection in the brain included the 
cerebral cortex, thalamus and pons (Figure 4-7C).  The medulla was also a common site to observe 
virus infection in WNVNSW2012-challenged mice (Figure 4-7C). 
 
 
Figure 4-8 Temporo-spatial distribution of CNS infection.   (A to D) Viral antigen load in 
different regions of the CNS in moribund/dead mice infected with WNVNSW2012 (100 (A) and 1000 
PFU (C)) and WNVNSW2011 (100 (B) and 1000 PFU (D)).  The diagram above the graphs indicates 
the three regions of the CNS represented by the different symbols.  Each data point represents the 
viral antigen load in one region of one animal.  Appendix 2 and Appendix 3 tabulate the 
corresponding neuropathology, CNS infection, and glial activation for each individual mouse, 
infected with either of the WNVNSW strains.  
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WNV antigen was detected in the cytoplasm of either intact (Figure 4-5E) or degenerating neurons 
(Figure 4-5F).  Lymphohistiocytic infiltrates were commonly associated with degenerating or 
necrotic infected neurons (Figure 4-5F), while intact infected neurons were commonly seen in areas 
that were distant from neuropil- or perivascular-infiltrating leucocytes (Figure 4-5E).  For the 
former, phagocytosis of infected neurons (neuronophagia) was evident, suggestive of neuronal 
dropout in progress (Figure 4-5F).  No WNV antigen labelling was detected in any non-CNS tissues 
except for the inner ear of one day 9 pi fatal case infected with 100 PFU of WNVNSW2012.  No viral 
antigen was detected in any of the survivors. 
4.4.4 Astrocytic and microglial activation 
In addition to the profile of end-point CNS infection, the activation state of glial cells in mice 
infected with WNVNSW2012 and WNVNSW2011 was also investigated, in order to assess whether a 
temporal trend corresponding to virus infection and pathology was present.  Astrocytosis and 
microgliosis were assessed using GFAP and Iba-1 immunohistochemical labelling of brain and 
spinal cord sections.  The degree of cellular hypertrophy and density of these glial cells were used 
to assess the level of activation.  Normal appearance of non-activated CNS is depicted in Figure 
4-9A and D. 
Glial activation (astrocytosis and/or microgliosis) was observed in all dead/moribund mice 
regardless of virus strain or dose inoculated (Figure 4-9B and E).  The overall degree of glial 
activation was not significantly different between the WNVNSW challenge groups (Figure 4-7D to 
F).  As for lethal neuropathology, and CNS infection, the variability in the glial activity associated 
with lethality was high in all WNVNSW-challenged groups (Figure 4-7D to F).  However, contrary to 
pathology and infection, glial activity remained at notable levels in moribund/dead mice beyond day 
9 pi (Figure 4-3A to D, and Figure 4-4A to D).  The overall incidence of moribund/ dead mice that 
had undetectable CNS infection, low-grade neuropathology, but generally moderate to severe glial 
activation was 23% (6/26).  Glial activation was also observed in a subset of survivors (Figure 4-9C 
and F; WNVNSW2012 at 100 PFU:  n = 3/6; at 1000 PFU: n = 1/3; WNVNSW2011 at 100 PFU: n = 1/2, 
at 1000 PFU: n = 1/3).  Thus, astrocytic and/or microglial activity did not invariably correlate with 
virus infection and pathology in the CNS. 
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Figure 4-9 Glial activation.   (A to F) Astrocytosis (A to C) and microgliosis (D to F) in the CNS 
of WNVNSW infected mice.  (A) Non-activated appearance of astrocytic labelling in the CNS.  (B) 
Moderate astrocytosis surrounding area of malacia (arrow, score 3) in a day 11 pi fatal end-point 
infected with 100 PFU of WNVNSW2011.  (C) Mild to moderate (score 2) astrocytosis in the brain of 
a survivor infected with 100 PFU of WNVNSW2012.  (D) Non-activated appearance of microglial 
labelling in the CNS. (E) Moderate to severe microgliosis (score 4) in the brain a day 10 pi fatal 
end-point infected with 1000 PFU of WNVNSW2012.  Inset of (E) depicts the clear distinction 
between microglial cells (arrow) and monocytes (arrowhead), as indicated by the non-branching 
morphology of the latter.  This inset was from a day 8 pi fatal end-point infected with 100 PFU of 
WNVNSW2011.  (F) Moderate microgliosis (score 3) in the spinal cord in a survivor infected with 100 
PFU of WNVNSW2012.  Magnification: 20x (A to E), 20x cropped (E inset), and 10x cropped (F). 
Scale bar represents 140μm for all panels.  
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4.5 Discussion 
The present study used the examples of two Australian WNV strains of intermediate virulence 
(WNVNSW2011 and WNVNSW2012) in the established flavivirus-virulence animal model, CD-1 Swiss 
white mice, to illustrate that intermediate levels of mortality and variable time from infection to 
severe morbidity/mortality are associated with different end-point disease outcomes.  Notably, 
WNVNSW2011 and WNVNSW2012 infections induced different severity of neuropathology, and CNS 
infection in a time-dependent manner in moribund/dead mice (Figure 4-3A to D and Figure 4-4A to 
D).  In particular, early lethal end-points typically had more profound neuropathology scores and 
CNS viral antigen load, as compared to late end-points (Figure 4-3A to D and Figure 4-4A to D).  
Glial activation did not vary in a notable temporal trend (Figure 4-3A to D and Figure 4-4A to D).  
Hence, WNV strains of intermediate virulence induce a variable disease phenotype amongst 
outbred CD-1 Swiss white mice progressing to clinically moribund state or death.  The relatively 
narrower spectrum of lethal brain neuropathology in MVEV-infected weanling Swiss white mice 
(Figure 4-1B and C) suggests that variability of lethal end-point disease in the target organ (i.e. 
brain) may differ with the “virulence phenotype” (i.e. the proportion of morbidity/mortality in 
infected groups) of the isolate in a particular model system (host species/strain and experimental 
methods).  
Variability in disease outcomes has been reported regularly for WNV infections in humans and 
certain mouse strains [258, 259].  Particularly relevant in an Australian context, variable end-point 
disease outcomes have been reported for other Australian WNV strains of intermediate virulence in 
the Swiss white mouse model [218].  However, the significance and implications of this variability 
have rarely been discussed in the literature. 
The variable outcomes in moribund/dead mice after infection with WNVNSW strains suggest that the 
mechanism of severe morbidity/death may differ depending on the time from infection to lethal 
end-point.  While the outcomes in early fatalities are consistent with the severe neuronal infection 
and neuropathology seen in most other mouse studies [28, 260], the relatively benign 
neuropathology and CNS infection of the late lethal end-points have only been reported on a few 
occasions, but have not been a focus of the investigations [218, 261].  In general, there is a lack of 
research effort towards understanding the mechanism of severe morbidity/death associated with this 
surprisingly benign phenotype, which is actually the main presentation in fatal human and equine 
WNV infections [21, 87].  Given the observation of neuronophagia in earlier fatalities (Figure 
4-5F), it is possible that the late lethal end-points in our study captured a temporal snapshot after 
complete clearance of infected neurons.  The cause of the severe symptoms/death in these late 
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fatalities, therefore, may be due to drop out of essential neurons in vital areas of the CNS, such as 
the brainstem or spinal cord [245, 262].  Complete characterisation of the distribution and degree of 
neuronal dropout is beyond the scope of the current study.  But these late lethal end-points do 
highlight that moribund/dead Swiss white mice infected with the same strain of WNV by the same 
route may not always progress through the same pathogenic pathways towards severe 
morbidity/death. 
Variability in the end-point disease has significant implications on downstream pathogenesis 
investigations.  Notably, the use of conventional time course sacrifice experiments may need to be 
cautious, since it relies on the assumption that the experimental infection would produce a uniform 
outcome.  This assumption allows the outcomes from randomly sacrificed animals at a particular 
time-point to accurately represent events along a timeline of pathogenesis towards a particular 
disease outcome, such as fatal encephalitis.  Prior to the present study, I attempted to investigate the 
neuropathogenesis of fatal WNVNSW2011 infection by random scheduled culling of infected female 
young adult Swiss white mice on day 3 and 7 pi (Chapter 3).  Mice were intraperitoneally infected 
with 1000 PFU of WNVNSW2011.  This was performed alongside investigations using two other 
contemporary Australian WNV-Kunjin isolates (WNVK68967 and WNVGu1009).  The time course 
experiment did not detect neuropathology nor virus infection in the brain of WNVNSW2011-infected 
mice, even on day 7 pi (Table 4-3).  In light of the wide spectrum of end-point diseases associated 
with WNV strains of intermediate virulence and the relatively small number of mice used in that 
experiment, it was uncertain whether the sacrificed mice were progressing towards the early or late 
lethal end-point.  It was also possible that the sacrificed mice were progressing towards survival.  
This illustrates the issue of loss-to-followup bias introduced by the time course experimental design, 
the magnitude of which is more notable when a wide spectrum of end-point disease outcomes is 
associated with the infection.
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Table 4-3. Time-point sacrifice experiment to investigate the neuropathogenesis of WNVNSW2011, WNVK68967, WNVGu1009 infections.  Prior to the 
present study, young adult Swiss white mice were infected with 1000 PFU of WNVNSW2011, WNVK68967, and WNVGu1009 via the intraperitoneal route 
(Chapter 3).   Additional three sham-inoculated mice were included in this experiment.  Random sacrifice of three mice per time-point on day 3 and 7 
pi was performed.  This table is a summary of the results in Chapter 3.  Information on WNV strains, WNVK68967 and WNVGu1009, will be available in a 
separate publication [219].  
 Brain Olfactory Lobe Cranial Spinal Cord Caudal Spinal Cord 
Sacrifice time-point Virus Strain Animal ID Histo IHC TCID50 Histo IHC Histo IHC Histo IHC 
Day 3 pi 
WNVNSW2011 
  
  
1 0 0 0 0 0 0 0 0 0 
2 0 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 
WNVK68967 
  
  
7 0 0 0 0 0 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 0 0 
WNVGu1009 
  
  
13 0 0 0 0 0 0 1 0 0 
14 0 0 0 0 0 0 0 0 0 
15 0 0 0 1 0 0 0 0 0 
Day 7 pi 
WNVNSW2011 
  
  
4 0 0 0 1 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 0 0 0 0 
WNVK68967 
  
  
10 0 0 0 0 0 0 0 0 0 
11 3 510 10 1 487 1 18 1 0 
12 1 278 6 1 0 1 0 0 0 
WNVGu1009 
  
  
16 2 8 0 0 0 0 0 0 0 
17 1 3 0 0 0 0 0 0 0 
18 2 0 0 0 0 0 0 0 0 
Histo, histopathology; IHC, immunohistochemistry; TCID50, 50% end-point tissue culture infective dose.  Histopathology was scored out of 5, where 0 indicates normal, while 5 
indicates severe pathology.  IHC refers to the number of WNV-NS1 immunolabel positive cells per mm
2
 of a 5μm thick section.  TCID50 refers to the log10 TCID50 titre of virus per 
gram of tissue, isolated from clarified 10% weight/volume homogenates of tissue in culture media (DMEM), as titrated on Vero cells [235, 263]. 
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Similar illustration of variable disease outcomes and loss-to-follow up bias associated with time-
point sacrifice experiments was observed in a previous study, involving an inbred mouse strain 
(BALB/c), a different virus strain (WNVNY99), route (intravenous) and dose (10
6
 PFU) of 
inoculation [261].  After infection, only a proportion of the moribund or dead adult BALB/c mice 
developed neuropathology and had detectable viral antigen in the brain, similar to the findings of 
the current study [261].  Furthermore, a notable range in the time to fatal end-point, ranging from 
day 6 to 14 pi, was observed in this model system [261].  When the investigators performed 
scheduled time-point sacrifice of infected mice, they failed to observe neuropathology and brain 
infection at the three time-points (day 3, 5 and 7 pi), similar to our pathogenesis study [261].  
Therefore, variability in disease outcomes as well as its associated implications for time-course 
experiments is not just a phenomenon in outbred mouse strains, such as the CD-1 Swiss white 
mouse model, or with more attenuated virus strains, such as WNVNSW, used in this study. 
Other inbred mouse strains, such as C57BL6, also produce variable disease outcomes, such as brain 
viral load, in moribund or dead mice when infected with specific WNV strains at specific doses and 
routes [262].  This highlights that the “virulence phenotype” of a virus isolate and its associated 
disease spectrum are dependent on the model system used.  Specifically, they are dependent on the 
in vivo infection, replication and dissemination capacity of a virus isolate within a host of a certain 
species, age, gender, breed/strain, immune status, homogeneity of genetic background, and specific 
colony or vendor.  Experimental factors, such as route and dose of inoculation, also affect the 
“virulence phenotype” in the model system.  
Conventionally, CD-1 outbred Swiss white mice have been used for assessing virulence of WNV 
and other flaviviruses [251, 253], thus justifying the use of this mouse strain in the current study.  
However, the correlation between intermediate levels of morbidity/mortality (i.e. intermediate 
virulence) and the variability of disease outcomes likely applies to other non-flavivirus challenge 
models, since isolates of intermediate virulence have been reported in other virus families (e.g. 
[264-266]).  Therefore, we recommend that routine assessment of the end-point disease spectrum 
should be performed for any new virus isolate in an established model system, or for existing 
isolates in a previously uncharacterised model system, in order to determine the validity of time-
course sacrifice experiments for downstream pathogenesis investigations.  We also recommend 
individual recording of pre-mortem clinical parameters, such as that performed in [252], so that 
disease outcomes may potentially be predicted pre-mortem. 
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For the problems associated with WNVNSW2011-Swiss outbred mouse model system outlined above, 
further experiments as suggested in Chapter 3, such as verifying the absence of virus from CNS 
tissue by more sensitive methods, are unlikely to provide additional meaningful information 
regarding the neuropathogenesis of WNVNSW2011.  For any virus challenge model system that 
produces large variability in the disease of interest, a large sample size per time-point should be 
used, if pathogenesis is to be investigated by sacrifice experiments in that model.  However, this 
only minimises, and does not overcome, the problem of loss-to-follow up bias associated with time 
course experiments.  Alternatively, the use of in vivo bioluminescence monitoring of host or virus 
gene expression will allow individual tracking of pathogenic events towards the different end-point 
outcomes [267].  Similarly, intra-vital imaging of dye-labelled cells may also allow tracking of live 
virus-host interactions on an individual and cellular level [268, 269].  These real-time monitoring 
tools, combined with transcriptomic and proteomic studies of the host immune response, may 
therefore be particularly ideal for pathogenesis investigation of virus strains that produce notable 
variability in disease outcomes in a particular model system. 
In conclusion, variable disease outcomes are likely associated with virus isolates of intermediate 
virulence in a specific model system.  We have demonstrated this, using the example of WNV 
strains of intermediate virulence in an established Swiss white mouse model.  This variability 
challenges the assumption of uniform outcome that is crucial for time course sacrifice experiments 
for pathogenesis investigation.  Our study has therefore highlighted a previously unacknowledged 
challenge to investigating pathogenesis of virus strains of intermediate virulence, as well as the 
importance of characterising the end-point disease spectrum during survival challenge studies. 
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Chapter 5. Experimental West Nile virus infection of rabbits: an 
alternative model for studying induction of disease and virus 
control 
5.1 Manuscript information 
The content of this chapter has been included in my publication [263].  As highlighted in the 
literature review chapter, an alternative animal model is required to study WNV pathogenesis and 
immune response, since the mouse/hamster models often do not recapitulate the human and equine 
manifestation of WNV-induced disease.  In this chapter, I have established a rabbit model for 
investigating pathogenesis and immune response of non-lethal WNV infection. Two species of 
rabbits, New Zealand White (Oryctolagus cuniculus) and North American cottontail (Sylvilagus 
sp.), were experimentally infected with virulent WNV and MVEV strains. Infected rabbits exhibited 
a consistently resistant phenotype, with evidence of low and transient viraemia, minimal-absent 
neural infection, mild-moderate neuropathology, and the lack of mortality, even though productive 
virus replication occurred in the draining lymph node. The kinetics of anti-WNV neutralising 
antibody response was also comparable to that commonly seen in infected horses and humans. This 
may be explained by the early IFNα/β and/or γ response evident in the draining popliteal lymph 
node. Given this similarity to the human and equine disease, immunocompetent rabbits are, 
therefore, a valuable animal model for investigating various aspects of non-lethal WNV infections. 
5.2 Introduction 
West Nile virus (WNV) is an important re-emerging neurotropic arbovirus, that continues to cause 
severe outbreaks world-wide. However, the majority of WNV infections in humans and horses, the 
incidental hosts of the transmission cycle, is non-lethal and subclinical [210, 270-273]. The reported 
mortality rate in humans and horses from neuroinvasive WNV disease is <1% and ~10%, 
respectively, of those infected [210, 270-273]. But the economic burden of non-lethal WNV disease 
is substantial. Nolan et al. has reported an estimated cost of $42 million for non-lethal West Nile 
fever (WNF) human cases in Texas alone during the period spanning 2002 to 2011 [274]. An 
estimated further $70 million was reported for West Nile neuroinvasive disease (WNND) cases in 
the same period [274]. Given the low case-fatality rate of ~9% of WNND in humans, the majority 
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of the $70 million would have been attributed to non-lethal neurological WNV cases [271]. This 
highlights the significance in investigating the mechanisms of non-lethal WNV disease. 
Currently, the mouse and hamster are the main small animal models for investigating WNV-associated 
pathogenesis and host immune response in humans and horses [31, 197, 235]. While these rodent 
models typically produce severe encephalitis after virulent WNV infection, the level of central 
nervous system (CNS) infection in these small animal models often is too severe to be reflective of 
most human and equine disease [31, 197]. Minimal levels of virus replication take place in the CNS 
of most human and equine infection, unless the individuals are immunocompromised [1, 49, 87, 
198]. This important difference suggests that the neuropathogenesis of WNV in immunocompetent 
rodents poorly reflects what happens in immunocompetent humans and horses. In addition, the 
relatively higher susceptibility of the mouse model means that investigations into mechanisms of 
virus control will often require the use of attenuated WNV strains [275, 276]. But whether these 
mechanisms reflect how most healthy humans and horses naturally overcome virulent WNV 
infection is questionable. 
Given these limitations associated with the current rodent models, there is a need to test and 
establish alternative small animal infection models to study natural mechanisms of virus control and 
induction of WNV disease. While non-human primate (NHP) and direct horse infection models can 
be used to better understand WNV pathogenesis, the cost and logistics of those models are greatly 
limiting. 
The present study established an alternative small animal model in laboratory New Zealand White 
rabbits (NZWR; Oryctolagus cuniculus) for investigating WNV-induced disease and host immune 
response. Comparative experimental infection was conducted in wild-caught North American 
cottontail rabbits (CTR; Sylvilagus sp.). A contemporary Australian equine-pathogenic outbreak strain, 
WNVNSW2011, was used as the main strain of interest as it has been shown to be highly virulent in the 
weanling CD1 Swiss mouse model and of intermediate virulence in the young adult model [100]. A 
2012 North American WNV isolate (WNVTX8667) and the Murray Valley encephalitis virus 
(MVEV) prototype strain, MVE1-51, were used as virulent flavivirus controls in CTRs and NZWRs 
respectively, since these strains are some of the most highly virulent strains available in the 
respective regions.  Furthermore, the use of MVEV is justified in NZWRs, due to the unavailability 
of appropriate Physical Containment level 3 facility for holding NZWRs infected with North 
American WNV strains at the University of Queensland. 
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The resultant mild clinical course without mortality, low viraemia, minimal to absent CNS 
infection, mild to moderate neuropathology, and fast neutralising antibody response in WNV-
infected rabbits mimic closely the features of most human and equine WNV infections. Based on 
the virus kinetics, the robust type I and/or II interferon (IFN-I and -II) responses detected in the 
draining popliteal lymph node (PLN) and brain appeared to be important as first defence against 
early virus replication. Neutralising antibodies then additionally restricted and resolved WNV 
infection. This consistently resistant phenotype in rabbits against virulent WNV infection suggests 
that rabbits are a superior model for studying resolution of virulent WNV infections compared to 
the relatively more susceptible mouse model. The rabbit model presented here will be valuable for 
identifying novel prognostic indicators, and for developing new therapeutics and prevention 
strategies. The model will also be amenable for studies of the effect of immunosuppression or co-
infection on the outcome of WNV-infection, which are well-known risk factors for development of 
severe neurological disease in humans and horses [87, 277]. 
5.3 Materials and methods 
5.3.1 Cell culture and virus 
African green monkey (Vero) and Aedes albopictus salivary gland (C6/36) cells were cultured as 
previously described [235]. Three strains of flaviviruses were used in this study. The isolation, 
propagation and characterisation of the equine pathogenic WNVNSW2011 outbreak strain and the 
prototype MVE1-51 have previously been described in details [100, 221, 222]. An additional passage 
on C6/36 cells was performed prior to use for inoculation. The North American WNVTX8667 was 
kindly provided by Robert Tesh, University of Texas Medical Branch (Galveston, TX, USA) and 
was originally isolated from a bluejay during the 2012 human outbreak in Texas; the virus was 
passaged once in Vero cells prior to use. 
5.3.2 Animals and experimental design 
Two species of rabbits, the laboratory New Zealand White (NZWR; Oryctolagus cuniculus) and the 
North American cottontail rabbit (CTR; Sylvilagus sp.), were used in this study. Experimental 
infection of these two species of rabbits was conducted separately in PC2 and BSL3 animal holding 
facilities at University of Queensland (UQ), Australia, and Colorado State University (CSU), USA, 
respectively. Ethical approval was granted from the UQ Animal Ethics Committee 
(SVS/369/12/ARC) and the CSU Institutional Animal Care and Use Committee (#14-5170). In 
total, 57 NZWRs were sourced from Nanowie Small Animal Production Unit (Belbrae, Victoria), 
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while 14 CTRs were trapped in peri-urban areas of Fort Collins, CO, USA. All rabbits used in this 
study were seronegative by a plaque reduction neutralisation test to WNV and MVEV prior to the 
experimental infection. 
The study was divided into three parts: a pilot experiment to explore an age-dependent susceptibility 
of NZWRs to flavivirus infection, a large scale study to characterise the kinetics of virus infection 
and pathology, and thirdly, a comparative kinetics study in CTRs. Assignment of rabbits into each 
virus challenge group is outlined in Table 5-1. Additionally, six NZWR and two CTR controls were 
sham-inoculated with cell culture media. 
Table 5-1 Assignment and number of rabbits per challenge group 
Rabbit Species New Zealand White Rabbit (NZWR) Cottontail Rabbit (CTR) 
Age 
Weanlings  
(4–5 Weeks Old, ~500–700 g) 
Adults  
(>3 Months Old, ~3000 g) 
Mixed Age  
(~250–900 g) 
Inoculum WNVNSW2011 MVE1-51 Sham WNVNSW2011 MVE1-51 WNVNSW2011 WNVTX8667 Sham 
Termination day (pi) Group 1 Group 2 Control Group 3 Group 4 Group 5 Group 6 Control 
3 3 3 N/D N/D N/D 3 3 1 
7 9 6 3 3 3 3 3 1 
12 6 6 N/D N/D N/D N/D N/D N/D 
18 6 6 3 N/D N/D N/D N/D N/D 
Totals 24 21 6 3 3 6 6 2 
N/D: not done. 
 
For all experiments, a dose of 10
5
 TCID50 (for NZWRs) or PFU (for CTRs) in 50 µL of cell culture 
media was inoculated intradermally in the left hind footpad. Inocula used for the infections were 
back-titrated and confirmed to be within one log10 of the expected amount. Scheduled euthanasia 
was performed by overdose with pentobarbitone (Lethabarb, Virbac Animal Health) injection and 
terminal cardiac bleed. 
 
  
93 
 
5.3.3 Clinical monitoring 
I performed daily clinical monitoring of infected rabbits for signs of malaise and neurological 
deficit. Measurements of rectal (for NZWRs) or body (for CTRs) temperature, as well as their 
weights were taken daily. For NZWR rabbits, a standard electronic thermometer was used per 
rectum. An IPTT300 temperature transponder (BioMedic Data Systems, Inc., Seaford, DE, USA) 
was implanted subcutaneously in CTRs for daily temperature measurement. The approximate size 
of both the draining and contralateral PLNs was also gauged by palpation in the NZWR groups. The 
general alertness, as well as food and water intake, were used as indicators of their well-being. 
Daily neurological examination by the hopping test was performed on NZWRs to observe for 
significant loss of coordination of hind and forelimbs [77]. Other neurological signs such as 
seizures and muscle twitching were monitored. 
5.3.4 Tissue sampling 
From day 1 to 7 pi, blood was collected daily in EDTA-coated or plain collection tubes from the ear 
vein. Additionally, terminal cardiac bleeds were performed at the time of euthanasia. Collected 
blood was centrifuged. Plasma/serum was extracted and immediately frozen at −80 °C for virus 
isolation, viral RNA quantitation, and antibody assays. 
Following euthanasia, a complete post-mortem examination was performed. Both neural (olfactory 
bulbs, brain, spinal cord, eyes and sciatic nerves) and extraneural (PLNs, spleen, tracheobronchial 
lymph nodes, adrenals, kidneys, liver, lungs, heart and thymus) tissues were harvested for one to 
three of the following assays: histopathological analysis, virus isolation, and viral RNA 
quantitation. 
5.3.5 Histopathology 
Samples were fixed in 10% neutral buffered formalin solution for 48 to 72 h. They were then 
transferred to 70% ethanol for storage until routine paraffin embedding was performed. Five 
micrometer sections were stained with haematoxylin and eosin (H&E) and examined on a Nikon 
YS100 light microscrope. Microphotographs were produced as previously described [235]. 
Histopathological scoring was performed independently by two pathologists, one of whom was 
blinded to the groups. Specific for the neural tissue, multiple transverse sections of the brain (5–6) 
and spinal cord (9–10) were examined. The olfactory bulbs and pituitary glands were analyzed and 
described separately from the rest of the brain. Scores were assigned according to the severity and 
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extensiveness of the lesions. The data presented are the consensus scores between the two 
pathologists. For neural tissues, the score matrix outline in Table 5-2 was used. 
Table 5-2 Neuropathology score matrix. 
Extensiveness 
 
SEVERITY 
Mild Moderate Severe 
Focal 1 2 3 
Multifocal 2 3 4 
Diffuse 3 4 5 
For lymphoid tissues, such as lymph nodes and spleen, a three-tiered scoring system was used to 
gauge the level of immunological activation, with a score of 3 indicating the most pronounced 
activation. 
5.3.6 Immunohistochemistry (IHC) 
Immunolabelling for flaviviral NS1 antigen has been previously described in detail [235]. 
Immunophenotyping of rabbit T lymphocytes and histiocytes in inflammatory aggregates was 
achieved using cross-reactive anti-human CD3 (CD3 clone F7.2.38, Dako) and anti-human 
myeloid/histiocytic antigen (Clone MAC387, Dako) mouse monoclonal antibodies, respectively, 
using previously described protocols [256]. For each IHC batch, a positive and negative antigen 
control was included. 
5.3.7 Virus isolation and titration 
For NZWR samples, virus isolation and titration was determined by 50% endpoint of tissue culture 
infective dose (TCID50) [235]. Ten-fold serial dilution in 2% FBS-DMEM of sera or 10% w/v 
tissue homogenates was performed [235]. Preparation of homogenates has been previously 
described [235]. Fifty µL of each dilution was added to a subconfluent monolayer of Vero cells in 
each well of a 96-well tissue culture plate (Costar, Corning). Six to ten replicate wells were used per 
dilution. The plates were incubated in a 37 °C incubator at 5% CO2 for 5 days, before fixation with 
20% acetone (supplemented with 0.02% BSA) for 12–24 h at 4 °C. Immunocytochemistry was 
performed on fixed cells, which involved blocking buffer incubated for one hour, anti-flavivirus E 
protein monoclonal antibody, 4G2, incubated for one hour [227], and HRP-conjugated goat-anti-
mouse antibody incubated for 30 minutes, all at room temperature. Staining of 4G2 positive Vero 
  
95 
 
cells in each well was achieved using DAB+ substrate (Dako) at 1:50 dilution. Each well was 
manually examined for positive cells under an inverted light microscope (Olympus LH50A). For 
each assay, both positive and negative controls confirmed the validity of the results. 
For CTR samples, standard plaque assay was performed on ten-fold dilutions of sera and 10% 
weight/volume tissue homogenates, previously described in [198, 278]. Hundred µL of inocula was 
added to confluent monolayers of Vero cells in 6-well tissue culture plates (Costar, Corning) and 
incubated for 1–2 h at 37 °C, before 2 mL of 0.5% agarose gel overlay was added to each well. 
Plates were incubated at 37 °C 5% CO2 for 2 days before 2 mL of a second gel overlay containing 
0.005% neutral red stain was added to each well. Plaques were read on the third and fourth day pi. 
In each run, both positive and negative controls confirmed the validity of the results. 
5.3.8 Serology 
An initial screen for flavivirus specific antibodies was performed on plasma/sera obtained from 
NZWR rabbits at termination by a 4G2 pan-flavivirus blocking ELISA [279, 280]. 
Specific anti-WNVNSW2011 and MVE1-51 neutralising antibodies in plasma/sera were assayed for by 
plaque reduction neutralisation test (PRNT90) in Vero cell culture, as previously described in [198, 
278]. Plasma/serum concentrations tested were 1:10 to 1:320, diluted in culture media (DMEM). 
For screening exposure status of pre-inoculated rabbits and control rabbits, only a 1:10 dilution of 
the plasma/serum was tested. Plasma/serum dilutions were then incubated with equal volume (100 
uL) of diluted virus stock for 1 at 37 °C. Hundred µL of the plasma/serum-virus mixture was used 
to inoculate subconfluent monolayers of Veros cells in each well of a 6-well tissue culture plate 
(Costar, Corning), as per plaque assay protocol [198, 278], with modification of agarose used (1% 
of SeaPlaque, Lonza) and method of plaque visualisation (1:40 dilution of neutral red dye (Sigma 
Aldrich) in sterile PBS, applied over the first gel overlay on day 3 pi). Plaques were counted on the 
fourth day after inoculation. Concentration of WNVNSW2011 and MVE1-51 inocula was back-titrated 
at neat, 1:2 and 1:4 dilutions in duplicate wells along with each assay to determine the number of 
plaque forming units used to incubate with plasma/serum dilutions. Neutralising antibody titres 
were determined as the inverse of the last plasma/serum concentration showing 90% plaque 
reduction. 
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5.3.9  RNA extraction 
Viral/total RNA was extracted from plasma/sera and tissues, using Qiamp viral RNA (Qiagen) and 
RNeasy lipid tissue RNA extraction kit (Qiagen), respectively. Protocol as outlined by the kit was 
followed, except for tissue harvested from CTR rabbits. For these samples, Qiazol (Qiagen) was 
substituted with Trizol (Invitrogen). Tissue was homogenised in 1 mL of Qiazol or Trizol using an 
Omni-tip homogeniser (Omni) or stainless steel beads with a mixer mill (Retsch, Inc.), respectively. 
The remaining steps were performed according to the manufacturer’s protocol. Additional DNase I 
digest in solution was performed on extracted RNA, followed by additional RNA clean up with 
RNeasy RNA extraction kit (Qiagen). The absence of genomic DNA was confirmed by performing 
PCR without reverse-transcription on a selection of RNA samples from each extraction batch. 
Quality and concentration of extracted RNA was determined by Nanodrop 1000 spectrophotometer 
(Thermo Scientific). RNA samples were kept at −80 °C. 
5.3.10 Viral RNA quantitation (qRT-PCR) 
Quantitative reverse-transcriptase PCR (qRT-PCR) was used for viral RNA quantitation. Two µL of 
RNA template was added in an optimised 15 µL reaction, using the one-step Rotor Gene SYBR 
green RT-PCR kit (Qiagen). Primers targeting WNVKUN and MVE1-51 specific NS5 [281] were used 
at 0.25 µM of the final PCR volume. Concentrations of the remaining reagents were used as 
recommended by the kit. Rotor gene 6000 platform (Qiagen) was used for qRT-PCR amplification. 
Optimised cycling conditions for the WNVNSW2011 assay involved reverse transcription at 55 °C for 
10 min, then PCR initial activation at 95 °C for 5 min, followed by 45 cycles of 95 °C for 5 s, 65 °C 
for 10 s and 72 °C for 5 s. The MVE1-51 assay cycling conditions were identical to that of 
WNVNSW2011, except the annealing temperature was 60 °C [281]. Standard melt curve analysis was 
performed at the end of each run to check for appropriate qRT-PCR amplification. Standard curve 
was also generated for both WNV and MVEV assays by serial dilutions of extracted RNA from 
previously titrated virus stock, similar to method described by Lanciotti et al. [200]. Minimal 
difference was detected when standard curve was generated from RNA extracted from previously 
diluted virus stock in control plasma. 
In each run, three biological replicates of plasma/serum or tissue sample per time-point, no template 
control, uninfected tissue controls, and viral RNA positive controls were included. The viral RNA 
titre in plasma/sera was expressed as TCID50 equivalent/mL. For tissue viral load, normalisation of 
viral RNA CT was performed first against the housekeeping gene glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH), primers for which have been published in [282]. The 2
−ΔΔCT
 method was 
used to quantify tissue viral load relative to background fluorescence from sham-infected controls 
[283, 284]. This relative viral burden was expressed as fold increase over sham-infected controls. 
Limit of detection of both the WNV and MVEV assays was around 29 and 6 TCID50 
equivalent/mL, as determined by limiting serial 10-fold dilutions. 
5.3.11 Cytokine transcription profiling assay (RT-qPCR) 
IFNα, β, and γ transcription profiling was performed by two-step RT-qPCR. Two µL of RNA was 
used in a 20 µL qScript first strand synthesis reaction (Quanta Bioscience), which consists of 4 µL 
of qScript reaction mix (5×) containing a mix of oligo-dT and random primers, and 1 µL of qScript 
reverse transcriptase. The remaining volume was made up by nuclease free water. First strand 
synthesis reaction was performed on Eppendorf mastercycler epGradient S PCR thermal cycler 
(Eppendorf), with cycling conditions involving 5 min of 22 °C for 5 min, 42 °C for 30 min and 85 
°C for 5 min. Two µL of cDNA was used in a 20 µL Rotor Gene SYBR green PCR (Qiagen); 0.25 
µM of each forward and reverse primer was used for each reaction. Concentration of the remaining 
reagents was used as recommended by kit’s protocol. IFNβ and γ primers have been previously 
described in [282]. Primers for IFNα were designed from NCBI reference sequence 
XM_002708065.1 (IFNα-5-like mRNA) using primer design software, Primer 3 plus. IFNα forward 
primer sequence is 5'-TGCTTGCAGGACAGACATGA-3' and reverse primer sequence is 5'-
ATCTCTGTGCTCCACGAGAT-3'. Validation of this primer pair was performed with gel 
electrophoresis of qPCR products to confirm the 95 base-pair long amplicons. Rotor Gene 6000 
platform was used for qPCR amplification with a common cycling conditions for all primer sets, 
which involves a PCR initial activation step of 95 °C for 5 min, followed by 40 cycles of 95 °C for 5 
s, 60 °C for 10 s and 72 °C for 5 s. Standard melt curve analysis was performed at the end of each 
run to confirm appropriate PCR amplification. In each run, one cytokine mRNA positive control, 
generated from concanavalin A (Sigma Aldrich) challenged ex vivo rabbit splenocyte culture, was 
used. No template control, as well as control tissue samples from sham-inoculated rabbits, was included 
in each run. Cytokine transcription in sample was normalised to that of the house-keeping gene 
GAPDH (Δ CT1) [282], and then calibrated to the normalised basal transcription in sham-inoculated 
control animals (Δ CT2). The 2
−ΔΔCT
 method was then used to calculate the relative fold change in 
transcription of each sample over that of the controls [283]. 
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5.3.12 Statistical analysis 
Clinical parameters, such as rectal temperature, were normally distributed. Virus titres from various 
tissues and sera/plasma, as well as antibody titres and cytokine transcription fold-change, were 
log10(Y+1) transformed in order to establish normal distribution. A two-way ANOVA with post-hoc 
multiple comparisons was performed on these data, in order to assess the effect of time, inoculated 
virus strain, age, and species of rabbits on the measurements mentioned above. p-values have been 
adjusted for multiple comparisons by either the Tukey or the Sidak method. One-way ANOVA or 
unpaired t-test with Welch’s correction was performed as appropriate. Fisher’s exact test was used 
to compare proportions of animals in each group with pathology. All statistical analyses were 
performed in statistical software, Graphpad Prism 6. 
5.4 Results 
5.4.1 Subclinical and non-lethal infection 
A total of 63 rabbits was experimentally infected with outbreak strains of flavivirus originally 
isolated from Australia (WNVNSW2011 and MVE1-51 [100, 254]) and North America (WNV TX8667). 
Inocula were administered intradermally in the left hind footpad at the dose of 10
5
 TCID50 for 
NZWRs infected with WNVNSW2011 and MVE1-51, or 10
5
 PFU for CTRs infected with WNVNSW2011 
and WNVTX8667. Table 5-1summarises the assignment of rabbits into each challenge group. None of 
the infected rabbits succumbed to the virus challenge. The only clinical sign of illness was a mild to 
moderate fever evident on day 1 post-infection (pi) in weanling NZWRs (Figure 5-1A; 
WNVNSW2011: mean: 39.71 °C ± 0.069, n = 24; MVE1-51: mean: 39.92 °C ± 0.13, n = 21; Control: 
mean: 39.17 °C ± 0.076, n = 6). No febrile response was detected in any of the infected adult 
NZWRs and CTRs (Figure 5-1B). Enlargement of the draining and contralateral PLNs was detected 
on palpation during clinical examination of the NZWRs (Figure 5-1C to F). However, there were no 
obvious signs of neurological deficit or dysfunction, nor were there any significant changes in 
weight of the infected rabbits. 
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Figure 5-1 Clinical parameters in weanling NZWRs and CTRs. Daily rectal temperature in 
NZWRs (A) and body temperature in CTRs (B). Dotted line at 39.5C indicates the normal upper 
limit of rectal/body temperature. Fold-increase in the size of the popliteal lymph nodes over the 
initial size on day 0 before inoculation (C-F). Each point and error bar on the line indicate the mean 
and SEM respectively. n = 21-24 for days 1-3 pi, 18-21 for days 4-7 pi, 12 for days 8-12 pi, and 6 
for days 13-17 pi. Two-way ANOVA with post-test Tukey was performed on the means of the 
measurements in each time-point. For panel A, comparison between the WNVNSW2011 group and 
controls (*), between the MVE1-51 group and controls (#), and between the WNVNSW2011 and MVE1-
51 groups (+). For panels C-F, statistical analysis was performed on the mean fold change of virus 
challenge groups to that of the control group (*). Statistical significance thresholds: * or # or + p ≤ 
0.05, ** or ## or ++ p ≤ 0.01, *** or ### or +++ p ≤ 0.001, **** or #### or ++++ p ≤0.0001  
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5.4.2 Neuropathology 
The neuropathology observed in rabbits infected with WNVNSW2011, WNVTX8667, and MVE1-51 
consisted of mild to moderate mononuclear leukocytic, and occasionally heterophilic, infiltration in 
the CNS, with the latter two strains producing the most frequent and severe lesions (Figure 5-2A to 
C). There was a trend for weanling NZWRs to develop more severe neuropathology than adults 
(Table 5-3). Table 5-4 summarises the kinetics of neuropathology observed in the different virus 
challenge groups at days 3, 7, 12, and 18 pi. Most severe and extensive leucocyte infiltration in the 
CNS was observed on day 7 pi for both weanling NZWR groups (Table 5-4). However, moderate 
neuropathology was still evident on day 12 pi in brains of weanling NZWRs infected with MVE1-51. 
The incidence of MVE1-51-induced neuropathology in weanling NZWRs on day 7 was significantly 
higher than those of the sham-inoculation control group (p = 0.0022), of adult NZWRs infected 
with MVE1-51 (p = 0.0333) and of weanling NZWRs infected with WNVNSW2011 (p = 0.0108). Mild 
to moderate perivascular cuffing, extensive gliosis, and occasional neuronal degeneration with 
neuronophagia were evident in brains of weanling NZWRs infected with MVE1-51 at all time-points 
beyond day 7 pi. This contrasts with the relatively milder lesions seen in weanling NZWRs infected 
with WNVNSW2011 (Figure 5-2A). Neuropathology seen in the WNVNSW2011-infected CTRs was 
comparable to that in weanling NZWRs infected with the same strain (Table 5-4). CTRs infected 
with WNVTX8667 showed more extensive and severe lesions in the CNS than ones infected with 
WNVNSW2011, though there was no evidence of neuronal degeneration in the former group (Figure 
5-2C). 
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Figure 5-2 Histopathology of the central nervous system (CNS) and heart. Mononuclear 
leukocytic infiltrate (black arrow) in the neuropil of brains from NZWRs infected with WNVNSW2011 
(A), MVE1-51 (B) and CTRs- infected with WNVTX8667 (C) on day 7 pi. Mononuclear leukocytic 
infiltrate in myocardium of a NZWR infected with WNVNSW2011 on day 7 pi (D). Panels (A–D) 
were stained with H&E stain. Magnifications: (A) 10×; (B) 20×, (C) 10×, and (D) 40×. Scale bar in 
each panel represents 150 µm (A,C), 100 µm (B), and 30 μm (D).  
Table 5-3 Comparison of the peak neuropathology scores in NZWRs on day 7 pi. 
Neuropathology Virus strain Weanling Adults 
Meningitis (Brain) 
WNVNSW2011 2 1 
MVE1-51 2 1 
Encephalitis (Brain) 
WNVNSW2011 2 1 
MVE1-51 3 1 
Meningitis (Olfactory bulbs) 
WNVNSW2011 2 1 
MVE1-51 2 1 
Encephalitis (Olfactory bulbs) 
WNVNSW2011 2 0 
MVE1-51 2 0 
Spinal Meningitis 
WNVNSW2011 2 0 
MVE1-51 1 0 
Myelitis 
WNVNSW2011 2 0 
MVE1-51 2 0 
Neuropathology was scored using a 5-tiered system, with 0 indicating normal and 5 indicating severe  
and diffuse lesions. This scoring system takes into account of the severity and extensiveness of the lesions 
(see Table 5-2). 
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Table 5-4 Comparison of neuropathology kinetics. 
 
Day 3 pi Day 7 pi Day 12 pi Day 18 pi 
WNVNSW2011 
(weanling 
NZWRs) 
Mn and rare htl near CVO 
and neuropil of brain 
(peak score = 1, n = 2/3) 
Mn in meninges, neuropil of brain,  
olfactory bulbs, spinal cord, perineurium 
and/or nerve fibres of spinal nerves in  
cauda equine (peak score = 2, n = 4/9) 
Mn in meninges, neuropil  
of brain and cranial cervical 
spinal cord (peak score = 1,  
n = 4/6) 
Mn in meninges, neuropil  
of brain near CVO and 
cranial cervical spinal cord 
(peak score = 1, n = 2/6) 
MVE1-51 
(weanling 
NZWRs) 
No pathology (n = 0/3) 
Mn with occasional htl in meninges, neuropil 
of brain (extensive with neuronophagia), 
olfactory bulbs, spinal cord, perineurium  
of spinal nerves and/or dorsal root ganglion in 
cauda equine (peak score = 3, n = 6/6) 
Mn,with occasional htl  
in meninges, neuropil of 
brain (extensive) with 
neuronophagia
+
  
(peak score = 3, n = 4/6) 
Mn,with occasional htl  
in meninges, neuropil of 
brain (extensive)
+
 (peak 
score = 2, n = 2/6) 
WNVNSW2011 
(adult 
NZWRs) 
N/D 
Mn in meninges of brain and olfactory bulbs 
(peak score: 1, n = 2/3) and in neuropil of 
brain (peak score 1, n = 1/3) 
N/D N/D 
MVE1-51 
(adult 
NZWRs) 
N/D 
Mn in meninges of brain and olfactory bulbs 
(peak score: 1, n = 2/3) and in neuropil of 
brain (peak score: 1, n = 1/3). 
N/D N/D 
WNVNSW2011 
(CTRs) 
No pathology (n = 0/3) 
Mn in meninges, neuropil of brain and spinal 
cord (peak score = 2, n = 1/3) 
N/D N/D 
WNVTX8667 
(CTRs) 
No pathology (n = 0/3) 
Mn in meninges and neuropil of brain 
(extensive; peak score = 3, n 2/3) 
N/D N/D 
Mn, mononuclear leucocytes; Htl, heterophils; CVO, circumventricular organ; peak score, peak neuropathology score in the CNS (out of 5). 
+
 Spinal cord and olfactory 
bulbs were not examined, N/D: not done. 
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In addition to the CNS, histopathology of the peripheral nervous system was analyzed in a 
subset of animals. There was no frank lesion in the sciatic nerve ipsilateral to the footpad 
inoculation, except for one CTR infected with WNVNSW2011 and sacrificed on day 3 pi. 
However, mild to moderate peri- and/or epineuritis was commonly observed in the ipsilateral 
nerve on day 3 pi and the contralateral nerve on day 3 and 7 pi (Table 5-5). 
Table 5-5 Incidence of neuritis and peri-/epi-neuritis in sciatic nerves 
 Day 3 pi Day 7 pi 
 Ipsilateral 
Sciatic Nerve 
Contralateral 
Sciatic Nerve 
Ipsilateral 
Sciatic Nerve 
Contralateral 
Sciatic Nerve 
WNVNSW2011 (weanling 
NZWR) 
2/2 ND 0/5 0/3 
MVE1-51 (weanling NZWR) 3/3 1/3 1/4 0/3 
WNVNSW2011 (adult NZWR) ND ND 0/3 0/3 
MVE1-51 (adult NZWR) ND ND 0/3 1/3 
WNVNSW2011 (CTRs) 1/3
# 
1/3 0/3 2/3 
WNVTX8667 (CTRs) 0/3 0/3 0/3 2/3 
# neuritis, N/D: not done 
 
Immunolabelling for leucocyte markers established that approximately half of the CNS-
infiltrating leucocytes for rabbits infected with WNVNSW2011 and MVE1-51 were CD3 positive 
T lymphocytes (Figure 5-3A and B). No signal was detected when sections were labeled for 
the myelomonocytic marker MAC387. However, this immune-marker appeared to only stain 
a subset of the monocytic/histiocytic cell lineage in rabbits, as evident when applied on 
spleen sections. There was no histological evidence of mature plasma cells in any of the CNS 
sections examined. Due to the lack of rabbit-specific or cross-reactive antibodies, the 
remaining population of infiltrating mononuclear leucocytes could not be phenotypically 
identified at this point in time. 
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Figure 5-3 CD3+ T cells in the brain (A,B), and viral NS1 antigen in the draining 
popliteal lymph node (PLN) (C) and dermis (D). CD3+ T lymphocytes (red stain) 
infiltrating from cerebral blood vessel (A) in a NZWR infected with WNVNSW2011 on day 7 
pi, and in neuropil of brain of a NZWR infected with MVE1-51 (B); Flavivirus NS1 antigen 
positive leucocyte (red strain) in the paracortical zone of the draining PLN (C); Arrow in 
panel (D) indicates viral NS1 staining in an individual leucocyte in the deep interstitium of 
the footpad dermis, ipsilateral to inoculation (D); Panels (A–D) were stained with AEC 
substrate and counterstained with Meyer’s haematoxylin. Magnifications: (A) 40×, (B) 40×, 
(C) 40× cropped, and (D) 40×. Scale bar in each panel represents 30 μm (A,B,D) and 20 μm 
(C).  
 
5.4.3 Extraneural pathology 
Lymphocyte activation, as suggested by formation of secondary follicles, paracortical 
hyperplasia, hypercellularity of the medulla, and hypertrophy of post-capillary endothelial 
venules, was observed commonly in the draining PLN on day 3 and 7 pi for rabbits infected 
with the three strains of flaviviruses (Table 5-6). Activation of the contralateral PLN was also 
occasionally observed in weanling NZWRs (WNVNSW2011: n = 1/2 examined on day 7 pi; 
MVE1-51: n = 1/3 examined on day 7 pi), but not in adult rabbits on day 7 pi. Notably, all 
examined contralateral PLNs of CTRs infected with either strain of WNV were activated to 
varying degree (WNVNSW2011 and WNVTX8667: n = 2/2 on day 3 pi, n = 3/3 on day 7 pi). 
Where present, there was mild to moderate activation of most tracheobronchial lymph nodes 
examined, regardless of virus challenge groups. The bronchus-associated lymphoid tissues 
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were also observed to be mildly activated in WNVNSW2011 infected weanling NZWRs on day 
7 pi (n = 3/3). 
Table 5-6 Frequency of flavivirus NS1 positive leucocytes and lymphocyte activation in 
the draining popliteal lymph node 
 Day 3 pi Day 7 pi 
 IHC (NS1) Activation IHC (NS1) Activation 
WNVNSW2011 
(weanling NZWR) 
2/2 1/2 0/2 5/5 
MVE1-51  
(weanling NZWR) 
2/2 2/2 0/2 4/4 
WNVNSW2011 (CTR) 2/2 2/3 1/2 2/2 
WNVTX8667 (CTR) 1/2 1/2 1/2 3/3 
 
Major organs were also examined for histopathological lesions in a subset of rabbits from 
each virus challenge group. Mild focal to multifocal lymphohistiocytic myocarditis with or 
without epi- and endo-carditis was consistently observed in rabbits infected with 
WNVNSW2011 on day 7 pi (Figure 5-2D, n = 6/6 weanling NZWRs, n = 1/3 adult NZWRs and 
n = 3/3 CTRs) and occasionally in animals infected with MVE1-51 (n = 1/3 weanling and n = 
1/3 adult NZWRs) and WNVTX8667 (n = 1/3 of CTRs). All other organs examined (lungs, 
kidneys, liver, adrenals, thymus, and eyes) were histologically unremarkable. 
5.4.4 Viral burden in the CNS 
Despite the induction of neuropathology, no infectious virus, viral protein, or viral RNA was 
detected in the brains of NZWRs and CTRs infected with WNVNSW2011. Similar absence of 
infectious virus was noted in the brains of CTRs infected with WNVTX8667. Only trace levels 
of MVE1-51 viral RNA were detected in 4/7 of brains that had an encephalitis score of 2 or 
more (n = 4/12 tested, median: 22-fold [increase in viral burden over control], interquartile 
range [IQR]: 5–43). This suggests a potential correlation between the degree of brain viral 
load and the degree of neuropathology. Amongst the MVE1-51 positive brains, two were 
harvested on day 7 pi, one on day 12 pi, and one on day 18 pi. However, virus isolation 
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and/or immunohistochemistry failed to detect infectious virus or viral protein from these viral 
RNA positive brains. 
5.4.5 Peripheral virus replication 
The main site of peripheral replication of WNVNSW2011 and MVE1-51 in weanling NZWRs 
appeared to be the draining PLN. From day 3 to 12 pi, viral RNA was detected in this lymph 
node, with peak levels reached on day 3 pi (Figure 5-4A; WNVNSW2011: median: 1678-fold, 
range: 414–7194; MVE1-51: median: 3666-fold, range: 1121–7750). This peak was 
significantly higher than levels detected on day 12 (WNVNSW2011: p = 0.0082; MVE1-51: p = 
0.0008) and 18 pi (WNVNSW2011: p < 0.0001; MVE1-51: p < 0.0001). For the MVE1-51 group, 
the day 7 pi viral burden was also significantly higher than on day 12 (p = 0.0433) and 18 pi 
(p = 0.0041). By day 18 pi, viral RNA level was mostly below the detection limit. The overall 
viral burden in this lymph node was not significantly different between these two virus 
challenge groups (F1,16 = 0.8479, p = 0.3708). On day 7 pi, the viral burden in the draining 
PLN of weanling NZWRs was significantly higher than that of adult NZWRs, regardless of 
flavivirus strain inoculated (Figure 5-4C, WNVNSW2011: p = 0.0141; MVE1-51: p = 0.0065). 
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Figure 5-4 Peripheral virus dissemination and neutralising antibody response. Viral load 
in the draining PLN of weanling and adult NZWRs (A,C) and CTRs (B). Viraemia in 
NZWRs (D) and CTRs (E). Viral burden in the contralateral PLN and spleen (F). Viral RNA 
in NZWRs was quantified using qRT-PCR, while virus load in CTRs was quantified by 
plaque assay. Neutralising antibody kinetics in weanling NZWRs (E), comparison of 
neutralising antibody titre between NZWRs and CTRs on day 7 pi (F), and between weanling 
and adult NZWRs on day 7 pi (I). Note for (F), the NZWR groups include data from both 
weanling and adult groups to give a closer comparison to the CTR groups. PRNT90 was used 
to determine neutralising antibody titres. Each data point for panels (A–F,H,I) represents titre 
for one animal. Horizontal line in these panels indicates the median titre of each time-point. 
For (E), the points on the line indicate the median titre of each time point (n = 3 for day 3 pi, 
6–9 for day 7 pi and 6 for both day 12 and 18 pi). Error bars indicate the interquartile range 
or range. Two-way ANOVA with post-test Sidak was performed on the log10(Y+1) 
transformed means of titres in each time-point for panels (A–G,I). One-way ANOVA with 
post-test Tukey was performed on the log10(Y+1) transformed means of titres in each 
challenge group for panel (H). Statistical significance thresholds: 
ns
 not significant, * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
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Similar kinetics of virus replication in the draining PLN was observed in CTRs infected with 
the two strains of WNV (Figure 5-4B). A peak median viral load of 1.4 × 10
6
 (range: 7.6 × 
10
3−2.8 × 106) and 3.5 × 105 PFU/g (range: 1.6 × 105–5.3 × 105) was reached on day 3 pi for 
CTRs infected with WNVNSW2011 and WNVTX8667, respectively (Figure 5-4B). But the viral 
burden was not significantly different between day 3 and 7 pi (F1,5 = 3.060, p = 0.1406) and 
between the two virus challenge groups (F1,5 = 0.3991, p = 0.5553). Viral RNA assay showed 
that the amount of WNVNSW2011 RNA in the draining PLN of WNVNSW2011-infected CTRs 
was 0.4 and 1.8-fold of that in weanling NZWRs infected with the same virus on day 3 and 7 
pi, respectively. This suggests comparable viral burden in the draining PLN between the two 
species. 
Flavivirus NS1 antigen was detected by IHC in pleomorphic leucocytes, suggestive of 
macrophages and/or dendritic cells, in the paracortical zone of draining PLNs (Figure 5-3C). 
Lymph nodes from day 3 pi were more consistently IHC positive for NS1 antigen than on day 
7 pi (Table 5-6). IHC of the footpad, ipsilateral to the inoculation, also revealed NS1 antigen 
in leucocytes in multiple sites of the deep dermis, in one MVE1-51 infected weanling NZWR 
culled on day 3 pi (Figure 5-3D). These dermal leucocytes were morphologically consistent 
with macrophages or dendritic cells. 
5.4.6 Peripheral virus dissemination 
Despite evidence of virus replication in the draining PLN, the associated viraemia was 
transient and of low magnitude for all virus challenge groups (Figure 5-4D and E). Peak 
viraemia was reached on day 1 pi for weanling (median: 64 TCID50 equivalent/mL, IQR: 40–
162) and adult NZWRs (median: 14 TCID50 equivalent/mL, range: 6–80) infected with 
WNVNSW2011 (Figure 5-4D). MVE1-51 infection in weanling NZWRs resulted in a higher 
median viraemia peak at 270 TCID50 equivalent/mL (range: 78–11234) on day 1 pi, which was 
significantly higher than the median peak of 14 TCID50 equivalent/mL (range: 3–19) reached 
in the adult group (Figure 5-4D, p = 0.0063). The overall viraemia was significantly different 
between the two weanling NZWR groups (F1,30 = 7.377, p = 0.0109), however, there was no 
single time-point where a significant difference was observed. 
A comparable kinetics of viraemia was seen in the WNV-infected CTRs (Figure 5-4E). Peak 
viraemia occurred on day 2 pi (WNVNSW2011: median: 400 PFU/mL, IQR: 0–1075; 
WNVTX8667: median: 2600 PFU/mL, IQR: 1125–3225). The overall viraemia between these 
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two CTR groups was significantly different (F1.34 = 11.28, p = 0.0019). But as for the 
comparison between the two weanling NZWR groups, there was no single time-point where 
the difference was significant. For all challenge groups, viraemia dropped below the detection 
limit by day 4 to 5 pi. 
The degree of virus replication in other peripheral tissues was limited in WNVNSW2011-
infected rabbits. Sites other than the draining PLN where WNVNSW2011 RNA was detected in 
infected weanling NZWRs and CTRs included the contralateral PLN and/or the spleen. Low 
levels of WNVNSW2011 RNA were frequently detected in the contralateral PLN on day 3 pi for 
NZWR weanlings (n = 3/3) and CTRs (n = 2/3). But the viral burden in this lymph node was 
considerably less than that of the draining PLN (Figure 5-4F, weanling NZWRs: median: 26-
fold, range: 7–750; CTRs: median: 1.6-fold, range: 0–116). It was rare to detect viral RNA in 
this tissue on day 7 pi (weanling NZWR: n = 1/3, viral burden: 12-fold; adult NZWR: n = 
0/3; CTRs: n = 0/3). Minimal levels of viral RNA were infrequently detected in the spleen 
collected from WNVNSW2011-infected weanling NZWRs on day 3 pi (n = 1/3; viral burden: 
67-fold). No viral RNA was detected in spleen samples from the remaining WNVNSW2011-
challenged groups (day 7 pi weanling and adult NZWRs, day 3 and 7 pi CTRs). 
In contrast, when compared to weanling NZWRs infected with WNVNSW2011, ones infected 
with MVE1-51 had significantly higher levels of viral RNA in the contralateral PLN (Figure 
5-4F, day 3 pi: median: 1152-fold, range: 1075–7033, p = 0.0384; day 7 pi: median: 324-fold, 
range: 217–867, p = 0.0066) and spleen (Figure 5-4F, day 3 pi, median: 690-fold, range: 
362–704, p = 0.0037 and day 7 pi: median: 1531, range: 461–3236, p = 0.0003). There was 
also infrequent detectable MVE1-51 RNA in the contralateral PLN (n = 1/3, 644-fold) and 
spleen of MVE1-51 infected adult NZWRs (n = 1/3, 41-fold), showing a higher capacity for 
MVE1-51 to disseminate to other lymphoid tissues in both age groups of NZWRs. 
5.4.7 Neutralising antibody response 
In order to study the potential host factors restricting viraemia, the virus-neutralising antibody 
response was measured using a plaque reduction neutralisation test (PRNT90). A pan-specific 
flavivirus blocking ELISA was also performed as described [285], with detection of flavivirus 
specific antibodies in both weanling and adult NZWR MVE1-51 challenged groups. An 
increasing titre of neutralising antibodies against the inoculated virus was detected, beginning 
on day 7 and 12 pi for WNVNSW2011- and MVE1-51- challenged weanling NZWRs, 
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respectively (Figure 5-4G). The overall neutralising antibody titres between the two weanling 
NZWR groups were not significantly different to each other (F1,8 = 2.425, p = 0.1253); 
however, the titres reached on day 7 pi for WNVNSW2011-challenged weanling NZWRs 
(median: 10, IQR: 10–20) were significantly higher than those observed in MVE1-51 
challenged weanling NZWRs (median: 0, IQR: 0–2.5, p < 0.0001). The neutralising antibody 
titres in the adult NZWR groups on day 7 pi (WNVNSW2011: median: 10, IQR: 10-20; MVE1-
51: median: 0, IQR: 0-0) were comparable to those in the weanlings challenged with the 
corresponding virus (Figure 5-4I, F1,17 = 0.02651, p = 0.8726). Notably, neutralising antibody 
titres in WNVNSW2011-challenged CTRs were significantly higher than those in WNVNSW2011-
challenged NZWRs on day 7 pi (Figure 5-4H; CTR median: 80, IQR: 40–80, p = 0.0094). 
Titres in CTRs infected with WNVTX8667 were comparable to those in CTRs infected with 
WNVNSW2011 (p = 0.3748). But between the two virulent-virus controls of each rabbit species, 
CTRs infected with WNVTX8667 had significantly higher neutralising antibody titres than 
NZWRs infected with MVE1-51 on day 7 pi (Figure 5-4H, p < 0.0001). 
5.4.8 IFN-I and -II transcription levels in the draining popliteal lymph node and brain 
Given the general resistance of NZWRs and CTRs to WNV and MVEV challenge and the 
early neutralising antibody response consequently observed, the type I and II interferon (IFN-
I and -II) responses in the brain and draining PLN were investigated. 
Overall, between WNVNSW2011 and MVE1-51 infected weanling NZWRs, there was a 
significant difference in the levels of IFN-I and -II transcription in the brain (Figure 5-5A, D, 
and G; IFNα: F1,16 =18.6700, p = 0.0005; IFNβ: F1,16 = 9.377, p = 0.0074; IFNγ: F1,16 = 
8.917, p = 0.0087), but not in the draining PLN (Figure 5-6A, D, and G; IFNα: F1,15 = 0.0094, 
p = 0.9242; IFNβ: F1,14 = 0.1487, p = 0.7056; IFNγ: F1,15 = 0.9710, p = 0.3401). 
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Figure 5-5 Type I and II IFN transcription kinetics in the brain. IFNα (A–C), β (D–F) 
and γ (G–I) transcription kinetics in the brain of weanling NZWRs (A,D,G) and CTRs 
(C,F,I). A comparison of the transcription profile on day 7 pi between weanling and adult 
NZWRs (B,E,H). Each data point represents the fold-change in transcription in one animal. 
Horizontal solid line in each time-point represents the median fold-change, with error bars 
indicating the range. Dotted line at Y = 1 signifies one-fold (basal level of transcription). 
Two-way ANOVA with post-test Sidak was performed on the log10(Y+1) transformed mean 
of fold-change in each time-point. Statistical significance thresholds: * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001.  
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Figure 5-6 Type I and II IFN transcription kinetics in the draining PLN. IFNα (A–C), β 
(D–F) and γ (G–I) transcription in the draining popliteal lymph node of weanling 
NZWRs (A,D,G) and CTRs (C,F,I). A comparison of the transcription profile on day 7 pi 
between weanling and adult NZWRs (B,E,H). Each data point represents the fold-change in 
transcription in one animal. Horizontal solid line in each time-point represents the median 
fold-change, with error bars indicating the range. Dotted line at Y = 1 signifies one-fold 
(basal transcription level). Two-way ANOVA with post-test Sidak was performed on the 
log10(Y+1) transformed mean of fold-change in each time-point. Statistical significance 
thresholds: * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  
 
IFNα, β, and γ transcription in the brain were comparable between the two groups on day 3 
pi, but were quite different from day 7 pi onwards, with brains from MVE1-51-infected 
weanling NZWRs having consistently upregulated levels of IFNα, β, and γ transcripts (Figure 
5-5A, D, and G). In the draining PLN, an earlier upregulation of IFNα (from day 3 pi) and a 
more consistent upregulation of IFNβ (from day 7 pi) transcript levels were observed in 
WNVNSW2011-infected weanling NZWRs, when compared to the MVE1-51 group (Figure 5-6A 
and D). The IFNγ transcription kinetics in the draining PLN was similar for the two weanling 
NZWR groups (Figure 5-6G). 
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The levels of IFN-I and -II transcription in the brains of WNVNSW2011 and WNVTX8667-
infected CTRs were similar to the profile seen in WNVNSW2011 infected weanling NZWRs, 
where only IFNγ mRNA was notably upregulated (Figure 5-5C, F, and I). Upregulation of 
IFN-I transcription was only observed in brain of one CTR in the WNVTX8667-challenge group 
culled on day 7 pi (Figure 5-5C and F). For the draining PLN, infrequent upregulation of 
IFNα mRNA was detected on day 7 pi (Figure 5-6C, n = 1/3 for both CTR challenge groups). 
IFNβ transcription in the draining PLN was consistently upregulated in all three 
WNVNSW2011-infected CTRs culled on day 7 pi (Figure 5-6F). Only 1/3 of the WNVTX8667-
infected rabbits on day 7 pi had elevated IFNβ transcription in the draining PLN (Figure 
5-6F). The overall levels of IFNγ transcription in the draining PLN in the two CTR groups 
were comparable to that in the weanling NZWRs (Figure 5-6G and I). There was no 
significant effect of age on levels of IFN-I and -II transcription in the brain and draining PLN 
of NZWRs on day 7 pi, regardless of the virus strain inoculated (Figure 5-5 and Figure 5-6B, 
E, and H; brain: IFNα: F1,8 = 0.1719, p = 0.6893; IFNβ: F1,8 = 0.5947, p = 0.4628; IFNγ: F1,8 
= 2.215, p = 0.1750; draining PLN: IFNα: F1,8 = 1.839, p = 0.2121; IFNβ: F1,8 = 0.4166, p = 
0.5367; IFNγ: F1,8 = 0.2250, p = 0.6479 
 
5.5 Discussion 
The current study characterised the clinical, pathological, virological, and immunological 
outcomes in rabbits after peripheral WNV and MVEV infection. We observed a low-
magnitude and transient viraemia, similar to that seen in horses, NHPs, and humans [198, 
286, 287]. Peripheral tissue tropism of WNVNSW2011 was restricted predominantly to the 
draining PLN, while MVE1-51 was more successful at disseminating to other lymphoid 
tissues, such as the contralateral PLN and spleen. However, regardless of the degree of 
peripheral dissemination, the inoculated virus was mostly undetectable in the brain. The 
associated early anti-WNV neutralising antibody production in WNV-infected NZWRs and 
CTRs was also comparable to that in infected horses and humans [288-290]. This may be 
explained by the early IFNα/β and/or γ response in the draining PLN. Our study has also 
highlighted the importance of the innate immune response in early restriction of virus 
dissemination, before the appearance of neutralising antibodies. The resultant mild clinical 
manifestation and neuropathology in infected rabbits are representative of the non-lethal disease 
reported for the majority of horse and human WNV infections [198, 210, 270, 272]. 
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Immunocompetent rabbits are, therefore, a useful animal model for investigating mechanisms of 
non-lethal neuropathogenesis and natural means of virus control against virulent WNV and 
MVEV challenge. 
5.5.1 Experimental design 
In this study, we used NZWRs (Oryctolagus cuniculus) and CTRs (Sylvilagus sp.). By 
including CTRs in this study, we were able to investigate the effect of different rabbit genetic 
and potential immunological backgrounds on the outcomes of peripheral flavivirus challenge. 
We also employed the footpad intradermal inoculation route, commonly used in the mouse 
and hamster models (e.g., [31, 197]). This allows appropriate comparison to natural human 
and equine mosquito bite inoculation. We chose an inoculation dose of 10
5
 TCID50 (for 
NZWRs) or PFU (for CTRs) per rabbit, as this is representative of a typical WNV dose 
delivered by a Culex sp. mosquito bite inoculation [291]. 
5.5.2 Rabbits can model non-lethal human and equine WNV infections 
The WNV strain of main interest in this study was the Australian equine pathogenic strain, 
WNVNSW2011 [100]. WNVNSW2011 has previously been shown to be highly virulent in 
weanling and intermediately virulent in adult CD1 Swiss outbred mice, causing typical 
neurological signs, such as ataxia, tremor, and seizure prior to death [100]. We have shown in 
the current study that immunocompetent rabbits do not succumb to inoculation with this strain, 
regardless of age or species. In fact, even when inoculated with the highly murine-virulent 
MVE1-51 and a virulent North American WNV strain, WNVTX8667, no mortality was observed 
in either rabbit species. This contrasts with the moderate to high mortality often associated 
with MVE1-51 and North American lineage I WNV strains in the mouse and hamster model 
[27, 31, 197, 222]. There were also no observable clinical signs, other than a mild to 
moderate febrile response on day 1 pi in weanling NZWRs. This relatively resistant 
phenotype in rabbits is representative of the majority of WNV infection in horses and humans 
[198, 210, 270, 272]. Figure 5-7 summarises how the NZWR model can be applied to study 
the different aspects of WNV infections in the humans and horses. 
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Figure 5-7 Schematic depiction of how NZWR can model the different aspects of human 
and equine WNV infections. Our study has shown that WNV-infected NZWRs produce a 
non-lethal phenotype that is representative of most human and equine infections. The 
asymptomatic nature of WNV infection in adult NZWRs makes this group of rabbits an 
appropriate model for determining factors responsible for asymptomatic resolution of human 
and equine WNV infections. Mild fever was observed in most weanling NZWRs infected 
with WNV, with some developing mild-moderate non-lethal neuropathology. This group is, 
therefore, a suitable model for investigating the mechanisms of WNV disease resolution. We 
also hypothesise that immunosuppression in weanling NZWRs may produce the lethal 
phenotype typically seen in fatal human and equine WNND cases. Further investigation is 
required for this particular aspect. This diagram used information obtained from [210, 270-
273, 292]. 
#
 the reported equine case-fatality rate does not distinguish between euthanatised 
cases and natural deaths.  
5.5.3 Productive flavivirus replication in draining PLN 
Both WNV and MVEV RNA were detected at substantial levels in the draining PLN of 
weanling NZWRs and CTRs. The detection of flavivirus NS1 antigen in these lymph nodes 
suggests that productive virus replication occurred in this tissue. Since the draining PLN is 
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the only tissue where viral RNA and antigen were consistently detected across most groups, it 
may, therefore, be the main site of peripheral virus replication. We identified the permissive 
cells in these lymph nodes to be pleomorphic leucocytes, consistent with macrophages or 
dendritic cells in the paracortical zone (Figure 5-3C). Notably, scant NS1 positive leucocytes 
were also present in the dermis of a virus-inoculated footpad, suggesting that virions have 
been phagocytosed by leucocytes from the site of inoculation, as suggested in the mouse 
model [158, 293]. Productive virus replication also occurred in these leucocytes, since 
flavivirus NS1 was expressed in these cells. But whether the virus was then transported inside 
phagocytes to the draining PLN remains to be determined. 
There was a notable difference in the draining PLN viral load between the two age groups of 
NZWRs (Figure 5-4C). This indicates that adults may be more effective at controlling early 
peripheral virus replication than weanling NZWRs. This was further supported by the 
generally low viral burden in all tissues examined, the very mild neuropathology and the 
afebrile clinical course observed in adults. However, the levels of IFN-I and II transcription 
in the draining PLN and neutralising antibody response were not significantly different 
between these two age groups (Figure 5-4I, and Figure 5-6B, E, and H). So the mechanisms 
for this effective control of virus replication by adult NZWRs remain to be investigated. 
Characterisation of the early immunological events prior to day 3 pi in infected adult and 
weanling NZWRs will likely shed light on the differences between the two age groups. 
Nevertheless, due to this benign phenotype, adult NZWRs may be a suitable model for 
investigating factors determining asymptomatic WNV infections in humans and horses (Figure 
5-7). 
5.5.4 Restricted viraemia and CNS infection in rabbits resemble human and equine 
WNV kinetics 
Despite productive infection in the draining PLN, the viraemia was low and transient for all 
virus challenge groups. Interestingly, the viraemia peaks observed in our study were lower 
than those reported in previous flavivirus infection studies in rabbits (peak ~10
1−3
 TCID50 
equivalent or PFU/mL, as compared to ~10
4−5
 CID50/mL or SMIC LD50/mL) [211, 212]. This 
may be explained by the different experimental conditions involved, such as the use of 
different WNV strains [211], route of inoculation [212], trapping region for CTRs (e.g., Iowa 
[211]), virus isolation methods (CID50 for [211] and SMIC LD50 for [212]), and a potentially 
different adult to weaner ratio in recruited wild rabbit groups. Characterisation of the effects 
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of the mentioned methodological differences is beyond the scope of the current study, but 
will be an important aspect for future refinement of the rabbit model. 
Nevertheless, the low viraemia, restricted peripheral virus dissemination, and CNS infection 
in WNV-infected rabbits of this study resemble the in vivo virus kinetics reported for 
experimentally infected NHPs and horses [198, 294]. Natural human and equine infections 
are also commonly associated with minimal to absent neural and extraneural infection [49, 
87, 205]. We, therefore, suggest that the in vivo virus kinetics of WNV in immunocompetent 
rabbits is similar to that in healthy horses and humans. 
5.5.5 Weanling NZWRs are an appropriate model to study non-fatal human and 
equine WNND 
Despite the lack of or only trace levels of viral RNA in the brain, mild to moderate non-lethal 
neuropathology was induced in flavivirus-infected rabbits, with animals infected with MVE1-
51 and WNVTX8667 producing the most frequent and severe lesions (Figure 5-2A to C). The 
low case-fatality rate of 9% from WNND in humans suggests that non-lethal neurological 
disease is common (91%) [271]. The equine case-fatality rate of 35–44% also suggests that 
approximately half of the symptomatic horses survive WNV infection [273, 292]. However, 
the true survival rate is likely to be higher, since the reported equine case-fatality rate does 
not distinguish between euthanised cases and natural deaths [273]. This highlights the 
relatively common occurrence of WNV-induced non-lethal neurological disease in the 
incidental hosts, yet the mechanism of which remains poorly understood. Furthermore, the 
economic impact of non-lethal WNV-induced disease in human is substantial, highlighting 
the significance of investigating this important presentation of the disease [274]. The natural 
development of mild-moderate non-lethal neuropathology mainly in flavivirus-challenged 
weanling NZWRs suggests that this group of rabbits may be an appropriate model to study the 
mechanisms of non-lethal neuropathogenesis in horses and humans (Figure 5-7). Further 
investigation of the expression kinetics of pro- and anti-inflammatory cytokines in neural and 
extraneural tissues may provide insights into the mechanisms behind the induction and 
resolution of neuropathology in flavivirus-infected weanling NZWRs. 
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5.5.6 Virus-dependent systemic virus dissemination, peripheral IFNα/β, and 
neutralising antibody response 
The degree of systemic virus dissemination was virus-dependent in weanling NZWRs. 
MVE1-51 appeared to be more successful in establishing infection in the non-draining PLN 
and spleen, when compared to WNVNSW2011 (Figure 5-4F). This was not surprising given the 
higher virulence of MVEV than WNVNSW2011 in mice [84, 100]. The slower induction of 
IFNα response in the draining PLN (Figure 5-6A) and neutralising antibody production 
(Figure 5-4G) in MVE1-51-infected weanling NZWRs, relative to ones infected with 
WNVNSW2011, likely have contributed to the more successful peripheral virus dissemination. 
This association between a delayed peripheral immune response and more profound 
peripheral virus replication has been reported in mice infected with highly virulent WNV 
strains, such as WNVKOU [235]. 
However, in contrast to the mouse model, weanling NZWRs infected with MVE1-51 did not 
establish widespread CNS infection. There were trace levels of MVE1-51 RNA in the brain of 
some of the infected weanling NZWRs. But the elevated and sustained brain IFN-I/II 
response in MVE1-51-infected weanling NZWRs likely played an important role in local virus 
control, especially when a delayed peripheral immune response failed to effectively restrict 
early viral dissemination (Figure 5-5A, D, and G). 
Conversely, the faster and more robust IFNα/β response in the draining PLN against 
WNVNSW2011 in weanling NZWRs may explain the limited dissemination of virus to the non-
draining PLN and spleen (Figure 5-4F). Direct IFNα/β restriction on WNV replication, 
especially for less pathogenic WNV strains, has been well documented [134, 193, 295]. 
However, this faster induction of IFN-I in the draining PLN may also be important for the 
development of a rapid and effective neutralising antibody response [183]. In fact, the 
kinetics of neutralising antibody production in WNV-infected rabbits mimics very closely 
that of WNV-infected horses, where PRNT90 neutralising antibody titres of 10 to 80 were 
reported on day 7 pi [288]. Castillo-Olivares et al. also detected anti-WNV neutralising 
antibody (~100% neutralisation at 1:10 serum dilution) from day 8 pi in experimentally-
infected horses [289]. This similarity may also apply to humans, since IgM seroconversion in 
humans has been estimated to occur around day 7 to 8 post-WNV infection (~4 days after 
peak viraemia) [290, 296]. This early neutralising antibody production in WNVNSW2011 
infected weanling NZWRs may have provided adequate peripheral protection against viral 
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neuroinvasion around the crucial time of day 6 to 7 pi, when flavivirus neuroinvasion 
typically occurs in mice [31]. This may explain the absence of WNVNSW2011 RNA in the brain 
of these animals. The lack of the continual stimulus in the brain, in turn, corresponds to the 
lack of upregulated brain IFNα/β transcription in these animals. The contrary was observed in 
MVE1-51 infected weanling NZWRs, in which the slower neutralising antibody production 
may have allowed viral neuroinvasion, which in turn induced a higher and more sustained 
upregulation of brain IFNα/β transcripts (Figure 5-5A and D). 
While we have highlighted the delayed neutralising antibody production in MVEV-infected 
NZWRs as a potential reason for the more extensive virus dissemination in the periphery, the 
previous rabbit study by Kay et al., reported an earlier detection of anti-MVEV neutralising 
antibodies (titre of ~<10–20) in MVEV-infected feral Australian rabbits (Oryctolagus 
cuniculus) on day 7 pi [212]. However, these feral rabbits may have had a different 
immunological background to laboratory NZWRs, since co-infection or prior infection with 
viruses, bacteria, fungi and/or parasites may have pre-stimulated the immune system in feral 
rabbits. 
5.5.7 Neutralising antibody and IFNγ response in CTRs 
Evidence of higher neutralising antibody titres in feral rabbits (CTRs), as compared to 
laboratory NZWRs, was also observed in the current study (Figure 5-4H). Since the level of 
neutralising antibody production has been reported to be associated with the intensity of IFNγ 
induction in lymph nodes [297], the higher neutralising antibody production in CTRs may be 
explained by the marginally higher IFNγ transcription in the draining PLNs of the CTRs 
compared to the NZWRs especially on day 7 pi (Figure 5-6G, H, and I). Furthermore, 
upregulated IFNγ expression in the spleen and the CNS has been reported to be associated 
with peripheral parasitic infection in mice [298, 299]. Potential background parasitic 
infection in feral CTRs may, therefore, play an important role in shaping the IFNγ and the 
associated neutralising antibody response in flavivirus-challenged feral rabbits. Wild rabbits 
may, therefore, be a useful model for investigating the interactions between parasitic and 
flavivirus co-infection. 
5.5.8 IFNγ Response in NZWRs 
Early upregulated IFNγ transcription was also observed in the draining PLN and the brain of 
most flavivirus-challenged NZWRs (Figure 5-5 and Figure 5-6G, H, and I). The only 
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exception was in the brain of adult NZWRs infected with WNVNSW2011. This upregulation in 
IFNγ transcripts may have provided early peripheral virus control before a detectable level of 
neutralising antibodies began to circulate (prior to day 7 pi for WNV-infected rabbits and 
prior to day 12 pi for MVE1-51 infected rabbits). The suggested mechanism of virus control by 
IFNγ is via its activation of macrophages/dendritic cells/microglial cells [300, 301], its 
support role in establishing a robust CD8+ T cell response [302], and its role in shaping the 
antibody response by class switching from IgM to IgG virus neutralising antibodies [303]. 
IFNγ also has an enhancement role in IFNα/β induction via the activation of interferon 
responsive factor I (IRF-1) [304]. We propose that IFNγ may play a key role in: (i) the 
control of viral load in the draining PLN by its activation of infected macrophages/dendritic 
cells; (ii) controlling virus infection in the brain by its activation of microglial cells and/or the 
infiltrated T cells; (iii) forming a competent neutralising antibody response by class switch; 
and (iv) co-activation of the IFN-I induction in the draining PLN and brain. 
Activated T lymphocytes, γδ T lymphocytes and natural killer (NK) cells have been reported 
to be the main producers of IFNγ [166, 305, 306]. It was, therefore, not surprising to observe 
IFNγ transcript upregulation in brains with evidence of CD3+ T cell infiltration (Figure 5-3A 
and B). In fact, CD3+ T cells infiltration into the CNS was a common observation in human, 
NHP, and equine WNV infections [49, 207, 307]. Furthermore, upregulated IFNγ gene 
transcription in nucleated cells isolated from CSF samples of WNV-infected horses has been 
reported [23]. This highlights the importance of T lymphocytes and likely the associated 
IFNγ response in virus control in the CNS in incidental hosts and rabbits. 
Notably, upregulated IFNγ transcription could also be observed in rabbit brains without 
pathology. While it is possible that rare CNS-infiltrating NK or T cells were not within the 
histological section examined, a non-leucocyte source(s) of IFNγ may be possible. In aged 
BALB/c mice, expression of IFNγ and its receptor has been reported in the cerebral and 
cerebellar microvascular endothelium, as well as in the choroid plexus [308]. While this did 
not apply to young adult mice, characterisation of such age-related differences has not been 
performed in rabbits. Furthermore, expression of IFNγ and its receptor has been reported in 
rat sensory neurons grown in culture [309]. These potential non-leukocytic sources of IFNγ 
should be investigated further in our rabbit model by IHC or in situ hybridisation for mRNA. 
The large variation, as indicated by the large error bars, observed in the rabbits’ response 
against WNV and MVEV infection is likely explained by their outbred background. 
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However, despite this large variation, all rabbits consistently controlled virus replication and 
survived virus challenge without display of severe clinical signs. This suggests that virus 
control in outbred rabbits can be achieved at various efficiencies. It is likely that such 
variability exists in natural human and equine WNV infections, as suggested by the large range 
of disease outcomes (Figure 5-7). The outbred rabbit model may, therefore, be a more 
appropriate tool for delineating the reasons for such variability than the typical inbred mouse 
models. 
5.5.9 Significance and Future Directions 
Little is known regarding how virulent flaviviruses induce non-lethal disease and are 
controlled in naturally resistant hosts. We have presented an alternative small animal model 
in rabbits for studying WNV-induced non-lethal neuropathogenesis and the natural 
mechanisms of virus control. We have demonstrated that rabbits, regardless of age or species, 
are consistently resistant to virulent WNV challenge. Because of this, rabbits are more suited 
for investigating mechanisms of virus control than the relatively more susceptible mouse 
model. Furthermore, this highly resistant phenotype is representative of most human and equine 
WNV infections. Better understanding of non-lethal neuropathogenesis and resolution of virus 
infection will help identify key molecules relevant for improving antiviral and therapeutics 
design for reducing WNV-associated morbidity and mortality in humans and horses. 
Identification of the factors that determine survival will also help identify novel prognostic 
indicators for disease progression. As further outbreaks of WNV are expected across the 
world, non-lethal WNV disease will continue to have great economic impact on global 
healthcare systems [274, 310]. The establishment of the rabbit model presented in this study 
is, therefore, an important tool for devising ways of ameliorating the impact of WNV on 
global health. 
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5.6 Conclusions 
The use of the mouse and hamster model for studying host control of virulent WNV 
infections is limited by their propensity to developing lethal CNS infection. Furthermore, 
most human and equine WNV infections are not fatal, highlighting the incompatibility of 
rodents to model the pathogenesis in the incidental hosts. The resistant phenotype induced in 
WNV-infected rabbits, observed in the current study, is representative of the non-lethal 
presentation of most human and equine infections. This suggests that rabbits are an 
appropriate alternative model for studying the induction and resolution of WNV-associated 
disease. As further outbreaks of WNV are anticipated globally, better understanding of the 
mechanisms of virus control is required, in order to identify novel prognostic indicators, and 
improve therapeutic and preventative strategies. The current study has, therefore, laid the 
foundation for addressing this important gap in knowledge. 
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Chapter 6. Tissue-specific transcription profile of cytokine 
and chemokine genes associated with flavivirus control and 
non-lethal neuropathogenesis in rabbits 
6.1 Manuscript information 
The content of this chapter has been included in my publication [311].  In chapter 5, I have 
demonstrated that NZWRs and CTRs are a suitable animal model for studying immune 
mechanisms behind virus control and non-lethal neuropathogenesis associated with WNV 
and MVEV infections.  In this chapter, I examine the transcriptional profile of a selection of 
important antiviral, pro-inflammatory and anti-inflammatory cytokine and chemokine genes 
in rabbits after WNV and MVEV infections.  I observed that MVEV infection induced high 
IFNα, TNFα, IL6, and CXCL10 transcript levels in the brains of weanling NZWRs, unlike 
infection with the less virulent WNVNSW2011.  These transcript levels also correlated with 
encephalitis severity.  Widespread STAT1 protein expression in brain with moderate 
neuropathology suggests that IFN-I signalling is crucial for limiting neural infection and 
mediating non-lethal neuropathogenesis.  Unlike NZWRs, CTRs limit neuroinvasion without 
upregulation of many cytokine/chemokine transcripts, suggesting a species-dependent virus 
control mechanism.  However, the common IFNγ, TNFα and IL6 transcript upregulation in 
specific lymphoid organs suggest some conserved elements in the response against 
flaviviruses, unique to all rabbits. 
6.2 Introduction 
Over 90% of West Nile virus (WNV) infections in humans and horses are non-lethal [210, 
271, 272].  Infections can range from asymptomatic infections to self-resolving febrile 
disease to more severe, but mostly non-lethal neuroinvasive disease [210, 271, 272].  We 
have recently established a non-lethal WNV infection model in rabbits [263].  None of the 
New Zealand white (NZWR) and cottontail (CTR) rabbits infected with the Australian WNV 
strain of intermediate virulence, WNVNSW2011, succumbed to the virus challenge, regardless 
of age or species of the rabbits [263].  We had chosen NZWRs and CTRs for the comparison, 
since we were interested in the susceptibility profile of rabbits from different genetic and 
environmental background to infection with this recently isolated outbreak strain [263].  
When challenged with the highly virulent and closely related Murray Valley encephalitis 
virus (MVEV) or the North American WNV strain, WNVTX8667, a similar resistant phenotype 
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was observed in all infected NZWRs and CTRs, respectively [263].  While all rabbits were 
asymptomatic following virus challenge, we observed varying degrees of neuropathology and 
virus dissemination to lymphoid tissues [263].  The preliminary assessment of type I and II 
interferon (IFN-I/II) gene transcription in the draining popliteal lymph node (dPLN) and 
brain of WNVNSW2011- and MVEV-infected weanling NZWRs (wNZWRs) suggested a 
different transcription pattern of cytokine genes between these two groups, which may 
explain the different kinetics of neutralising antibody production, the extent of systemic virus 
dissemination and neuropathology observed [263]. 
The present study further investigated the transcription profile of important cytokine and 
chemokine genes in rabbits post-flavivirus infection.  We characterised the transcription 
kinetics of selected pivotal inflammatory genes in the dPLN, non-draining popliteal lymph 
node (ndPLN), spleen, and brain of WNVNSW2011-infected NZWRs and CTRs from the 
previous study [263].  Comparative transcription profiles were characterised in MVEV-
infected NZWRs and WNVTX8667-infected CTRs.  Genes profiled included tumour necrosis 
factor-alpha (TNFα), interleukin 6 (IL6), interleukin 4 (IL4), chemokine (C-X-C motif) 
ligand 10 (CXCL10) and interleukin 10 (IL10).  In addition, the transcription profiles of IFN-
I/II were also expanded to the ndPLN and spleen in the current study.  These genes have been 
selected, in order to cover the spectrum of antiviral (IFNα/β and γ), pro-inflammatory (TNFα, 
IL6, IL4), chemotactic (CXCL10) and anti-inflammatory (IL10) response in infected rabbits.  
Some of these cytokines can also have the opposite function under specific conditions (e.g. 
TNFα and IL6) [312, 313].  These cytokines/chemokine have also been reported to be 
important determinants of the disease outcomes after WNV infections in humans [151, 314], 
horses [23, 315] and the mouse [40, 276, 316, 317].  Since the existing mouse models do not 
consistently recapitulate non-lethal disease associated with virulent WNV infections in 
humans and horses, as already discussed in length in [1, 263], we were interested in the 
relevance of these genes in the phenotypically resistant rabbit model.  Via this investigation, 
we also aimed to characterise the association between cytokine/chemokine response in the 
brain and non-lethal neuropathogenesis.  To this end, using immunohistochemical (IHC) 
labelling, we characterised the expression of pivotal transcription factors responsible for 
mediating inflammation, such as nuclear factor kappaB (NF-kB) (p100/p52), signal 
transducers and activators of transcription (STAT)-1 and STAT3, in brains with high 
cytokine/chemokine transcript levels.   
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6.3 Methods 
6.3.1 Virus 
An Australian equine pathogenic WNV strain (WNVNSW2011), a North American outbreak 
WNV strain (WNVTX8667) and the virulent MVEV prototype strain (MVE1-51) were used for 
the in vivo challenges.  The justification for the use of MVEV and WNVTX8667 as control 
strains has been discussed previously [263].  WNVNSW2011 was originally isolated from the 
brain of an infected horse during the 2011 Australian outbreak of WNV in horses [100].  
WNVNSW2011 was passaged initially in Aedes albopictus C6/36 cells, followed by one passage 
in African green monkey (Vero) cells, and an additional passage in C6/36 cells prior to use.  
MVE1-51 was originally isolated during the 1951 Australian human outbreak  [221, 254].  It 
has since been passaged multiple times in suckling mouse brains, as well as in Vero cells.  A 
final passage in C6/36 cells was performed prior to use of MVE1-51. WNVTX8667 was isolated 
from a bluejay during the 2012 human WNV outbreak in Texas, and was kindly provided by 
Prof. Robert Tesh, University of Texas Medical Branch (Galveston, TX, USA).  WNVTX8667 
was passaged once in Vero cells prior to use [263].   All virus stocks were titrated in Vero 
cells, with titres expressed as either fifty percent endpoint of tissue culture infective dose 
(TCID50) for WNVNSW2011 and MVEV, or plaque forming units (PFU) for WNVNSW2011 and 
WNVTX8667 [263].  The TCID50 and PFU titre for the WNVNSW2011 stock varied by less than 1 
log10 (10
9.7
 TCID50/mL and 10
8.8
 PFU/mL).   
6.3.2 Animals and experimental design 
The in vivo challenge of NZWRs and CTRs has been previously described in detail [263].  
Briefly, a total of 63 rabbits were inoculated with 10
5
 TCID50 for NZWRs or PFU for CTRs, 
intradermally in the left hind footpad.  Three to nine rabbits were selected at random for 
scheduled euthanasia at time-points, day 3 and 7 post-infection (pi) for CTRs, day 3, 7, 12 
and 18 pi for weanling NZWRs, and day 7 pi only for adult NZWRs (aNZWRs).  A total of 
six NZWRs and two CTRs were sham-inoculated with cell culture media.  All animals were 
monitored daily by a registered veterinarian with measurements of rectal/body temperature, 
weight and clinical scores recorded [263].  Experimental infections were conducted in 
Physical Containment Level 2 (for NZWRs) and Biosafety Level 3 (for CTRs) animal 
holding facilities at the University of Queensland (UQ) and Colorado State University (CSU), 
respectively, as described in [263].  Ethical approval had been granted by the respective 
animal ethics committee (UQ Animal Ethics Committee (SVS/369/12/ARC); CSU 
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Institutional Animal Care and Use Committee (#14-5170)).  In order to assess the differences 
in the transcription profiles of the cytokine/chemokine genes, we selected three rabbits per 
each of the available time-points for the comparisons (Table 6-1).  The specific group 
comparisons for assessing virus, species and age-dependent transcription profiles in this study 
are outlined in Table 6-1. 
6.3.3 Tissue sampling, RNA extraction and real-time reverse-transcriptase PCR (RT-
qPCR) assay 
Tissue samples were collected during a complete post-mortem examination at each scheduled 
cull time-point, as previously described [263].  Tissue samples from three NZWRs and CTRs 
per time-point were homogenised in Qiazol (Qiagen, Chatstone Centre, Vic, Australia) or 
Trizol (Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA), respectively, at 10% 
weight/volume ratio.  RNA was extracted as per manufacturers’ instructions.  DNase I 
digestion was performed in solution, with subsequent RNA cleanup using RNeasy RNA 
extraction kit (Qiagen, Chatstone Centre, Vic, Australia) to remove genomic DNA from RNA 
samples.  For each RNA extraction batch, quantitative PCR (qPCR) was performed on 
randomly selected RNA samples to ascertain absence of genomic DNA.  cDNA synthesis 
was performed using qScript first strand synthesis kit in 20uL reactions (Quanta Bioscience, 
Gaithersburg, MD, USA).  qPCR was performed using the Rotorgene SYBR green qPCR kit 
(Qiagen, Chatstone Centre, Vic, Australia) in 20µL reactions, as described in [263].  Primers 
for all cytokine and chemokine genes have been previously described in detail [263, 282].  In 
each qPCR run, one cytokine mRNA positive control, generated from concanavalin A (Sigma 
Aldrich, Castle Hill, NSW, Australia)-challenged ex vivo rabbit splenocyte culture, was used.  
No template control, as well as control tissue samples from sham-inoculated rabbits, was 
included in each run. Cytokine/chemokine transcript levels were first normalised to house-
keeping gene, GAPDH, transcript levels for each sample (Δ CT1) [282], and then calibrated to 
the normalised basal transcription in sham-inoculated control animals (Δ CT2). The 2
−ΔΔCT
 
method was then used to calculate the relative fold change in transcription of each sample 
over that of the controls [283].  Data for IFNα, β and γ transcript levels in the brain and dPLN 
have been previously published in [263].  However, for appropriate comparison with the 
remaining cytokine and chemokine gene transcriptions, we have included these historical data 
in the current manuscript.  These have been clearly differentiated from the new data produced 
in this study. 
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Table 6-1 Outline of comparisons in this study 
Comparisons 
Weanling NZWRs Adult NZWRs CTRs 
WNVNSW2011 
(n = 12) 
MVEV 
(n = 12) 
WNVNSW2011 
(n = 3) 
MVEV 
(n = 3) 
WNVNSW2011 
(n = 6) 
WNVTX8667 
(n = 6) 
Virus-dependent profile (in NZWRs) X X     
Virus-dependent profile (in CTRs)     X X 
Species-dependent profile against WNVNSW2011 X    X  
Species-dependent profile against virulent control strains  X    X 
Age-dependent profile in NZWRs against WNVNSW2011 X  X    
Age-dependent profile in NZWRs against MVEV  X  X   
X, comparison of the groups; Virulent control strains refer to MVEV for NZWRs and WNVTX8667 for CTRs.  Note that 6 sham-inoculated wNZWRs and 2 sham-inoculated CTRs were used as 
calibrators.  However, due to the discovery of an abscess in the right hock of one of the CTR controls, we have excluded this animal from analysis, since the active inflammatory process may 
have biased the transcription profile for this animal.
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6.3.4 Immunohistochemistry 
IHC labelling of NF-kB (p100/52), STAT1 and STAT3 was performed using protocols 
described in [256, 263].  Brain sections were selected on the basis of the corresponding IFNα, 
IFNβ, IFNγ, TNFα, IL6 and IL10 transcript levels.  Specifically, to further characterise the 
pro-inflammatory response in brains with non-lethal neuropathology, sections from two 
wNZWRs infected with MVEV (rabbit 101 and 105) with high transcriptional upregulation 
of IFNα, IFNβ, IFNγ, TNFα and/or IL6 were selected for IHC labelling of NF-kB and 
STAT1 (Table 6-2).  In order to assess the activity of the negative regulator of NF-kB, 
STAT3, we selected brain sections corresponding to high IL10 transcript levels and in the 
presence or absence of infiltrated leucocytes (MVEV- and WNVNSW2011 infected wNZWR, 
respectively; Table 6-2).  Each IHC batch included control sections consisting of no primary 
antibody and rabbit/mouse antibodies targeting irrelevant antigen, such as gamma herpesvirus 
and adenovirus.  Table 6-3 summarises the specific conditions used for each antibody. 
Table 6-2 The corresponding transcript levels of cytokine and chemokine genes in brain 
sections selected for immunolabelling of STAT1, NFkB (p100/52) and STAT3. 
Rabbit 101 105 102 RA5 306 
Virus challenge MVEV MVEV MVEV MVEV WNVNSW2011 
Encephalitis 
score 
3/5 2/5 3/5 0/5 1/5
# 
IFNα 17 7 6 2 0 
IFNβ 0 16 17 1 0 
IFNγ 8 7033 4096 82 0 
TNFα 303 39 47 1 1 
IL6 28.1 11 8 2 2 
IL4 0 0 0 86 39 
CXCL10 2988 2656 1547 8 3 
IL10 0 3 4 5 4 
Immunolabelling STAT1 NF-kB 
(p100/52) 
STAT3 STAT3 STAT3 
Transcript levels are in units of fold-change relative to those from sham-inoculated rabbit controls (see methods for more 
details).  # while the encephalitis score for this animal is 1/5, there was no infiltrated leucocytes observed on the specific 
brain section selected for STAT3 immunolabelling.  
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Table 6-3 Specific conditions for immunohistochemical labelling of the transcription 
factors, NF-kB (p100/52), STAT1 and STAT3. 
 NF-kB (p100/52) STAT1 STAT3 
Host species Rabbit Mouse Rabbit 
Target retrieval EDTA (pH 9) Citrate (pH 6) EDTA (pH 9) 
Antibody 
concentration 
1:500 1:500 1:250 
Antibody 
incubation 
2 hours 2 hours Overnight 
Catalogue number Aviva Systems 
Biology 
(ARP32718_P50) 
Aviva Systems 
Biology 
(OALA02042) 
Aviva Systems 
Biology 
(AVARP09057_P050) 
 
6.3.5 Statistical Analysis 
All cytokine/chemokine transcriptional fold-change data were initially transformed using the 
formula: Y = log10(Y+1).  Statistical significance of group comparisons were obtained by 
performing either a one- or two-way analysis of variance (ANOVA), with post-test Sidak or 
Tukey for adjusting the p-values for multiple comparisons.  Phenotypic association between 
neuropathology and transcriptional upregulation was determined by the R
2
 and its associated 
p-value from one-way ANOVA.  Correlation matrix was performed by Pearson correlation 
on log-transformed fold-change data.  Statistical analyses were performed using statistical 
package, Graphpad Prism 6 (Graphpad Software Inc., San Diego, CA, USA).  
6.4 Results 
6.4.1 Virus-dependent profile in weanling NZWRs 
The difference in the levels of neuropathology and systemic virus dissemination in wNZWRs 
infected with WNVNSW2011 and MVEV suggested that the mechanism of virus control may be 
different between these two groups [263].  Figure 6-1 and Figure 6-2 show that the tissue-
specific kinetics of cytokine and chemokine genes was different between these two groups.  
In particular, the median transcription level of most pro-inflammatory genes in the brain of 
MVEV–infected wNZWRs increased from day 3 pi onwards, with most reaching a peak on 
day 12 pi, whereas WNVNSW2011-infected wNZWRs had peak transcription levels in the brain 
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on day 3 pi (Figure 6-1A and Figure 6-2A).  Because of this general difference in the 
transcription kinetics, we examined the specific differences, as well as similarities, in the 
transcript levels in each time-point between these two virus challenge groups (Figure 6-3A  to 
H and Figure 6-4A to D). 
 
 
Figure 6-1 Temporal kinetics of cytokine and chemokine gene transcription in the brain 
(A), draining popliteal lymph node (dPLN; B), non-draining popliteal lymph node 
(ndPLN; C), and spleen (D) from wNZWRs infected with WNVNSW2011.  Each bar 
represents the median of biological triplicate per time-point.  Error bars represent data range.  
Multiple t-tests using the Holm-Sidak method with alpha at 0.05 were performed on the log10 
transformed means of transcript levels on day 3 pi against the remaining time-points. 
Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  Note: data 
in grey (IFN-I/II in the brain and dPLN) have been previously published in [263] and Chapter 
5, and are included for comparison.   
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Figure 6-2 Temporal kinetics of cytokine and chemokine gene transcription in the brain 
(A), draining popliteal lymph node (dPLN; B), non-draining popliteal lymph node 
(ndPLN; C), and spleen (D) from wNZWRs infected with MVE1-51.  Each bar represents 
the median of biological triplicate per time-point.  Error bars represent data range.  Multiple 
t-tests using the Holm-Sidak method with alpha at 0.05 were performed on the log10 
transformed means of transcript levels on day 3 pi against the remaining time-points.  
Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  Note: data 
in grey (IFN-I/II in the brain and dPLN) have been previously published in [263] and Chapter 
5, and are included for comparison.   
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Figure 6-3 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between WNVNSW2011- and MVEV-infected weanling NZWRs (days 3 and 7 pi).  
Cytokine and chemokine transcription profiles on day 3 pi (A to D) and day 7 pi (E to H) in 
the brain (A and E), draining popliteal lymph node (dPLN; B and F), non-draining popliteal 
lymph node (ndPLN; C and G), and spleen (D and H).  Each point represents the median of a 
biological triplicate, while the limits of the error bars indicate the range.  Horizontal dotted 
line indicates basal expression level at 1-fold.  Statistical significance: * p < 0.05, ** p < 
0.01, *** p < 0.001, **** p < 0.0001.  Arrows indicate common transcript upregulation 
between the two comparison groups.  Note: data points in grey (IFN-I/II in the brain and 
dPLN) have been previously published in [263] and Chapter 5, and are included here for 
comparison.   
 133 
 
 
Figure 6-4 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between WNVNSW2011- and MVEV-infected weanling NZWRs (days 12 and 18 pi).  
Cytokine and chemokine transcription profiles on day 12 pi (A and B) and day 18 pi (C and 
D) in the brain (A and C), and draining popliteal lymph node (dPLN; B and D).  Each point 
represents the median of a biological triplicate, while the limits of the error bars indicate the 
range.  Horizontal dotted line indicates basal expression level at 1-fold.  Statistical 
significance: : * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  Arrows indicate 
common transcript upregulation between the two comparison groups.  Note: data points in 
grey (IFN-I/II in the brain and dPLN) have been previously published in [263] and Chapter 5, 
and are included here for comparison.  
 
6.4.1.1 Day 3 pi 
The levels of transcription of TNFα from the dPLN, IFNγ from the ndPLN and spleen, and 
CXCL10 from the spleen were significantly higher in wNZWRs infected with WNVNSW2011 
than in those infected with MVEV (Figure 6-3B to D).  Conversely, IFNα and IL10 
transcripts in the spleen were significantly higher in MVEV infected wNZWRs, relative to 
those infected with WNVNSW2011 (Figure 6-3D).  Despite these differences, the transcription 
profile in the dPLN, ndPLN and brain was mostly comparable between the two groups on day 
3 pi, with several genes being commonly upregulated (Figure 6-3A to C).  The most 
consistently upregulated gene amongst all biological replicates between the two virus 
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challenge groups was IL10 in all tissues examined (Figure 6-3A to D).  Moreover, consistent 
upregulation was also observed for IFNγ and TNFα mRNA in the brain, dPLN, and ndPLN 
(Figure 6-3A to C).   
6.4.1.2 Day 7 pi 
On day 7 pi, the levels of transcription of most cytokine genes and the CXCL10 gene 
between the two virus challenge groups were comparable in all tissues examined (Figure 
6-3E to H).  The only exception was TNFα in the spleen (Figure 6-3H).  IL10 and IFNγ 
transcripts were again consistently upregulated between the two groups, but only in 
peripheral lymphoid tissues (Figure 6-3F to H). 
6.4.1.3 Day 12 and 18 pi 
The levels of brain IFNα, TNFα, IL6 and CXCL10 transcripts on day 12 pi and IFNγ on day 
18 pi were significantly higher in wNZWRs infected with MVEV than in those infected with 
WNVNSW2011 (Figure 6-4A and C).  The peripheral response in the dPLN between the two 
groups was comparable in these late time-points (Figure 6-4B and D).  Consistently 
upregulated amongst these two groups was CXCL10 in the brain (day 12 and 18 pi) and 
dPLN (Figure 6-4A to C, day 12 pi).  The consistent peripheral IL10 transcript upregulation 
was maintained in these late time-points (Figure 6-4B and D). 
6.4.2 Virus-dependent profile in CTRs 
A comparison of the cytokine/chemokine gene transcription was performed between CTRs 
infected with WNVNSW2011 and WNVTX8667, in order to examine the effect of different virus 
strains on the immune response in this comparative rabbit species.  We previously reported 
that some CTRs infected with WNVTX8667 developed more severe neuropathology, relative to 
those infected with WNVNSW2011 [263].  However, the overall frequency of CTRs with 
neuropathology was lower than that in wNZWRs [263].   
In the current study, we expanded the characterisation of virus kinetics in WNV-infected 
CTRs by assessing the viral RNA load in the ndPLN and spleen (Figure 6-5A).  We observed 
that WNVTX8667 was more successful at disseminating to the ndPLN and spleen on day 3 and 
7 pi, similar to MVEV in wNZWRs (Figure 6-5A).  However, in general, the transcription 
profile of cytokine and chemokine genes was mostly comparable between the two CTRs 
groups (Figure 6-6A to H and Figure 6-8).  The tissue with the most different transcription 
profile was the ndPLN on day 3 (Figure 6-6C).  In particular, the transcription levels of IFNα, 
IL6 and IL10 genes were significantly higher in the WNVTX8667 group, relative to CTRs 
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infected with WNVNSW2011 (Figure 6-6C).  In addition, the notable upregulation of IL4 
mRNA in the brain of 2/3 CTRs infected with WNVTX8667 was significantly higher than that 
in CTRs infected with WNVNSW2011 on day 3 pi (Figure 6-6A).  On day 7 pi, there were no 
significant differences in the transcription profile between the two virus challenge groups for 
all tissues examined (Figure 6-6E to H).  Similar to wNZWRs, IFNγ in the dPLN was 
consistently upregulated in CTRs on day 3 and 7 pi, regardless of virus strain (Figure 6-6B 
and F).  However, notably across both time-points, many cytokine and chemokine genes were 
not upregulated for either CTR group, suggesting a different immunological mechanism or 
different kinetics of the response leading to virus control in CTRs (Figure 6-7A to H).  
 
Figure 6-5 Viral load in non-draining popliteal lymph node and spleen of CTRs (A), and 
MVE1-51 infected weanling and adult NZWRs (B).  Each data point represents the viral 
load in one rabbit.  Horizontal bar represents the median of the biological triplicate.  
Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  Fold-change 
was calculated by first normalising viral RNA cycle threshold (CT) against the housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) before using the 2
−ΔΔCT
 method, 
as previously described in [263].  This relative viral burden was expressed as fold increase 
over sham-infected controls. 
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Figure 6-6 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between WNVNSW2011- and WNVTX8667-infected CTRs (days 3 and 7 pi).  Cytokine and 
chemokine transcription profiles on day 3 pi (A to D) and day 7 pi (E to H) in the brain (A 
and E), draining popliteal lymph node (dPLN; B and F), non-draining popliteal lymph node 
(ndPLN; C and G), and spleen (D and H).  Each point represents the median of a biological 
triplicate, while the limits of the error bars indicate the range.  Horizontal dotted line 
indicates basal expression level at 1-fold.  Statistical significance: : * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001.  Arrows indicate common transcript upregulation between 
the two comparison groups.  Note: data points in grey (IFN-I/II in the brain and dPLN) have 
been previously published in [263] and Chapter 5, and are included here for comparison.   
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Figure 6-7 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between WNVNSW2011- infected weanling NZWRs and CTRs (days 3 and 7 pi).  Cytokine 
and chemokine transcription profiles on day 3 pi (A to D) and day 7 pi (e to h) in the brain (a 
and e), draining popliteal lymph node (dPLN; B and F), non-draining popliteal lymph node 
(ndPLN; C and G), and spleen (D and H).  Each point represents the median of a biological 
triplicate, while the limits of the error bars indicate the range.  Horizontal dotted line 
indicates basal expression level at 1-fold.  Statistical significance: ¥  p < 0.05, ¥ ¥  p < 0.01, ¥ 
¥ ¥  p < 0.001, ¥ ¥ ¥ ¥  p < 0.0001.  Arrows indicate common transcript upregulation between 
the two comparison groups.  Note: data points in grey (IFN-I/II in the brain and dPLN) have 
been previously published in [263] and Chapter 5, and are included here for comparison.   
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Figure 6-8 Temporal kinetics of cytokine and chemokine gene transcription in the brain 
(A), draining popliteal lymph node (dPLN; B), non-draining popliteal lymph node 
(ndPLN; C), and spleen (D) from CTRS infected with either WNVNSW2011 or WNVTX8667.  
Each bar represents the median of biological triplicate per time-point.  Error bars represent 
data range.  Multiple t-tests using the Holm-Sidak method with alpha at 0.05 were performed 
on the log10 transformed means of transcript levels on day 3 pi against the remaining time-
points.  Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
Note: data in grey (IFN-I/II in the brain and dPLN) have been previously published in [263] 
and Chapter 5, and are included for comparison. 
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6.4.3 Species-dependent profile against WNVNSW2011 
There were significant differences in cytokine/chemokine gene transcription between the two 
rabbit species infected with WNVNSW2011 on day 3 pi (Figure 6-7A to D).  In particular, the 
IFN-I/II transcript upregulation in the brain and ndPLN was significantly higher in wNZWRs 
than in CTRs (Figure 6-7A and C).  Conversely, splenic IFNα transcript was significantly 
higher in CTRs compared to wNZWRs on day 3 pi (Figure 6-7D).  Differential transcription 
levels of TNFα were also observed in the brain, dPLN and spleen (Figure 6-7A, B and D).  
On both day 3 and 7 pi, the levels of the anti-inflammatory IL10 transcript in both the brain 
and the lymphoid tissues were mostly significantly higher in wNZWRs relative to CTRs 
(Figure 6-7A to H). 
Common to both species of rabbits infected with WNVNSW2011, IFNγ and CXCL10 in the 
dPLN were upregulated on both day 3 and 7 pi (Figure 6-7B and F).  Common upregulation 
of inflammatory gene transcript was also seen in the ndPLN (TNFα), and spleen (IL6 and 
CXCL10) on day 3 pi (Figure 6-7C and D).  These commonalities suggest a conserved 
transcriptional signature associated with the control of WNVNSW2011 infection unique to 
rabbits. 
6.4.4 Species-dependent profile against virulent control strains 
Consistently across both day 3 and 7 pi, the levels of transcription of CXCL10 in the brain, 
TNFα in the dPLN, and IL10 in both the dPLN and spleen were significantly higher in 
MVEV-infected wNZWRs compared to WNVTX8667-infected CTRs (Figure 6-9A, B, E and 
F).   Additionally, brain IL10 and dPLN IL6 transcripts were also higher in the former group 
on day 3 pi (Figure 6-9A and B).  Conversely, the levels of ndPLN IL4 and splenic CXCL10 
transcripts were significantly higher in WNVTX8667 infected CTRs, relative to MVEV-
infected wNZWRs (Figure 6-9C and D).   
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Figure 6-9 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between MVEV-infected weanling NZWRs and WNVTX8667-infected CTRs (days 3 and 7 
pi).  Cytokine and chemokine transcription profiles on day 3 pi (A to D) and day 7 pi (E to H) 
in the brain (A and E), draining popliteal lymph node (dPLN; B and F), non-draining 
popliteal lymph node (ndPLN; C and G), and spleen (D and H).  Each point represents the 
median of a biological triplicate, while the limits of the error bars indicate the range.  
Horizontal dotted line indicates basal expression level at 1-fold.  Statistical significance: ¥  p 
< 0.05, ¥ ¥  p < 0.01, ¥ ¥ ¥  p < 0.001, ¥ ¥ ¥ ¥  p < 0.0001.  Arrows underneath the x-axis 
indicate common transcript upregulation between the two comparison groups.  Note: data 
points in grey (IFN-I/II in the brain and dPLN) have been previously published in [263] and 
Chapter 5, and are included here for comparison.   
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Despite these differences, a number of common transcript upregulations were observed 
between these two groups, with most of the commonalities observed in the ndPLN (Figure 
6-9A, B, C, E and H).  Notably, IFNγ, IFNα and IL6 transcripts were commonly upregulated 
in more than one tissue on day 3 pi (Figure 6-9B, C, and D).  Consistent upregulation of IFNγ 
transcription was again observed in the dPLN on both day 3 and 7 pi, similar to the 
WNVNSW2011-infected wNZWRs and CTRs (Figure 6-9B and F). 
6.4.5 Age and gender 
The transcription profiles of cytokine and chemokine genes were comparable between 
wNZWRs and aNZWRs on day 7 pi (Figure 6-10A to H).  Exceptions to this include splenic 
TNFα for WNVNSW2011-infected NZWRs (Figure 6-10D), and ndPLN IFNα and β for 
MVEV-infected NZWRs (Figure 6-10G).  The only gene where the transcription level was 
higher in wNZWRs relative to aNZWRs was brain CXCL10 (Figure 6-10E).  The remaining 
comparisons of gene transcription between the two age groups were not significantly 
different.  Notably, the consistent peripheral IL10 response was also observed in all 
aNZWRs, regardless of the virus inoculated (Figure 6-10B, C, D, F, G, and H). 
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Figure 6-10 Comparison of tissue-specific cytokine and chemokine transcription profiles 
between flavivirus-infected weanling and adult NZWRs (day 7 pi).  Cytokine and 
chemokine transcription profiles in the brain (A and E), draining popliteal lymph node 
(dPLN; B and F), non-draining popliteal lymph node (ndPLN; C and G), and spleen (D and 
H) of weanling (A to D) and adult (E to H) NZWRs.  Each point represents the median of a 
biological triplicate, while the limits of the error bars indicate the range.  Horizontal dotted 
line indicates basal expression level at 1-fold.  Statistical significance: #  p < 0.05, ##  p < 
0.01, ### p < 0.001, #### p < 0.0001.  Arrows indicate common transcript upregulation 
between the two comparison groups.  Note: data points in grey (IFN-I/II in the brain and 
dPLN) have been previously published in [263] and Chapter 5, and are included here for 
comparison.   
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We also compared the overall levels of transcription of cytokine and chemokine genes 
between the two genders, pooling data from all virus challenge groups (Figure 6-11).  There 
were no significant gender-dependent differences in the gene transcription levels (Figure 
6-11). 
 
Figure 6-11 Comparison of cytokine and chemokine gene transcription in the brain, 
draining popliteal lymph node, non-draining popliteal lymph node, and spleen from 
male and female rabbits, infected with various flavivirus (pooled).  All bars represent the 
median of biological triplicate per time-point.  Error bars represent the range.  There was no 
statistical difference in the cytokine/chemokine gene transcription between the two genders 
(two- way ANOVA: p = 0.2998).  Br, brain; dPLN, draining popliteal lymph node; ndPLN, 
non-draining popliteal lymph node, SP, spleen. 
 
6.4.6 Correlation of cytokine and chemokine gene profile with non-lethal disease 
outcomes 
The levels of transcription of most pro-inflammatory cytokine or chemokine genes in the 
brain were positively correlated with the severity of encephalitis when data were pooled from 
all groups (Figure 6-12A, B, C, D, E, and G).  But the correlation between transcription of 
these genes and the severity of meningitis was less obvious (Figure 6-13). 
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Figure 6-12 Association between brain cytokine/chemokine transcript levels and 
severity of non-lethal encephalitis in flavivirus-infected rabbits. IFNα (A), IFNβ (B), 
IFNγ (C), TNFα (D), IL6 (E), IL4 (F), CXCL10 (G) and IL10 (H) transcription levels in the 
brain of all 42 rabbits used this study, separated by the encephalitis score given for the 
corresponding brain.  Each data point represents one rabbit.  Horizontal line represents the 
median fold change.  n = 25 for encephalitis score 0, n = 7 for encephalitis score 1, n = 7 for 
encephalitis score 2, and n = 3 for encephalitis score 3.  Note that the encephalitis scores are 
graded on a 5-tier system, as described in [263] and Chapter 5.  Statistical significance: * p < 
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  R
2 
and its associated p-value were 
calculated using one-way ANOVA. 
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Figure 6-13 Association between brain cytokine/chemokine transcript levels and 
severity of non-lethal meningitis in flavivirus-infected rabbits. IFNα (A), IFNβ (B), IFNγ 
(C), TNFα (D), IL6 (E), IL4 (F), CXCL10 (G) and IL10 (H) transcriptional levels in the 
brain, separated by the encephalitis score given for the corresponding brain.  Statistical 
significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  R
2 
and its associated 
p-value were calculated using one-way ANOVA. 
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Pooling data from all virus challenge groups, the correlation coefficients between the acute 
viral load (day 3 and 7 pi) and the gene transcription levels locally in the lymphoid tissues 
were all less than 0.4 (weak correlation), even though some of the correlations were 
significant (Table 6-4).  Scatterplots and linear regression of the two strongest correlations 
showed that the associations between cytokine transcript levels and local tissue viral load 
were only weakly positive (Figure 6-14).  Therefore, the local tissue viral load was not a 
strong predictor of the magnitude of cytokine gene upregulation, at least not for the genes that 
I have examined in this study.  
 
Figure 6-14 Correlation between IFNγ (A) and IL6 (B) transcription and local viral load 
in the non-draining popliteal lymph node.  Solid line represents the line-of-best-fit, with 
curved dotted lines indicating the 95% confidence interval of the position of this line-of-best-
fit.  Each data point represents the transcript level and viral RNA load in one rabbit.  R
2
 and 
its associated p-value were calculated from a simple linear regression model on the 
log10(Y+1) transformed data.  
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Table 6-4 Pearson’s correlation test on log10 transformed transcriptional fold-change of cytokine/chemokine genes and viral load, 
pooling data from all virus challenge groups on day 3 and 7 pi. 
Cytokine/chemokine 
genes 
Viral Load 
Draining Popliteal Lymph Node 
Non-draining Popliteal Lymph 
Node Spleen 
R squared p (two-
tailed) 
p value 
summary 
R squared p (two-
tailed) 
p value 
summary 
R squared p (two-
tailed) 
p value 
summary 
IFNα 0.05375 0.2177 ns 0.2195 0.009 ** 0.003973 0.7407 ns 
IFNβ 0.0001781 0.9442 ns 0.08407 0.1201 ns 0.01626 0.5019 ns 
IFNγ 0.1337 0.0469 * 0.3386 0.0007 *** 0.01416 0.5311 ns 
TNFα 0.02599 0.3948 ns 0.1606 0.0282 * 0.1522 0.033 * 
IL6 0.05494 0.2125 ns 0.3123 0.0013 ** 0.001605 0.8335 ns 
IL4 0.003522 0.7554 ns 0.1261 0.0542 ns 0.0002744 0.9308 ns 
CXCL10 0.128 0.0522 ns 0.1158 0.0658 ns 0.001635 0.832 ns 
IL10 0.06567 0.1717 ns 0.04557 0.2574 ns 0.0345 0.3258 ns 
ns – not significant, statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  
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6.4.7 STAT1, NF-kB (p100/52) and STAT3 expression associated with non-lethal 
neuropathogenesis 
Sections from brain with high levels of IFN-I/II, TNFα, IL6, and IL10 transcripts were 
selected for immunolabelling of transcription factors, NF-kB (p100/52), STAT1 and STAT3, 
in order to identify the extent of and cell types with detectable expression level of these 
pivotal signalling molecules.  Figure 6-15A summarises the involvement of these 
transcription factors in the downstream signalling pathway from IFN-I/II, TNFα, IL6 and 
IL10 for the mediation of the immune response in the model cell, macrophage [318-320].   
STAT1 expression in the brain of MVEV-infected wNZWRs was widespread, with signal 
detectable in the cytoplasm and occasionally nuclei of perivascular and neuropil-infiltrating 
mononuclear leucocytes, as well as brain cells with elongated cytoplasmic processes and 
dense round to ovoid nuclei, the morphology of which is consistent with glial cells (Figure 
6-15C and C inset).  NF-kB immunoreactivity was mainly detected in the cytoplasm of a 
subset of perivascular mononuclear leucocytes in the brain (Figure 6-15B).  STAT3 
immunolabelling was also predominantly detected in cytoplasm of a subset of mononuclear 
leucocytes in the meninges (Figure 6-15D), intracerebral perivascular spaces, and leucocyte 
infiltrates in the hippocampus.  Notably, STAT3 labelling was absent in brain sections 
without detectable infiltrating leucocytes, even though the associated IL10 transcription was 
upregulated to comparable levels as those of brains with infiltrating leucocytes (Table 6-2).  
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Figure 6-15 Immunohistochemical labelling of transcription factors, NF-kB (p100/52), 
STAT1 and STAT3 in the brain.  Simplified schematic diagram of NF-kB, STAT1, and 
STAT3 signalling pathway (grey arrows) relevant for the cytokines included in the current 
study (A).  Blue solid curved line represents the cell plasma membrane.  Black dotted curved 
line represents the nuclear membrane.  Black arrows indicate gene transcription.  Red dotted 
lines with flat end represent inhibition of JAK and NF-kB by STAT3 related induction of 
negative regulators, such as suppressor of cytokine signalling (SOCS) 3.  Note: STAT3 has a 
variety of functions that are cell-dependent [321]. TNF-R1 and 2, tumour necrosis factor 
receptor 1 and 2; IL6-R, IL6 receptor; IFNAR, interferon α/β receptor; IFNγ-R, interferon-γ 
receptor; IL10-R, IL10 receptor; JAK, Janus kinase; IkBs, inhibitor of kBs; P, 
phosphorylated.  This diagram was constructed based on information from [318-320].  
Immunohistochemical labelling (red staining) of pivotal transcription factors, regulating 
inflammatory response, NF-kB (p100/p52) (B), STAT1 (C) and STAT3 (D) in brain sections 
from rabbits infected with MVEV exhibiting mild-moderate non-lethal neuropathology.  
Intense nuclear staining of STAT1 in perivascular mononuclear cell (C inset).  Magnification: 
40x for (b to d), 40x cropped for (C inset).  Scale bars represent 50 μm. 
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6.5 Discussion 
We have previously shown that rabbits, regardless of age and species, present with a resistant 
phenotype after intradermal inoculation of virulent strains of WNV and MVEV [263].  Viral 
neuroinvasion was not observed for all groups, except for MVEV-infected NZWRs, where 
trace viral RNA was detected in a subset of animals on day 7. 12, and 18 pi [263].  In the 
latter group, the initiation of neutralising antibody and dPLN IFNα response was slower than 
that in WNVNSW2011-infected wNZWRs, and therefore may have explained the more 
pronounced systemic dissemination of MVEV [263].  Nevertheless, virus infection was 
controlled effectively in all groups, despite the varying degree of systemic virus 
dissemination [263].  In the current study, we have further identified common and differing 
elements of the innate immune response in rabbits challenged with virulent WNV and 
MVEV, furthering the understanding of the mechanisms of flavivirus control in a natural 
phenotypically resistant animal species.  We have also identified that the most severe non-
lethal neuropathology observed in rabbits (i.e. MVEV-infected wNZWRs) was associated 
with widespread STAT1 immunoreactivity.  This suggests that even though virus 
dissemination was marginally more pronounced in these animals, the neuropathology was 
crucial for averting establishment of virus infection in the brain, likely via the actions of the 
local IFN-I response. 
The acute transcriptional upregulation of IFN in the dPLN, TNF in the ndPLN and IL6 in 
the spleen were common amongst all wNZWRs and CTRs, after challenge with various 
flavivirus strains.  These commonalities may highlight a conserved mechanism of virus 
control in rabbits against flavivirus.  The cellular sources of upregulated IFNγ transcripts 
were likely activated T cells, γδ T lymphocytes and/or natural killer cells in the dPLN, since 
they are the main producers of IFNγ [166, 305, 306].  Activation of T cells was likely a 
consequence of the productive infection of macrophages or dendritic cells in the dPLN, as 
evident in our previous study [263].  Infection of these cells may result in the production of T 
cell co-stimulatory molecules, such as CD80, CD86 and IL12 [322].  IL12, in particular, has 
been shown to be an important stimulatory cytokine for natural killer (NK) and T cells to 
produce IFNγ [323].  However, it remains uncertain why NZWRs and CTRs have a common 
IFNγ response in the dPLN, rather than a common IFNα/β response, which has been 
suggested to be a major common response against WNV in many published reviews [66, 
324].  Further investigation into the expression pattern of I kappa B kinase epsilon (IKKε), a 
key regulator of IFN-I and IFN-II response, may give clues into this common bias towards 
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IFNγ transcript induction in rabbits [325].  The common IFNγ response may be involved with 
virus control locally, via macrophage and/or dendritic cell activation in the dPLN, or 
indirectly via its support in an early and competent neutralising antibody response, as we 
have previously discussed in details [263].   
Since viral loads in ndPLN and spleen were not consistently present amongst all virus-
challenged groups ([263] and Figure 6-5), the common transcriptional upregulation of TNFα 
in the ndPLN and IL6 in spleen on day 3 pi were unlikely to be due to local stimulation.  
Instead, they may be a consequence of indirect stimulation from acute systemic 
inflammation, which has been reported in non-lethal WNV infections in humans [326].  
Evidence of cytokine and chemokine transcript upregulation in peripheral blood mononuclear 
cells of WNVNSW2011-infected wNZWRs suggests that PBLs may contribute to cytokinaemia, 
which in turn may induce systemic inflammation [145].  Alternatively, a systemic 
inflammatory response may be induced by early haematogenous circulation of virus 
(viraemia), stimulating viral sensors, such as Toll-like receptors, at the blood-tissue 
interphase [327-329].   
The role of TNFα and IL6 in restricting peripheral WNV replication and CNS infection has 
been investigated in the mouse model [51, 316].  These restrictive mechanisms may involve 
the mediation of leukocytic chemotaxis to site of infection [316, 330], macrophage  activation 
[331, 332] and acute phase protein production [333, 334].  Additionally, their dual role as 
anti-inflammatory cytokines may be important for modulating the immune response, in order 
to achieve appropriate virus control [333].  The upregulation of TNFα and IL6 in tissues 
suggests that the importance of these cytokines in virus control, as previously suggested by 
the mouse model, is also applicable in rabbits.  However, our study has also shown that this 
common TNFα and IL6 response in rabbits is time- (day 3 pi) and tissue-dependent (ndPLN 
for TNFα and spleen for IL6), suggesting a well-orchestrated conserved mechanism of virus 
control amongst rabbits, that involves multiple tissue types.   
Despite the conserved elements of the immune response, the degree of virus dissemination 
and neuropathology varied between the groups.  It was therefore not surprising to have 
observed differences in the tissue-specific transcription profile of cytokine and chemokine 
genes between the groups.   Differences in the host response likely reflect the intrinsic 
differences in the immune system between NZWRs and CTRs (e.g. [335-337]), as well as the 
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different virulence factors of the virus strains, demanding different inhibitory mechanisms 
(e.g. [101, 338]).  
CTRs have been reported to exhibit greater resistance to myxoma and cottontail rabbit 
papilloma virus challenge, relative to NZWRs [339-341].  Recent genomic studies have 
highlighted differences in certain chemokine genes, such as CCL8, between CTRs and 
NZWRs [342], which may explain the difference in the susceptibility to viruses between the 
two species.  In the present study, the innate immune response against WNV differed 
between the two rabbit species.  One of these differences was the response in the spleen.  In 
particular, splenic IFNα transcript levels were consistently higher in the CTR groups relative 
to the wNZWRs (Figure 6-7D and Figure 6-9D).  This may explain the faster and relatively 
more pronounced neutralising antibody response in CTRs than that in NZWRs, as evident in 
our previous study [263].  The splenic IFNα response may also have mediated direct antiviral 
action against WNV, via the induction of interferon-stimulated genes (ISGs) and associated 
effectors, such as 2’-5’-oligoadenylate synthase (OAS), RNase L, protein kinase R (PKR), 
interferon-induced protein with tetratricopeptide repeats (IFITs), interferon-induced 
transmembrane proteins (IFITMs), and viperin (reviewed in [66]).  Therefore, the splenic 
immune response may be an important feature of virus control in CTRs. 
In general, a higher frequency of upregulated transcripts was observed in the brain and 
peripheral lymphoid tissues of wNZWRs than in CTRs, regardless of the flavivirus 
inoculated, particularly on day 3 pi (Figure 6-7 and Figure 6-9).  This suggests that flavivirus 
infection induces a more pronounced systemic innate immune response in NZWRs, as 
compared to that in CTRs, highlighting a species-dependent virus control mechanism.  
However, we have not excluded the possibility that our earliest time-point (day 3 pi) failed to 
capture the peak of the CTRs’ systemic response against WNV.  Alternatively, the observed 
difference in the frequency of upregulated transcripts may be due to the genes selected for 
this study.  It is possible that CTRs mediated their cytokine/chemokine response via immune 
molecules that we have not included in this study, thus potentially explaining the overall 
limited upregulation in transcripts in this species.  For these reasons, although beyond the 
scope of the current study, global transcriptomic and proteomic investigations into the host 
response, especially during the peracute phase of the infection, will be necessary to 
comprehensively delineate differences and similarities in molecules involved in virus control 
between NZWRs and CTRs.  Global transcriptomic and proteomic assays will also allow a 
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comprehensive assessment of the role of the remaining important cytokines and chemokines, 
such as IL1, IL12, and CCL2, for virus control and neuropathogenesis in the rabbit model. 
The virus strain inoculated also determined the tissue-specific temporal transcription profile 
in rabbits, most evidently in wNZWRs.  Notably, the highly virulent MVEV induced 
significantly higher levels of pro-inflammatory gene transcription in the brain, relative to 
WNVNSW2011, during the late phase of the infection (Figure 6-4A and C).  The higher levels of 
pro-inflammatory cytokine/chemokine transcription corresponded to the more severe 
neuropathology in MVEV-infected wNZWRs [263].  This is consistent with our suggestion 
in the previous study that the marginally slower peripheral neutralising antibody and IFNα 
response may have led to the wider virus dissemination, leading to a heavier reliance on the 
brain to restrict virus infection locally [263].  Reasons for this virus-dependent host response 
in wNZWRs remain to be investigated, but they likely involve differences in viral 
determinants affecting infectivity, replication and immune evasion capability of the virus 
strains. 
The moderate severity of the neuropathology observed in MVEV-infected wNZWRs 
presented a unique opportunity to study immune mechanisms associated with non-lethal 
neuropathogenesis.  We have examined the immunoreactivity of a selected panel of 
transcription factors, pivotal in mediating inflammatory responses, in brains of MVEV-
infected wNZWRs.  The widespread STAT1 immunoreactivity was consistent with the high 
levels of IFNα transcript, suggesting that the brain IFNα response is crucial in restricting the 
establishment of MVEV infection in the CNS.  This response appeared to be mediated by 
infiltrating mononuclear leucocytes and glial cells, as supported by the detection of STAT1 
labelling in these cell types (Figure 6-15C).   Relative to the STAT1 immunoreactivity, the 
less widespread labelling of NF-kB suggests that the brain pro-inflammatory response may be 
regulated by negative regulators, such as STAT3 [320].  In our investigation, the 
immunoreactivity of STAT3 appeared to have a similar distribution and extent as that of NF-
kB, suggesting a possible relationship between these two molecules.  However, the diverse 
pro-inflammatory, anti-inflammatory and homeostatic actions mediated by STAT3 warrant 
further investigations into its role in flavivirus-induced non-lethal neuropathogenesis [321]. 
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6.6 Conclusions 
Our study suggests that successful immune control of virulent flavivirus infection can be 
achieved by different mechanisms that are dependent on host and virus factors.  When 
peripheral control is inadequate in restricting the dissemination of virus, as in the case of 
MVEV-infected wNZWRs, the development of non-lethal neuropathology is essential for 
virus control locally in the brain, likely via the associated antiviral IFN-I response.  
Therefore, using this phenotypically resistant rabbit model, we have provided further 
information that can help identify prognostic factors that drive human and equine flaviviral 
infections to developing non-lethal but potentially debilitating neurological diseases. 
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Chapter 7. General discussion and conclusions 
The 2011 equine outbreak of WNV in south-eastern Australia is a reminder that WNV is a 
globally significant virus that places significant burden on human and veterinary healthcare.  
Extensive research has been conducted into the pathogenesis and the immune response 
against WNV in the mouse model, typically the C57BL/6 strain, and to a lesser extent in the 
hamster model (Chapter 1 literature review).  However, the route of viral neuroinvasion 
remains unclear [1].  Furthermore, the development of non-lethal neurological disease and the 
mechanism of virus control against virulent WNV strains are poorly understood, mainly due 
to the absence of a model that is consistently clinically resistant to virulent WNV infection. 
The work performed for this thesis aimed to address these two major deficiencies in WNV 
research.  Firstly, a Swiss white CD1 mouse model, typically producing high mortality rate 
when infected with the virulent Australian strain, WNVNSW2011, was used to explore WNV 
neuropathogenesis [100, 219, 246] (Chapter 3 and 4).  The second half of this thesis 
established a phenotypically resistant animal model in rabbits for studying the clinical, 
virological, pathological and immunological features of non-lethal WNV infections with 
equine-virulent strains, which are the predominant presentation of human and equine WNV 
infections [263, 311] (Chapter 5 and 6).  
7.1 Neuropathogenesis of WNV in the Swiss white CD1 mouse model 
The high mortality rate reported previously, associated with intraperitoneal infection of 
WNVNSW2011 in the Swiss white CD1 mice suggested that this model system may be suitable 
for studying the mechanism of viral neuroinvasion [100].  In chapter 3, a pilot time-course 
challenge experiment was conducted using this model system.  However, contrary to my first 
hypothesis in which I stated “1a)  Swiss white CD1 mice may allow investigation into the 
mechanism of viral neuroinvasion, due to high mortality rate observed in previous cohorts.” 
(Chapter 1, Section 1.8), the CD1 mouse model system is associated with some significant 
limitations for studying WNV neuroinvasion (Chapter 3).  In particular, the use of 
WNVNSW2011 in this challenge model did not demonstrate CNS virus infection at a time-point 
when mortality was expected (i.e. on day 7 pi) [100].   
7.1.1 Variability and validity of time-point sacrifice experiments 
In chapter 4, I demonstrated that the end-point disease phenotype associated with 
WNVNSW2011 infection in the Swiss white CD1 mouse model system is highly variable.  
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Similar variability has also been observed in other studies using different mouse and WNV 
strains (e.g. [261, 262]).  Yet, variability in disease outcome has not been well recognised as 
a significant factor influencing the interpretation of results from time-point sacrifice 
experiments.  The large variability in the end-point disease suggested that a time-point 
snapshot may capture a group of mice undertaking different disease processes towards 
different outcomes.  The failed attempt to observe CNS infection in mice sacrificed on day 7 
pi in the pilot experiment (Chapter 3) may therefore be explained by a combination of low 
sample size and the variable outcome to be expected of CD1 mice infected with WNVNSW2011.  
At each of the sacrifice time-point, it was unknown whether each individual mouse would be 
an early or late fatality or a survivor.   
In chapter 4, I have suggested that pathogenesis investigation for virus strains of intermediate 
virulence should account for the expected variability in disease outcomes associated with 
these virus strains.  Use of larger sample size for sacrifice experiments and/or intravital 
monitoring of labelled viruses or host genes/proteins/cells may be of value for these virus 
strains.  The latter may also allow determination of pre-mortem markers (i.e., “biomarkers”) 
useful for determining the fate of the infected animal.  Therefore, contrary to the convention 
that sacrifice experiments are suitable for studying the pathogenesis of virus strains of any 
virulence, my investigation using the CD1 mouse-WNVNSW2011 model system shows that 
special considerations are required for virus strains of intermediate virulence, due to their 
intrinsically large degree of variability in the resultant disease outcome. 
7.1.2 Variability in disease outcome is organ specific 
In the comparison of MVEV-challenged mice to WNVNSW2011 challenged mice, the 
difference in the degree of variability between these two groups was organ specific.  In 
particular, while the severity of neuropathology in MVEV-challenged mice was significantly 
less variable than that of WNVNSW2011 and WNVNSW2012-infected mice, this trend was not 
observed in the spinal cord.  This organ specific variability may reflect differing organ-
specific host-virus interactions amongst the infected mice. 
I hypothesise that within a group of infected animals, a narrow spectrum of disease outcome 
should be observed in any organ during the initial interaction between the host organ and the 
virus (Figure 7-1).  As the interaction between host immune response and virus advances, the 
disease outcomes in the organ may vary between the animals, depending on the balance of 
the virus’s ability to infect/replicate in host cells and the host’s ability to control the virus 
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infection/replication.  Therefore, the spectrum of disease outcomes during this phase may 
increase and become variable.  If represented on a graph with disease severity on the Y-axis 
and time on the X-axis, the progression of the organ specific variable (e.g. viral load or host 
transcript levels) in each animal may take on a modal, multimodal, sigmoid, exponential, 
logarithmic, or random distribution during this phase.  However, equilibrium in the host-virus 
interaction should be reached eventually in any organ, such as when the virus has been 
cleared from or persists in the organ.  Therefore, during this final phase, a narrow spectrum in 
the outcomes should be observed in the group of challenged animals.  However, since 
different organs may undergo the initial and final phase at different time post-infection, many 
organs within one host may not reach the final phase if the animal succumbs to the infection 
prematurely.  
This concept perhaps is better observed in the rabbit cytokine/chemokine transcription profile 
(Chapter 6) than in the mouse experiments, since I have characterised the variables over 
multiple time-points in multiple organs.  The bars in Figure 7-1 show the range in the 
transcript levels for each cytokine/chemokine in the brain, dPLN, ndPLN and spleen 
inWNVNSW2011 – infected wNZWRs.  One can appreciate that the range for some of the 
transcripts in the brain, such as IFNγ (Figure 7-1A), is relatively smaller in the first time-
point as compared to that in the later time-points.  This trend may be highlighting the 
initiation phase of the response for these cytokines/chemokine in the brain, where the 
variability of the response is minimal amongst infected rabbits. 
In contrast, large variability in the cytokine/chemokine gene transcription in the dPLN was 
observed on day 3 pi (Figure 7-1).  This suggests that by day 3 pi, the initiation phase has 
already passed and that animals have already progressed to different stages of the virus-host 
interaction by this day in this particular organ.  The dPLN is also anatomically closer to the 
inoculation site in the footpad than the brain.  Therefore, the dPLN would be expected to be 
stimulated earlier than the brain.  Furthermore, viral RNA was detectable in the dPLN at 
significant levels on day 3 pi, suggesting that establishment of host-virus interaction in this 
organ was earlier than day 3 pi (Figure 7-1).   
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Figure 7-1 Range of cytokine/chemokine transcription in the brain (A), draining popliteal lymph node (PLN, B), non-draining popliteal 
lymph node (ndPLN, C) and spleen (D) in wNZWRs infected with WNVNSW2011.  Each bar represents the range of the maximum and 
minimum of the transcriptional fold-change.  Data below 1-fold (basal level) has been excluded, since the focus of these graphs is the degree of 
transcript upregulation from basal level. 
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Similar trends in the variation of range over time were also observed in other variables that 
are measured repeatedly in each animal, such as rectal temperature (Figure 7-2).  The range 
of rectal temperature increased from day 0 to day 1 pi, and began to decrease from day 2 pi 
onwards, as the median rectal temperature returned to basal level.  This may be highlighting 
the different phases of the virus-host interactions, as suggested above. 
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Figure 7-2. Median and range of rectal temperature of wNZWRs infected with 
WNVNSW2011.  The range increased beginning on day 1 pi and eventually becomes smaller as 
the median temperature returns to basal levels.  The notable range on day 0 (pre-inoculation) 
may be due to the variable individual stress response to the initial handling of the animals. 
 
There are however several limitations to these interpretations.  Firstly, I am interpreting these 
trends retrospectively.  In order to confirm the validity of this concept, similar trends should 
also be observed in future separate challenge trials.  Secondly, intrinsic methodological 
variation has not been accounted for in my interpretations.  For example, the level of 
cytokine/chemokine transcripts in two pieces of the same tissue may differ due to different 
proportions of cell types in each sample.  This may contribute to the observed variability.  
Use of flow cytometry to measure cytokine/chemokine protein expression may allow 
standardisation of expression level in a particular proportion of cell types.  Furthermore, the 
small sample size per time-point used in the cytokine/chemokine study may raise questions as 
 160 
 
to whether the observed small ranges for some of the transcripts on certain time-points were 
purely due to chance.  Repeat of the experiments with large sample sizes may confirm the 
proposed association of variability and the different phases of host-virus interaction.   
Lastly, variation in the basal level of the variables of interest amongst the virus-challenged 
individuals may affect the variability of the resultant fold changes of these variables.  For 
example, rabbits with high basal expression of anti-viral cytokines (e.g. IFNα) in the draining 
lymph node may only require minimal upregulation in the expression of these cytokines in 
order to adequately control virus replication.  Therefore, intrinsic differences in the basal 
cytokine/chemokine expression amongst rabbits used in a challenge trial may contribute to 
the resultant variability in the variable of interest post-infection.  Further investigation into 
this potential association between basal and post-challenge variability is required. 
Nevertheless, the proposed concept of the different phases of organ specific variability may 
be useful in identifying the tissue-specific sequence of virus replication and immune 
activation in the body.  This may also help in estimating the initiation and final phase of the 
organ-specific host-virus interaction, which may in turn guide future selection of appropriate 
time-points for examining the events during these phases. 
7.1.3 End-point and time-point 
In my investigations, I have highlighted the clear differences between end-point and time-
point investigations and their specific implications (Table 7-1).  The end-point is reflective of 
the terminal disease state, whereas time-point is a snapshot of a randomly selected group of 
live animals post-challenge.  Therefore, disease outcomes from these two clearly different 
states should be interpreted separately.  Pooling of these two entities may bias the disease 
processes of interest, since end-point data may reflect a more severe disease state than time-
point data obtained from randomly selected live animals.   My investigation into this matter 
in Chapter 4 therefore serves as a reference to this important distinction for these two entities. 
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Table 7-1 Delineating the concept of time-point and end-point. 
 Time-point End-point 
Recruiting method Animals are sacrificed at 
random 
Animals either die naturally 
or are sacrifice on 
development of severe 
disease 
Components of group Represents animals at one 
time-point (i.e. a snapshot) 
Represents animals at the 
worst clinical scenario/stage 
Time post-infection At one particular time pi May range over several days 
pi 
Commonly used To examine pathogenesis To examine disease 
processes associated with 
severe morbidity/mortality. 
Assess Assesses a snapshot of 
disease outcomes at one 
time-point. 
Assess whether animals 
succumb from the same 
process(es) despite different 
time of end-point. 
Cautions If the host-pathogen 
interaction is variable 
between challenged animals, 
pooling of time-point 
outcomes may provide a 
confusing picture of 
pathogenesis. 
The mechanism of mortality 
may differ depending on the 
time of end-point.  Pooling of 
end-point results should 
therefore be performed with 
care. 
 
7.1.4 Route of WNV neuroinvasion 
Because of the failure to observe CNS infection by time-point sacrifice on day 7 pi, I did not 
reach a conclusion for the aim of identifying the route of WNV neuroinvasion (Aim 1.1 and 
1.2).  However, the end-point investigation in Chapter 4 showed that the earliest deaths had 
higher incidence of thoracic spinal cord WNV antigen upon intraperitoneal infection, 
suggesting the possibility that the spinal cord was one of the initial sites of viral 
neuroinvasion (Appendix 7 and Appendix 8).  The route by which the virus enters the 
thoracic spinal cord has not been identified in my investigation.  However, transneural 
transport of virus from nerves innervating the peritoneum to the spinal cord is possible [343].   
Nevertheless, as discussed in Chapter 1 and [1], the route of neuroinvasion is likely to vary 
depending on various experimental, host and virus factors (i.e. the model system).  The most 
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appropriate inoculation route to model the natural mosquito infections in humans and horses 
is the intradermal route.  Therefore, further investigations into the mechanism of WNV 
neuroinvasion should involve the intradermal route of inoculation in an appropriate model 
system.  Ideally, labelled virions should be used to monitor the in vivo kinetics of virus 
infection, dissemination and neuroinvasion. 
7.1.5 Virulence may be model system dependent 
As discussed in Chapter 4, disease outcome variability is dependent on a variety of virus, host 
and experimental factors within the model system used, rather than a singular factor.  In this 
thesis, I have observed that the same virus (WNVNSW2011) infecting different species (mice 
and rabbits) by different routes (IP vs footpad) and doses (100-1000 PFU vs 10
5
 TCID50) 
produce significantly different outcomes (e.g. mortality rate, CNS infection etc.).  Therefore, 
the “virulence phenotype” also appears to be dependent on the model system used.   
I propose that specifically for flaviviruses, viral quasispecies as influenced by interhost and 
intrahost passages [344, 345], as well as intrinsic isolate-specific viral determinants [219, 
253], likely contribute to the different virulence phenotype between different virus isolates.  
Similarly, the host’s background genetic composition, age, gender, and immunity (prior 
exposure, co-infection, co-morbidity), as well as where the animals are sourced (colonies or 
vendors), likely determine the susceptibility profile of the host to the virus challenge.  
Experimental factors within the model system such as the inoculation dose and route likely 
further modify the host-virus interaction. 
Since disease outcome may vary depending on the model-system used, the “virulence” 
phenotype of a particular virus strain in one species may not necessarily translate to another.  
In the example of WNV, the mortality rate in Swiss white CD1 caused by intraperitoneal or 
intracerebral infection has been conventionally used to determine the neuroinvasiveness and 
neurovirulence of different WNV strains, respectively [253].  However, these rates of 
mortality are not observed in WNV infected humans or horses.  Even when naturally infected 
with the most neuroinvasive/neurovirulent strains of WNV (e.g. WNVNY99), humans and 
horses do not succumb to the infection at rates observed in mice.  Does this mean that mouse-
virulent WNV strains are in fact “attenuated” in humans/horses, where <10% mortality is 
commonly observed [210, 270-273]?  Certainly in these incidental hosts, interventions, such 
as medical treatment and in the case of horses euthanasia, may be major factors that skew the 
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reported mortality rate.  However, the discrepancy of the mortality rates in the “virulence” 
models and those in the target population has not been properly addressed.   
Perhaps when ascribing the “virulence” of a virus strain, the following questions should be 
considered: 1) which model system has been used to demonstrate the capacity of the virus 
strain to cause disease?  2) does this model system accurately represent the range of disease 
outcomes and the epidemiology of the disease in the host species that it is attempting to 
model?  3) which parameter(s) of disease outcomes is/are the most relevant for determining 
the degree of “virulence” of the virus strain e.g. mortality, morbidity, pathology, and/or viral 
load?  4) is the level of “virulence” of a strain referring to a relative measure to other strains 
in the virus family or relative to all other virus groups within or outside of the family?   
 
7.1.6 Pathogenesis may be model system dependent 
If the virulence phenotype is dependent on the specific animal model systems used, disease 
processes (i.e. pathogenesis) associated with virus challenge may also vary from one system 
to another.   Therefore, overreliance on any one particular animal model system will likely 
give a biased understanding of the pathogenesis in the target populations.  In particular, 
exclusive reliance on the C56Bl/6 model for WNV pathogenesis would give the impression 
that disease processes in other species would lead to high CNS viral load (e.g. [28]), which is 
actually not the case in the target populations, humans and horses [21, 87] (Bielefeldt-
Ohmann et al., 2016, unpublished data).  The experimental WNV challenges in rabbits 
conducted for this thesis has also demonstrated that, unlike the mouse model, infected rabbits 
do not have significant levels of CNS virus infection post-challenge (Chapter 5). 
In order to make reliable inferences of pathogenesis from animal models to target 
populations, I propose that multiple model systems are needed to examine for common and 
varying elements in host-virus interaction.  Common elements may highlight conserved 
mechanisms in pathogenesis of WNV in mammals, while varying elements may highlight 
factors responsible for the different disease outcomes in the target populations.  The 
establishment of a novel rabbit model in this thesis attempts to address this aim. 
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7.2 Evaluation of the rabbit model for WNV neuropathogenesis 
investigation 
Experimental infection of rabbits with flavivirus has only been performed in a few studies 
with limited scope [211, 212].  The generally higher mortality rate and higher levels of CNS 
infection in the mouse model has prompted the need for an alternative animal model for 
studying WNV pathogenesis. 
Rabbits were chosen for virus challenge model in this study due to several advantages 
associated with using a larger animal species.  These include the ease of performing various 
sampling procedures (repeated blood sampling over multiple days), assessment of essential 
clinical parameters (rectal temperature, heart rate, hydration and neurological assessment), 
post mortem examination and tissue harvest.  Larger organs also enable sharing of tissues for 
different assays.  This is therefore superior to the small rodent models, since pooling of 
samples prior to assays is not needed in the rabbits. 
Since this study is the first to investigate the pathogenic events in WNV-infected rabbits, my 
initial hypothesis is based on a previous study involving CTRs [211]: 
“Hypothesis 2:  NZWRs may be a suitable animal species for studying the pathogenesis and 
immune response against WNVNSW2011, based on CTRs response to WNVNY99 in a previous 
investigation.” 
I have addressed this hypothesis by conducting an initial pilot challenge trial (Aim 2.1), 
where footpad inoculation with the outbreak strain WNVNSW2011 in weanling NZWRs were 
compared to that in adult NZWRs.  By examining the day 7 pi neuropathology, the weanling 
NZWRs are found to be more susceptible than adults (Aim 2.5), although no significant 
morbidity or mortality was observed in either group.  Due to this observation, 
characterisation of the early acute (day 3 pi) and subacute phase (day 12 and 18 pi) in vivo 
virus kinetics, immune response and neuropathology were expanded in wNZWRs infected 
with WNVNSW2011 (Aim 2.2).  In addition, as a comparison to the pathogenic events in 
WNVNSW2011 infected wNZWRs, an additional group of wNZWRs were infected with the 
highly virulent MVE1-51 (Aim 2.4).  To examine whether there is a species specific response 
to WNVNSW2011 infection, wild-caught North American cottontail rabbits were infected with 
WNVNSW2011 and the virulent North American strain WNVTX8667 (Aim 2.3).   
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The generally phenotypically resistant response against WNVNSW2011, WNVTX8667 and MVE1-
51 infection in both NZWRs and CTRs, with development of neuropathology, tissue viral 
load, cytokine gene transcription, and neutralising antibody levels of varying degree, suggest 
that these two species of rabbits are suitable animal models for studying the pathogenesis, 
including immune responses, associated with non-lethal flavivirus infection, which is the 
more common presentation in human and equine infections. 
7.2.1 Virus kinetics 
The experiments conducted in Chapter 5 characterised the viral load in the serum/plasma, 
dPLN, ndPLN, spleen and brain.  From these experiments, I have identified that the infecting 
virus was able to disseminate early into the serum/plasma from day 1 pi, and to the draining 
PLN on or before day 3 pi where it established productive infection, as supported by the 
positive NS1 antigen straining in pleomorphic cells consistent with macrophages or dendritic 
cells (Figure 5-3).  These two aspects of the in vivo virus kinetics seem to align with that in 
the mouse model [27, 346].  However, the ability of the flavivirus to disseminate to other 
tissues, in particular to the brain, was limited in infected rabbits, which contrasts with the 
high CNS infection typically seen in WNV-infected mice (e.g. [27, 28, 31]).  Therefore, I 
have concluded that rabbits are able to control virus infection/systemic dissemination and 
thus are a superior model for studying mechanism of virus control compared to the mouse. 
7.2.1.1 Serum vs cell-associated viraemia 
However, the viraemia assays were limited to quantifying viral RNA/infectious virus in the 
serum/plasma, rather than the whole blood or peripheral blood leucocytes. Studies into viral 
pathogenesis of bovine viral diarrhoea virus (BVDV ) [72] and Nipah virus [347] have 
suggested that viruses can either be trafficked inside or on the surface of leucocytes in the 
blood with or without productive replication.  Therefore, the serum/plasma viraemia levels in 
Chapter 5 may not represent the true amount of virus in the blood, if WNV/MVEV were cell-
associated.  Hence, quantification of WNV/MVEV RNA in the leukocytic and erythrocytic 
fractions of the blood is required to address this limitation [348]. 
As for the role of haematogenous cells as a source for virus production, Uddin et al. have 
shown that over the first 24 hours, the levels of WNVNSW2011 RNA in in vitro inoculated 
rabbit PBMCs increased approximately 2-fold [145].  A similar trend was observed in in vitro 
inoculated equine PBMCs [146].  However, beyond the first 24 hours pi, equine PBMCs 
were unable to support productive replication of WNVNSW2011 [146].   The equine PBMCs 
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were negative for NS1 antigen labelling, suggesting that WNVNSW2011 was either unable to 
productively replicate in PBMCs, that replication was abortive or that the replication level 
was below the detection level of the NS1 assay [145, 146].  The restricted replication may be 
attributable to the observed early IFNα and IFNγ responses detected in the inoculated equine 
PBMCs from 2-6 hour pi [146].  Similar host responses were observed in in vitro WNV-
infected rabbit PBMCs [145].  However, one previous study using a 2002 North American 
isolate of WNV has demonstrated productive virus replication in in vitro inoculated equine 
PBMCs [68].   Therefore, there may be a virus-strain dependency in the permissiveness of 
PBMCs.  Further investigations involving challenging rabbit and equine PBMCs with a panel 
of WNV strains may identify virulence determinants relevant for productive replication in 
these cell types.  Also, Uddin et al. have not identified the proportion of the different cell 
types within the PBMCs used for the in vitro infectivity study [145, 146].   Therefore, the 
observed limited virus replication may be explained by a relatively smaller proportion of 
permissive cells present in the PBMCs, as compared to the PBMCs used in the study by 
Garcia-Tapia et al. [68].   Flow cytometry may therefore be a useful tool in identifying 
permissive cell types and its/their proportion(s) within the PBMCs used. Alternatively 
double-immunolabelling of cytopreparations can be used for identification of flavivirus 
infected PBMC subsets [349, 350].   Until then, the role of circulating blood leucocytes in 
virus replication remains unclear.    
7.2.1.2 Varying degree of virus dissemination 
The degree of virus dissemination to other lymphoid organs was variable and appears to be 
dependent on the virulence of the virus.  Specifically, and consistent in the two rabbit species, 
the ndPLN and splenic viral load in rabbits infected with the virulent controls, MVE1-51 (for 
NZWRs) and WNVTX8667 (for CTRs), were significantly higher than the viral loads in rabbits 
infected with the less virulent, WNVNSW2011 (Figure 5-4F and Figure 6-5A).  This likely 
reflects different virulence determinants between the viruses, which may allow MVE1-51 and 
WNVTX8667 to either evade tissue innate immune response, and more avidly bind to, infect 
and replicate in permissive cells in the distant organs.  Alternatively, intra-host viral 
quasispecies selection by each organ may create a “bottleneck” for the fittest genotype for 
local replication and systemic dissemination.  In the study by Grubaugh et al. (2015), birds 
that are more disease susceptible to WNV infection (i.e. American crows) tend to have wider 
spectrum of viral genotypic variants in the blood than resistant birds (i.e. American robins) 
[351].  This suggests that intrahost viral quasispecies selection does indeed occur.  Further 
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investigation into the role of the viral quasispecies spectrum at the tissue level may provide 
novel insight into the reasons for the varying degree of systemic dissemination between 
different flaviviruses/WNV strains. 
7.2.1.3 Permissive cell types in rabbits 
In my investigations, I have not characterised the full range of permissive cells in rabbits.  
Using IHC, I have identified that pleomorphic cells consistent with macrophages or dendritic 
cells in the deep dermis of the footpad and the draining lymph node expressed NS1 and 
therefore were productively infected (Figure 5-3C).  However, I did not identify any 
involvement of keratinocytes in flavivirus replication at our earliest time point of day 3 pi.  
Similarly, whether rabbit brain cells are permissive to flavivirus infection remains to be 
investigated.  The evidence of trace MVEV RNA at late time-points such as day 7 to 18 pi in 
a small subset of the rabbits suggests that at least some of the brain cells may support limited 
virus replication, which may be below the detection limit for the NS1 IHC assay or the 
infected cells may be so few and scattered that the chance of encountering them in one or a 
few 5μm sections is remote.  Identification of these permissive brain cell type(s) may be 
helpful in locating possible cellular sources for neural viral persistence, and investigations of 
mechanism of local virus control.  To address the above gaps, primary cell culture of the skin, 
lymphoid tissue (spleen, lymph nodes) and brain cells are needed to explore the 
permissiveness of cell types within these organs. 
For this thesis, I attempted to characterise the virus replication kinetics in in vitro cultured 
rabbit kidney cells (RK13) (Appendix 9).  However, the cell line was subsequently found to 
be persistently infected with non-cytopathic BVDV (Appendix 10).  This therefore likely has 
contributed to the general lack of detectable WNV and MVEV replication, possibly due to a 
superinfection exclusion mechanism [352].  Repeat of the experiment with uncontaminated 
RK13 cells is therefore warranted. 
7.2.1.4 Role of lymphatics in virus dissemination and mediating immune response 
Post-footpad inoculation in rabbits, flaviviruses were detectable in the dPLN by day 3 pi.  
The mechanism of virus transport from the footpad to the dPLN is currently unclear in 
rabbits.  Murine studies have suggested that WNV likely travels to the dPLN via the 
lymphatics [143].  In WNV-infected rabbits, notable NF-kB2 signal was detected in 
leucocytes in the subcapsular sinus of the dPLN, suggesting that the route of entry into the 
lymph node is likely via the afferent lymphatics (Bielefeldt-Ohmann et al., 2016, unpublished 
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data) though it remains unclear whether the virions are transported to the dPLN as cell-free or 
cell-associated virions.  Definitive investigation of this mechanism will require intravital 
monitoring of inoculated labelled virions during the peracute phase (< day 1 pi) of the 
infection.  This technique may also allow examination into the role of the lymphatics in 
disseminating virus beyond the dPLNs, which so far has not been well characterised for 
WNV.   
7.2.1.5 Viraemia and neutralising mechanism – gap that is unexplained 
While neutralising antibodies are likely to play a major role in limiting circulating WNV 
from day 7 pi in WNVNSW2011 infected rabbits, the mechanism of control of circulating viral 
RNA levels during the early phase of the infection (< day 7 pi) has not been investigated in 
the studies conducted for this thesis.  Two methodological limitations prevented this 
investigation.  Firstly, the limit of detection of the PRNT90 assay has not been determined in 
my study.  Therefore, it is unknown whether there are circulating neutralising antibodies 
already on day 3 pi.  Secondly, the time-points used for assessing neutralising antibodies 
were limited to days 3, 7, 12 and 18 pi.  Therefore, it is unclear when exactly neutralising 
antibody production began.   Investigation of the levels on days 4 to 6 pi may allow further 
refinement of the kinetics of circulating neutralising antibodies, and ELISPOT-type assays 
could be used for detection of virus-specific B-lymphocytes at time points prior to and 
including days 3-6 [353].  Other promising avenues for future investigation into the control 
mechanism of haematogenous virus from day 1 to 7 pi include the role of 1) haematogenous 
opsonising antibodies, 2) the complement system, 3) circulating plasma/serum 
interferon/antiviral cytokines, 4) tissue-derived circulating cytokines and 5) PBMC-derived 
cytokines. 
7.2.2 Immune response 
The immune response to the footpad infection was evident on day 3 pi in most rabbit 
challenge groups with upregulation of several important cytokine genes, mostly at varying 
levels between the groups (Chapter 6).  Generally, a tissue specific, species and virus-
dependent profile of transcription was observed between the different rabbit groups.  This is 
not surprising, since the different host and virus factors likely have contributed to different 
degrees of stimulation in the organs.  However, common elements are also identified, such as 
IFNγ, TNFα and IL6 responses in the dPLN, ndPLN and spleen, respectively.  This may be 
highlighting some conserved elements of the immune response to flavivirus infection, leading 
to effective virus control and the fast neutralising antibody response.  Targeted silencing of 
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these genes, such as by RNA silencing technology, in specific tissue types may allow further 
investigations into their role in virus control in rabbits. 
A major limitation to my investigations is the limited characterisation of the downstream 
protein expression of the upregulated transcripts.  While the widespread STAT1 
immunoreactivity in the brains of MVEV-infected wNZWRs has provided some validation of 
the downstream activation of the IFNα/β/γ pathway, the in vivo kinetics of this antiviral 
pathway activation is unclear.  In my investigations, there was also a clear trend that IL10 
transcripts were upregulated frequently in multiple tissues in wNZWRs (Figure 6-1 to Figure 
6-4).  The exact role of this anti-inflammatory cytokine in regulating pro-inflammatory 
response needs further examination, especially via functional protein assays for actual 
cytokine activity.  Comparison of the expression pattern of the key signalling molecules, such 
as STAT1, NF-kb, SOCs, and STAT3, in different tissues and between groups may help 
delineate the role of pro- and anti-inflammatory cytokines in tissue-specific virus control 
mechanisms.  Early circulating levels of pyrogenic cytokines such as IL1 and IL6 should also 
be investigated, since pyrexia was commonly observed in flavivirus infected wNZWRs on 
day 1 pi.  Given these limitations, transcriptomic and proteomic assays in various tissue-types 
at time-points < day 3 pi may be of value, particularly given the limited availability of rabbit 
reagents (e.g. anti-rabbit antigen antibodies).   
Furthermore, the role of basal cytokine expression in virus control needs to be better 
characterised in flavivirus infected animals.  Seng et al. has shown that basal expression of 
IFN stimulated genes in in vitro cultured human bronchial epithelial cells (BEAS-2B) played 
an important role in resistance to influenza A virus [354].  Similar phenomena likely exist in 
a species- and tissue-specific manner in flavivirus-infected rabbits, and may therefore 
potentially be another explanation for the general lack of upregulated cytokine/chemokine 
transcripts in the CTRs (Figure 6-6). 
7.2.3 Limitations of the rabbit model and future directions 
The virus challenge experiments conducted in chapter 5 and 6 involved immunocompetent 
rabbits, since the main aim for this project was to establish the virus kinetics, pathology and 
immune response in this novel animal model.  However, the generally phenotypically 
resistant phenotype observed in these rabbits may not be able to provide direct insights into 
the mechanisms of lethal WNV infections.  Further investigation into the effect of 
immunosuppression in rabbits should be conducted, since compromised immunity has been 
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highlighted as a well-known risk factor for lethal human and likely equine infections [87].  
Immunosuppression in rabbits can be achieved by using immunosuppressive drugs [355] or 
co-infection with immunosuppressive viruses such as myxoma virus [356] or bovine 
herpesviruses [357]. 
Another limitation associated with the rabbit model is the relatively limited availability of 
reagents for characterising host response, as compared to those available to well-established 
models, such as the mouse.  However, advances in genomics, transcriptomics, and 
proteomics can allow molecular investigation of the rabbit immune responses post-flavivirus 
inoculation, without the need of conventional tools such as poly- or mono-clonal antibodies 
targeting for host proteins.  These technologies are also becoming more widely available, 
making them ideal tools for future investigations in the rabbit model.   
Limitations also apply to some of the comparisons performed in Chapter 5 and 6, due to the 
use of different viruses in the different rabbit challenge groups.  Specifically, differences of 
the cytokine/chemokine transcript levels between MVEV-infected wNZWRs and 
WNVTX8667-infected CTRs (Section 6.4.4) could not be interpreted, since there could be 
numerous reasons for them (e.g. different virulence factors in different flaviviruses and 
intrinsic differences in responses in different rabbit species).  While the use of different 
viruses for the virulent virus comparison in the different rabbit species was not ideal, I limited 
the interpretations of the experiments to comparisons within the same rabbit species (i.e. 
MVEV vs WNVNSW2011 in NZWRs and WNVTX8667 vs WNVNSW2011 in CTRs) and across the 
different species only for WNVNSW2011 (See Section 5.5 and 6.5).  However, the comparison 
between MVEV-infected wNZWRs and WNVTX8667-infected CTRs could show similarities 
in the general response in rabbits against flaviviruses.  In fact, across all challenge groups, 
there was a common signature in the temporal and tissue-specific upregulation of TNFα, IL6 
and IFNγ in all rabbits challenged with the different flaviviruses (Section 6.5).  Thus, despite 
the limitations, useful information can arise from such comparisons and can be used to help 
guide future investigations.  For this rabbit model, transcriptomic and proteomic 
characterisation of tissues from these rabbits may allow further identification of common 
molecular pathways in the rabbits’ response against flaviviruses.  This information will 
undoubtedly aid the development of broad-spectrum therapeutics against flaviviruses. 
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7.3 Conclusions 
In this multidisciplinary PhD project, I have employed skills from fields such as veterinary 
medicine, pathology, virology and immunology to advance the knowledge of WNV 
pathogenesis and immune control, and explored the gaps in the general principles behind 
pathogenesis investigation.  While I did not achieve the aim of identifying the route of WNV 
neuroinvasion using the CD1 mouse model system, I have advanced the field of viral 
pathogenesis studies by highlighting the distinction between end-point and time-point data, 
the importance of characterising the disease outcome variability, and the need for a virulence-
dependent approach to pathogenesis investigation.  My findings in this part of the thesis are 
relevant not only for flavivirus research, but also for research into the pathogenesis of all 
other virus families containing strains of intermediate virulence.  In this project, I have also 
established a novel, phenotypically resistant animal model in rabbits, which provided a much 
needed alternative to the mouse and hamster models for studying non-lethal WNV 
pathogenesis, including the host immune response.  This work has therefore laid the 
foundation for the use of the model in future vaccine and therapeutic trials against 
flaviviruses.  In conclusion, this PhD project has provided new insights into traditional 
methods, and introduced new tools useful for furthering the knowledge of WNV research and 
for a wide range of possible future studies pointed out in the above discussion.  
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Appendices 
Appendix 1 Repeat of BLAST analyses on selected sequences of virus stock performed on the 4
th
 December, 2016 
Virus strains Primer BLAST result 
(highest identity) 
Identity 
WNVK68967 FU2 WNVK68967 100% 
WNVNSW2011 FU2 WNVNSW2011 100% 
WNVGu1009 FU2 WNVGU1009 99% 
WNVGu0631 FU2 WNVGU0631 100% 
MVE1-51 FU2 MVE1-51 99% 
Note: the first and last 20 nucleotides of the sequence have been trimmed for BLAST analyses. 
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Appendix 2 Neuropathology, glial activation and viral antigen load in the central nervous system of female young adult CD-1 Swiss 
white mice infected with WNVNSW2011 
V
ir
u
s 
D
o
se
 
Mouse 
# 
Endpoint 
(DPI) 
Neuropathology Glial activation Viral antigen 
Mng Eph My 
Br 
Ast 
Br 
Mic 
SC 
Mic 
Overall 
Br 
Olf 
Nuc Ctx Hip Thl Pon Med 
Bas 
Gan Cbl SC 
W
N
V
N
S
W
2
0
1
1
 
1
0
0
 
71 8 2 3 3 2 4 4 2 0 0 0 1 0 0 2 0 2 
76 8 2 2 2 3 3 3 2 1 0 0 0 1 1 0 0 3 
77 8 2 5 3 2 1 0 3 1 3 0 0 3 0 0 1 1 
74 10 2 2 2 1 2 2 1 0 1 0 0 0 0 1 0 1 
75 10 1 4 1 4 2 4 3 0 3 3 3 0 0 0 0 0 
69 11 2 5 2 3 3 3 3 0 0 3 1 1 0 0 0 0 
70 11 0 1 2 1 4 3 0 0 0 0 0 0 0 0 0 0 
62 12 2 1 2 0 3 0 0 0 0 0 0 0 0 0 0 0 
68 22 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
72 22 0 0 0 0 ND 0 0 0 0 0 0 0 0 0 0 0 
1
0
0
0
 
64 7 2 4 3 3 3 2 2 0 0 0 0 2 0 0 0 1 
61 8 2 4 2 3 3 3 2 0 1 0 1 0 0 1 0 1 
63 8 3 4 2 4 4 0 3 0 3 3 2 0 2 0 2 3 
67 8 4 5 2 3 3 2 3 0 3 0 0 0 0 3 0 2 
56 10 0 2 1 4 3 3 3 0 2 0 0 0 0 3 0 0 
58 10 1 2 4 4 2 3 1 0 0 0 0 1 0 0 0 1 
66 10 0 2 0 1 0 1 0 0 0 0 0 0 0 0 0 0 
57 22 0 0 0 0 ND ND 0 0 0 0 0 0 0 0 0 0 
60 22 0 2 2 0 3 2 0 0 0 0 0 0 0 0 0 0 
59 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Neuropathology and glial activation score is out of 5, while viral antigen score is out of 3 (see methods section for more details).  DPI, day post-infection; ND, not done; 
Mng, meningitis; Eph, encephalitis, My, myelitis; Br, brain; SC, spinal cord; Ast, astrocytosis; Mic, microgliosis; Olf nuc, olfactory nucleus; Ctx, cerebral cortex; Hip, 
hippocampus; Thl, thalamus; Pon, pons; Med, medulla oblongata; Bas Gan, basal ganglia; Cbl, cerebellum.  Note:  The overall IHC score for the brain is determined by the 
following scoring system:  an overall score of 1, if only one area has a score of 1; an overall score of 2, if two or more regions have a score of 1, and/or if one area has a score 
of 2; an overall score of 3, if any of the areas has a score of 3, or if two or more regions have a score of 2)  
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Appendix 3 Neuropathology, glial activation and viral antigen load in the central nervous system of young adult CD-1 Swiss white mice 
infected with WNVNSW2012 
V
ir
u
s 
D
o
se
  Mouse 
# 
End-
point 
(DPI) 
Neuropathology Glial activation Viral antigen load 
Mng Eph My 
Br 
GFAP 
Br 
IBA1 
SC 
IBA1 
Overall 
Br 
Olf 
Nuc Cbm Hip Thl Pon Med 
Bas 
Gan Cbl SC 
W
N
V
N
S
W
2
0
1
2
 
1
0
0
 
101 8 3 4 2 1 3 4 3 0 2 0 1 2 2 2 0 3 
98 9 3 3 3 1 2 2 3 0 3 1 3 3 3 0 0 3 
97 10 1 1 0 3 1 2 0 0 0 0 0 0 0 0 0 0 
92 14 0 0 0 3 ND 0 0 0 0 0 0 0 0 0 0 0 
96 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
89 22 0 0 1 0 2 2 0 0 0 0 0 0 0 0 0 0 
91 22 0 0 0 0 ND ND 0 0 0 0 0 0 0 0 0 0 
93 22 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 
95 22 0 2 1 2 2 3 0 0 0 0 0 0 0 0 0 0 
99 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1
0
0
0
 
100 6 2 3 3 1 2 ND 3 0 0 0 0 0 3 2 0 3 
79 7 2 4 3 3 2 2 3 0 0 0 3 0 3 0 0 3 
82 7 4 4 3 1 4 2 3 0 3 3 3 2 0 2 0 1 
85 8 2 2 3 3 4 3 2 0 0 0 1 2 2 0 0 1 
83 9 0 4 0 2 3 2 3 0 1 3 0 0 0 0 0 0 
84 10 0 1 2 3 4 2 1 0 0 0 1 0 0 0 0 1 
80 11 1 1 0 1 3 1 0 0 0 0 0 0 0 0 0 0 
81 22 0 0 2 0 0 2 0 0 0 0 0 0 0 0 0 0 
86 22 0 0 0 0 ND 0 0 0 0 0 0 0 0 0 0 0 
88 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Neuropathology and glial activation score is out of 5, while viral antigen score is out of 3 (see methods section for more details).  Doses are expressed as PFU; DPI, day post-
infection; ND, not done; Mng, meningitis; Eph, encephalitis, My, myelitis; Br, brain; SC, spinal cord; Ast, astrocytosis; Mic, microgliosis; Olf nuc, olfactory nucleus; Ctx, 
cerebral cortex; Hip, hippocampus; Thl, thalamus; Pon, pons; Med, medulla oblongata; Bas Gan, basal ganglia; Cbl, cerebellum.  Note:  The overall IHC score for the brain is 
determined by the following scoring system:  an overall score of 1, if only one area has a score of 1; an overall score of 2, if two or more regions have a score of 1, and/or if 
one area has a score of 2; an overall score of 3, if any of the areas has a score of 3, or if two or more regions have a score of 2)  
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Appendix 4 Neuropathology in weanling CD-1 Swiss white mice infected with MVE1-51 
V
ir
u
s 
D
o
se
 
Mouse # 
Endpoint 
(DPI) 
Neuropathology 
Mng Eph My 
M
V
E
1
-5
1
 
1
0
 
2 6 2 2 0 
3 6 2 2 0 
5 6 2 3 0 
4 6 2 3 1 
6 6 2 2 2 
1 6 3 3 2 
8 7 1 2 0 
9 7 3 3 0 
7 7 2 3 1 
49 7 2 1 2 
1
0
0
0
 
17 6 2 2 0 
15 6 2 2 1 
23 6 3 2 1 
16 6 2 2 2 
14 6 2 2 4 
19 7 1 2 0 
18 7 2 2 1 
21 8 2 2 2 
20 8 3 2 2 
22 20 0 0 0 
Neuropathology score is out of 5 (see methods section for more details).  Doses are expressed as TCID50; DPI, day post-infection; Mng, meningitis; Eph, encephalitis, My, 
myelitis. 
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Appendix 5 Neuropathology in weanling CD-1 Swiss white mice infected with MVEK68838 
V
ir
u
s 
D
o
se
 
Mouse # 
Endpoint 
(DPI) 
Neuropathology 
Mng Eph My 
M
V
E
K
6
8
8
3
8
 
1
0
 
25 7 2 2 0 
24 7 2 2 1 
27 7 2 2 2 
28 8 2 2 0 
31 8 2 3 0 
30 8 2 3 3 
29 8 2 2 ND 
32 9 2 3 2 
33 10 3 4 4 
34 20 0 0 0 
1
0
0
0
 
46 6 2 2 1 
45 6 2 2 3 
50 7 2 1 0 
51 7 2 2 1 
47 7 3 5 1 
52 7 2 1 ND 
48 7 3 3 ND 
53 8 4 3 2 
54 9 2 4 2 
55 20 5 5 1 
Neuropathology score is out of 5 (see methods section for more details).  Doses are expressed as TCID50; DPI, day post-infection; Mng, meningitis; Eph, encephalitis, My, 
myelitis. 
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Appendix 6  Number of rabbits needed to infect (number needed to harm) before one animal is expected to have the following 
neuropathology on day 7 pi.  The higher number needed to harm (NNH) associated with WNVNSW2011 infected weanling NZWRs (Group 1), as 
compared to ones infected with MVE1-51 (Group 2), suggests that WNVNSW2011 is less consistent in causing neuropathology than MVE1-51 in 
weanling NZWRs.  This may be an indicator of the relatively lower pathogenicity of the WNVNSW2011 strain.  
Groups Meningitis 
(brain) 
Encephalitis 
(brain) 
Meningitis (olfactory 
bulbs) 
Encephalitis (olfactory 
bulbs) 
Spinal 
Meningitis 
Myelitis 
1 3 5 (4.5) 5 (4.5) 5 (4.5) 5 (4.5) 3 
2 1 2 (1.5) 4 2 3 3 (2.3) 
3 2 (1.5) 3 2 (1.5) 3 NA NA 
4 3 3 2 (1.5) NA NA NA 
5 3 3 ND ND NA 3 
6 2 (1.5 ) 2 (1.5) ND ND 2 (1.5) NA 
Number in brackets is the raw results before the figure was rounded to the nearest integer.  NA, unable to calculate NNH, since there was no reported incidence of that particular pathology.  ND, 
not done, since these sites were not examined.  Group 1: WNVNSW2011 infected weanling NZWRs (N=9); Group 2: MVE1-51 infected weanling NZWRs (N=6); Group 3: WNVNSW2011 infected 
adult NZWRs (N=3); Group 4: MVE1-51 infected adult NZWRs (N=3); Group 5: WNVNSW2011 infected CTRs (N=3); Group 6:   WNVTX8667 infected CTRs (N=3).
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Appendix 7 Temporospatial distribution of viral antigen load in regions of the CNS in 
dead/moribund mice infected with 100 PFU of WNVNSW2012 (upper panel) and 
WNVNSW2011 (lower panel).  The x-axis has been arranged to illustrate the most rostral 
location of the CNS (olfactory nucleus) on the left and the most caudal location (lumbar 
spinal cord) on the right of the x-axis for each day of death. SC: spinal cord.  
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Appendix 8 Temporospatial distribution of viral antigen load in regions of the CNS in 
dead/moribund mice infected with 1000 PFU of WNVNSW2012 (upper panel) and 
WNVNSW2011 (lower panel).  The x-axis has been arranged to illustrate the most rostral 
location of the CNS (olfactory nucleus) on the left and the most caudal location (lumbar 
spinal cord) on the right of the x-axis for each day of death.  SC: spinal cord.  
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Appendix 9 In vitro virus growth kinetics of WNVNSW2011 (NSW2011), WNVK68967 
(K68967), and MVE1-51 (MVE1-51) on RK13 cells at MOI 1. 
 
 
Appendix 10 In vitro grown RK13 cells positive for bovine viral diarrhoea virus (BVDV) 
antigen.  Magnification: 40x (IHC courtesy of Dr. H. Bielefeldt-Ohmann) 
  
 210 
 
 
Appendix 11 Weblinks to journal articles that I have authored or co-authored during 
my candidature 
 
Suen, W.W., Prow, N.A., Hall, R.A., Bielefeldt-Ohmann, H. (2014).  Mechanism of West 
Nile virus neuroinvasion: a critical appraisal. Viruses, 6 (7), 2796-825. 
Link:  http://www.mdpi.com/1999-4915/6/7/2796 
 
Suen, W.W., Uddin, M.J., Wang, W., Brown, V., Adney, D.R., Broad, N., Prow, N.A., 
Bowen, R.A., Hall, R.A., Bielefeldt-Ohmann, H. (2015). Experimental West Nile virus 
infection in rabbits: An alternative model for studying induction of disease and virus control. 
Pathogens, 4, 529-558.  
Link:  http://www.mdpi.com/2076-0817/4/3/529 
 
Suen, W. W., Prow, N. A., Setoh, Y. X., Hall, R. A., & Bielefeldt-Ohmann, H. (2016). End-
point disease investigation for virus strains of intermediate virulence as illustrated by 
flavivirus infections. J Gen Virol, 97(2), 366-377. doi: 10.1099/jgv.0.000356 
Link:  http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000356#tab2 
 
Suen, W. W., Uddin, M. J., Prow, N. A., Bowen, R. A., Hall, R. A., & Bielefeldt-Ohmann, 
H. (2016). Tissue-specific transcription profile of cytokine and chemokine genes associated 
with flavivirus control and non-lethal neuropathogenesis in rabbits. Virology, 494, 1-14. doi: 
http://dx.doi.org/10.1016/j.virol.2016.03.026 
Link:  http://www.sciencedirect.com/science/article/pii/S0042682216300551 
  
 211 
 
 
Prow, N. A., Edmonds, J. H., Williams, D. T., Setoh, Y. X., Bielefeldt-Ohmann, H., Suen, 
W. W., . Hobson-Peters, J., van den Hurk, A. F., Pyke, A. T., Hall-Mendelin, S., Northill, J. 
A., Johansen, C. A., Warrilow, D., Wang, J., Kirkland, P. D., Doggett, S., Andrade, C. C., 
Brault, A. C., Khromykh, A. A. & Hall, R. A. (2016). Virulence and Evolution of West Nile 
Virus, Australia, 1960–2012. Emerg Infect Dis, 22(8), 1353-62. doi: 10.3201/eid2208.151719 
Link:  http://wwwnc.cdc.gov/eid/article/22/8/15-1719_article 
 
Uddin, M. J., Suen, W. W., Prow, N. A., Hall, R. A., & Bielefeldt-Ohmann, H. (2015). West 
Nile virus challenge alters the transcription profiles of innate immune genes in rabbit 
peripheral blood mononuclear cells. Front. Vet. Sci., 2, 76. doi: 10.3389/fvets.2015.00076 
Link:  http://journal.frontiersin.org/article/10.3389/fvets.2015.00076/full 
 
Uddin, M. J., Suen, W. W., Bosco-Lauth, A., Hartwig, A.-E., Hall, R. A., Bowen, R. A., & 
Bielefeldt-Ohmann, H. (2016). Kinetics of the West Nile virus induced transcripts of selected 
cytokines and Toll-like receptors in equine peripheral blood mononuclear cells. Veterinary 
Research, 47, 61. doi: 10.1186/s13567-016-0347-8 
Link:  http://veterinaryresearch.biomedcentral.com/articles/10.1186/s13567-016-0347-8 
 
Colmant, A. M., Bielefeldt-Ohmann, H., Hobson-Peters, J., Suen, W. W., O'Brien, C. A., van 
den Hurk, A. F., & Hall, R. A. (2016). A newly discovered flavivirus in the yellow fever 
virus group displays restricted replication in vertebrates. J Gen Virol. 97, 1087-93. doi: 
10.1099/jgv.0.000430 
Link:  http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000430#tab2 
 
 
 
 212 
 
Appendix 12 Licenses to reuse my published papers in this thesis 
For Chapter 4: 
 
 213 
 
 
 
 
 214 
 
 
For Chapter 6: 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
Aug 24, 2016 
 
 
 
This Agreement between Willy Suen ("You") and Elsevier ("Elsevier") consists of your 
license details and the terms and conditions provided by Elsevier and Copyright Clearance 
Center. 
License Number 3920080706963 
License date Aug 01, 2016 
Licensed Content Publisher Elsevier 
Licensed Content Publication Virology 
Licensed Content Title Tissue-specific transcription profile of cytokine and 
chemokine genes associated with flavivirus control 
and non-lethal neuropathogenesis in rabbits 
Licensed Content Author Willy W. Suen,Muhammad Jasim Uddin,Natalie A. 
Prow,Richard A. Bowen,Roy A. Hall,Helle Bielefeldt-
Ohmann 
Licensed Content Date July 2016 
Licensed Content Volume Number 494 
Licensed Content Issue Number n/a 
Licensed Content Pages 14 
Start Page 1 
End Page 14 
Type of Use reuse in a thesis/dissertation 
Portion full article 
Format both print and electronic 
Are you the author of this Elsevier article? Yes 
Will you be translating? No 
Order reference number 01082016WS 
Title of your thesis/dissertation Investigation of neuropathogenesis and control of 
an equine-pathogenic Australian West Nile virus 
isolate in an established CD1 Swiss white mouse 
and a novel rabbit model 
Expected completion date Nov 2016 
Estimated size (number of pages) 229 
Elsevier VAT number GB 494 6272 12 
 215 
 
Requestor Location Willy Suen 
U3, 50 mitre st 
 
 
brisbane, QLD 4067 
Australia 
Attn: Willy Suen 
  
Total 0.00 AUD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in 
connection with completing this licensing transaction, you agree that the following terms 
and conditions apply to this transaction (along with the Billing and Payment terms and 
conditions established by Copyright Clearance Center, Inc. ("CCC"), at the time that you 
opened your Rightslink account and that are available at any time 
at http://myaccount.copyright.com). 
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject 
to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another source, permission 
must also be sought from that source.  If such permission is not obtained then that material 
may not be included in your publication/copies. Suitable acknowledgement to the source 
must be made, either as a footnote or in a reference list at the end of your publication, as 
follows: 
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of 
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE 
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The 
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier." 
4. Reproduction of this material is confined to the purpose and/or media for which 
permission is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, 
deletions and/or any other alterations shall be made only with prior written authorization of 
Elsevier Ltd. (Please contact Elsevier at permissions@elsevier.com) 
6. If the permission fee for the requested use of our material is waived in this instance, 
please be advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of this 
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
transaction, provided that you have disclosed complete and accurate details of your 
proposed use, no license is finally effective unless and until full payment is received from 
you (either by publisher or by CCC) as provided in CCC's Billing and Payment terms and 
conditions.  If full payment is not received on a timely basis, then any license preliminarily 
granted shall be deemed automatically revoked and shall be void as if never 
granted.  Further, in the event that you breach any of these terms and conditions or any of 
  
 216 
 
CCC's Billing and Payment terms and conditions, the license is automatically revoked and 
shall be void as if never granted.  Use of materials as described in a revoked license, as 
well as any use of the materials beyond the scope of an unrevoked license, may constitute 
copyright infringement and publisher reserves the right to take any and all action to protect 
its copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the 
licensed material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and 
their respective officers, directors, employees and agents, from and against any and all 
claims arising out of your use of the licensed material other than as specifically authorized 
pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a 
writing signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's Billing and 
Payment terms and conditions.  These terms and conditions, together with CCC's Billing 
and Payment terms and conditions (which are incorporated herein), comprise the entire 
agreement between you and publisher (and CCC) concerning this licensing transaction.  In 
the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC's Billing and Payment terms and conditions, these 
terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions 
described in this License at their sole discretion, for any reason or no reason, with a full 
refund payable to you.  Notice of such denial will be made using the contact information 
provided by you.  Failure to receive such notice will not alter or invalidate the denial.  In 
no event will Elsevier or Copyright Clearance Center be responsible or liable for any costs, 
expenses or damage incurred by you as a result of a denial of your permission request, 
other than a refund of the amount(s) paid by you to Elsevier and/or Copyright Clearance 
Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional translator 
must perform all translations and reproduce the content word for word preserving the 
integrity of the article. 
16. Posting licensed content on any Website: The following terms and conditions apply 
as follows: Licensing material from an Elsevier journal: All content posted to the web site 
must maintain the copyright information line on the bottom of each image; A hyper-text 
must be included to the Homepage of the journal from which you are licensing 
athttp://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books 
athttp://www.elsevier.com; Central Storage: This license does not include permission for a 
scanned version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the 
Elsevier homepage at http://www.elsevier.com . All content posted to the web site must 
maintain the copyright information line on the bottom of each image. 
 217 
 
 
Posting licensed content on Electronic reserve: In addition to the above the following 
clauses are applicable: The web site must be password-protected and made available only 
to bona fide students registered on a relevant course. This permission is granted for 1 year 
only. You may obtain a new license for future website posting. 
17. For journal authors: the following clauses are applicable in addition to the above: 
Preprints: 
A preprint is an author's own write-up of research results and analysis, it has not been peer-
reviewed, nor has it had any other value added to it by a publisher (such as formatting, 
copyright, technical enhancement etc.). 
Authors can share their preprints anywhere at any time. Preprints should not be added to or 
enhanced in any way in order to appear more like, or to substitute for, the final versions of 
articles however authors can update their preprints on arXiv or RePEc with their Accepted 
Author Manuscript (see below). 
If accepted for publication, we encourage authors to link from the preprint to their formal 
publication via its DOI. Millions of researchers have access to the formal publications on 
ScienceDirect, and so links will help users to find, access, cite and use the best available 
version. Please note that Cell Press, The Lancet and some society-owned have different 
preprint policies. Information on these policies is available on the journal homepage. 
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an 
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author 
communications. 
Authors can share their accepted author manuscript: 
          immediately 
o via their non-commercial person homepage or blog 
o by updating a preprint in arXiv or RePEc with the accepted 
manuscript 
o via their research institute or institutional repository for internal 
institutional uses or as part of an invitation-only research 
collaboration work-group 
o directly by providing copies to their students or to research 
collaborators for their personal use 
o for private scholarly sharing as part of an invitation-only work group 
on commercial sites with which Elsevier has an agreement 
          after the embargo period 
o via non-commercial hosting platforms such as their institutional 
repository 
o via commercial sites with which Elsevier has an agreement 
In all cases accepted manuscripts should: 
          link to the formal publication via its DOI 
          bear a CC-BY-NC-ND license - this is easy to do 
          if aggregated with other manuscripts, for example in a repository or other site, 
be shared in alignment with our hosting policy not be added to or enhanced in any 
way to appear more like, or to substitute for, the published journal article. 
Published journal article (JPA): A published journal article (PJA) is the definitive final 
record of published research that appears or will appear in the journal and embodies all 
value-adding publishing activities including peer review co-ordination, copy-editing, 
formatting, (if relevant) pagination and online enrichment. 
 218 
 
Policies for sharing publishing journal articles differ for subscription and gold open access 
articles: 
Subscription Articles: If you are an author, please share a link to your article rather than 
the full-text. Millions of researchers have access to the formal publications on 
ScienceDirect, and so links will help your users to find, access, cite, and use the best 
available version. 
Theses and dissertations which contain embedded PJAs as part of the formal submission 
can be posted publicly by the awarding institution with DOI links back to the formal 
publications on ScienceDirect. 
If you are affiliated with a library that subscribes to ScienceDirect you have additional 
private sharing rights for others' research accessed under that agreement. This includes use 
for classroom teaching and internal training at the institution (including use in course packs 
and courseware programs), and inclusion of the article for grant funding purposes. 
Gold Open Access Articles: May be shared according to the author-selected end-user 
license and should contain a CrossMark logo, the end user license, and a DOI link to the 
formal publication on ScienceDirect. 
Please refer to Elsevier's posting policy for further information. 
18. For book authors the following clauses are applicable in addition to the 
above:   Authors are permitted to place a brief summary of their work online only. You are 
not allowed to download and post the published electronic version of your chapter, nor 
may you scan the printed edition to create an electronic version. Posting to a 
repository: Authors are permitted to post a summary of their chapter only in their 
institution's repository. 
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may 
be submitted to your institution in either print or electronic form. Should your thesis be 
published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
the complete thesis and include permission for Proquest/UMI to supply single copies, on 
demand, of the complete thesis. Should your thesis be published commercially, please 
reapply for permission. Theses and dissertations which contain embedded PJAs as part of 
the formal submission can be posted publicly by the awarding institution with DOI links 
back to the formal publications on ScienceDirect. 
  
Elsevier Open Access Terms and Conditions 
You can publish open access with Elsevier in hundreds of open access journals or in nearly 
2000 established subscription journals that support open access publishing. Permitted third 
party re-use of these open access articles is defined by the author's choice of Creative 
Commons user license. See our open access license policy for more information. 
Terms & Conditions applicable to all Open Access articles published with Elsevier: 
Any reuse of the article must not represent the author as endorsing the adaptation of the 
article nor should the article be modified in such a way as to damage the author's honour or 
reputation. If any changes have been made, such changes must be clearly indicated. 
The author(s) must be appropriately credited and we ask that you include the end user 
license and a DOI link to the formal publication on ScienceDirect. 
If any part of the material to be used (for example, figures) has appeared in our publication 
with credit or acknowledgement to another source it is the responsibility of the user to 
ensure their reuse complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new 
works from the Article, to alter and revise the Article and to make commercial use of the 
 219 
 
Article (including reuse and/or resale of the Article by commercial entities), provided the 
user gives appropriate credit (with a link to the formal publication through the relevant 
DOI), provides a link to the license, indicates if changes were made and the licensor is not 
represented as endorsing the use made of the work. The full details of the license are 
available at http://creativecommons.org/licenses/by/4.0. 
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, 
abstracts and new works from the Article, to alter and revise the Article, provided this is 
not done for commercial purposes, and that the user gives appropriate credit (with a link to 
the formal publication through the relevant DOI), provides a link to the license, indicates if 
changes were made and the licensor is not represented as endorsing the use made of the 
work. Further, any new works must be made available on the same conditions. The full 
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0. 
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the 
Article, provided this is not done for commercial purposes and further does not permit 
distribution of the Article if it is changed or edited in any way, and provided the user gives 
appropriate credit (with a link to the formal publication through the relevant DOI), 
provides a link to the license, and that the licensor is not represented as endorsing the use 
made of the work. The full details of the license are available 
at http://creativecommons.org/licenses/by-nc-nd/4.0. Any commercial reuse of Open 
Access articles published with a CC BY NC SA or CC BY NC ND license requires 
permission from Elsevier and will be subject to a fee. 
Commercial reuse includes: 
          Associating advertising with the full text of the Article 
          Charging fees for document delivery or access 
          Article aggregation 
          Systematic distribution via e-mail lists or share buttons 
Posting or linking by commercial companies for use by customers of those companies. 
  
20. Other Conditions: 
  
v1.8 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777.   
 
